[{"category": "company", "datetime": 1625157180, "headline": "Abiomed Inc. stock rises Thursday, still underperforms market", "id": 68571434, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. inched 0.26% higher to $312.91 Thursday, on what proved to be an all-around positive trading session for the stock market, with the...", "url": "https://finnhub.io/api/news?id=69e75827e968c9ed0d2fa8c61892075b808c4752f3446c0b640b7e5aa274f10f"}, {"category": "company", "datetime": 1625070780, "headline": "Abiomed Inc. stock outperforms competitors despite losses on the day", "id": 68571435, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. shed 0.37% to $312.11 Wednesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index...", "url": "https://finnhub.io/api/news?id=88d1a56e3b208d905b05dd0073593c49f4198acc06c833f5293b0ba5699a2f46"}, {"category": "company", "datetime": 1625058361, "headline": "Abiomed's (ABMD) Impella RP With SmartAssist Gets FDA Nod", "id": 68536674, "image": "https://s.yimg.com/uu/api/res/1.2/5Q_hUjtCGiFNkT7hRMCFWw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4e34facdd1fb2dc7d4782bd97cabacb5", "related": "ABMD", "source": "Yahoo", "summary": "Abiomed's (ABMD) Impella RP with SmartAssist gets the highest level of approval from the FDA for treatment of right heart failure.", "url": "https://finnhub.io/api/news?id=d966cad054811f7cf65e08a68b61a7ee993f9543d62a06825ed401705a3d7fa8"}, {"category": "company", "datetime": 1625054001, "headline": "Noteworthy ETF Outflows: RSP, GNRC, RMD, ABMD", "id": 68646297, "image": "https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?1636537797", "related": "ABMD", "source": "Nasdaq", "summary": "Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Invesco S&P 500\u2014 Equal Weight ETF (Symbol: RSP) where we have detected an approximate $992.6 million dollar outflow -- that's a 3.4% decre", "url": "https://finnhub.io/api/news?id=f0fc2cd5b3dd6a9d48ce7b71da8b54f78774a5a68c7988281d32b29025e5a3be"}, {"category": "company", "datetime": 1624984380, "headline": "Abiomed Inc. stock outperforms competitors on strong trading day", "id": 68571436, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. inched 0.27% higher to $313.27 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P...", "url": "https://finnhub.io/api/news?id=6ae4dd748d006d8a3a3f2617d463c48d204d7f1fdf97cc0dd7c1c41dce208ed0"}, {"category": "company", "datetime": 1624968180, "headline": "FDA Grants Highest Level of Approval to the Next Generation of Impella RP to Treat Right Heart Failure", "id": 68526991, "image": "https://s.yimg.com/uu/api/res/1.2/R1_dw4nRFq_Gpx6MdRu28g--~B/aD00ODA7dz0zMzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/97fbc2235fda78071579a22c0d57d988", "related": "ABMD", "source": "Yahoo", "summary": "DANVERS, Mass., June 29, 2021--Abiomed\u2019s (NASDAQ: ABMD) newest right heart pump, the Impella RP with SmartAssist, has received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) as safe and effective to treat acute right heart failure for up to 14 days.", "url": "https://finnhub.io/api/news?id=d298146c4e9a0947b3ac609084b6a8c6cf11158879848a470c7ae0b5c6695c05"}, {"category": "company", "datetime": 1624897920, "headline": "Abiomed Inc. stock outperforms market on strong trading day", "id": 68571437, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. inched 0.29% higher to $312.44 Monday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500...", "url": "https://finnhub.io/api/news?id=5c327234dae734691f442b15d97b01fd46bf2117d8c6834b92481ac5040eaac5"}, {"category": "company", "datetime": 1624567733, "headline": "10 Medical Device Stocks for 2021", "id": 68473233, "image": "https://s.yimg.com/uu/api/res/1.2/zYUSulj.G3A0gz_auaM4ow--~B/aD01MDA7dz03NTA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/82a4af94e90942ec120dbb80f48cb463", "related": "ABMD", "source": "Yahoo", "summary": "In this article, we will take a look at some of the best medical device stocks for 2021. To skip our detailed analysis on the medical device industry, the impact of the COVID-19 pandemic on the industry, and its future outlook, click to see the 5 Medical Device Stocks for 2021. The COVID-19 pandemic certainly [\u2026]", "url": "https://finnhub.io/api/news?id=1606fce214d860868187e4daf1342f59cac0605218cc2e180efced6137e3c141"}, {"category": "company", "datetime": 1624545151, "headline": "Thursday Sector Laggards: Utilities, Healthcare", "id": 68473729, "image": "https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?1770573398", "related": "ABMD", "source": "Nasdaq", "summary": "In afternoon trading on Thursday, Utilities stocks are the worst performing sector, not showing much of a gain.  Within the sector, American Water Works Co, Inc. (Symbol: AWK) and CenterPoint Energy, Inc (Symbol: CNP) are two of the day's laggards, showing a loss of 1.2% and 0.", "url": "https://finnhub.io/api/news?id=9c08bd1b54ffd892322613cfcf43947ee28bd9b4258a892e89804114b542bce7"}, {"category": "company", "datetime": 1624506960, "headline": "U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.95% By Investing.com", "id": 68470307, "image": "https://i-invdn-com.investing.com/news/LYNXNPEB8R0JA_L.jpg", "related": "ABMD", "source": "Investing.com", "summary": "U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.95%", "url": "https://finnhub.io/api/news?id=b02c93ac5d77ae8549ecfe583c4fb5e9965c3a0ea567c3e57c9be9e1e7b568e6"}, {"category": "company", "datetime": 1624500960, "headline": "Abiomed Inc (ABMD) Chairman, President, CEO Michael R Minogue Sold $8.1 million of Shares", "id": 68470758, "image": "", "related": "ABMD", "source": "GuruFocus", "summary": "GuruFocus Article or News written by insider and the topic is about: ", "url": "https://finnhub.io/api/news?id=952fedfda80cc7220e2df1938229166b0778ebbeb6c87d8bd3121056dbee645f"}, {"category": "company", "datetime": 1624459978, "headline": "Wednesday Sector Laggards: Utilities, Healthcare", "id": 68473507, "image": "https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?231164975", "related": "ABMD", "source": "Nasdaq", "summary": "Looking at the sectors faring worst as of midday Wednesday, shares of Utilities companies are underperforming other sectors, showing a 0.8% loss.  Within that group, American Water Works Co, Inc. (Symbol: AWK) and Entergy Corp (Symbol: ETR) are two of the day's laggards, showin", "url": "https://finnhub.io/api/news?id=f3620d563df64f48966df107db661760214f9a5d5018fa29b04a99d63e0e576f"}, {"category": "company", "datetime": 1624379580, "headline": "Abiomed Inc. stock outperforms competitors on strong trading day", "id": 68433466, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. inched 0.65% higher to $327.19 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P...", "url": "https://finnhub.io/api/news?id=53221ef304cf6a78d4d85c5891a1f28c86abd16de4fa5b703849f15ac4eb14c0"}, {"category": "company", "datetime": 1624364952, "headline": "Abiomed (ABMD) Enters Overbought Territory", "id": 68430181, "image": "https://s.yimg.com/uu/api/res/1.2/_LT6pKD_Fk90UGSt.TnE5Q--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/e10425bef32c421f16ccc0d2a8c8bb61", "related": "ABMD", "source": "Yahoo", "summary": "Abiomed (ABMD) has moved higher as of late, but there could definitely be trouble on the horizon for this company", "url": "https://finnhub.io/api/news?id=c77a3037ed34a3a84cf15c4ead704f57ab38feea787ec9d1fbc79ec8219a8233"}, {"category": "company", "datetime": 1624293180, "headline": "Abiomed Inc. stock outperforms competitors on strong trading day", "id": 68433467, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. advanced 2.05% to $325.09 Monday, on what proved to be an all-around great trading session for the stock market, with the S&P 500...", "url": "https://finnhub.io/api/news?id=aa2f64a4fefce6dbfa9fbdba7545267daead4b881e30ee8ad42025c2a09d8644"}, {"category": "company", "datetime": 1624033980, "headline": "Abiomed Inc. stock outperforms market on strong trading day", "id": 68433468, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. advanced 1.91% to $318.57 Friday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500...", "url": "https://finnhub.io/api/news?id=1192dc5e52ee4407b070cd927774781867ab3049f17df8fb6d5dae5ec520210e"}, {"category": "company", "datetime": 1624023623, "headline": "Noteworthy Friday Option Activity: ABMD, UNP, CCL", "id": 68371362, "image": "https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?1853165106", "related": "ABMD", "source": "Nasdaq", "summary": "Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in ABIOMED, Inc. (Symbol: ABMD), where a total of 1,296 contracts have traded so far, representing approximately 129,600 underlying shares.  That amounts to about 49.5% of A", "url": "https://finnhub.io/api/news?id=24ad7df17873afdb8c18530d26c66ad49c90adcf38c333efd13f3bf653862f68"}, {"category": "company", "datetime": 1624019940, "headline": "Noteworthy Friday Option Activity: ABMD, UNP, CCL", "id": 68355974, "image": "", "related": "ABMD", "source": "Stock Options Channel", "summary": "Staff article entitled Noteworthy Friday Option Activity: ABMD, UNP, CCL, about stock options, from Stock Options Channel.", "url": "https://finnhub.io/api/news?id=4fdecca261da15c2b2f364bd038b19396735d9576150fa37459757faf3ba5947"}, {"category": "company", "datetime": 1624006560, "headline": "Early notable gainers among liquid option names on June 18th", "id": 68349229, "image": "", "related": "ABMD", "source": "Thefly.com", "summary": "Early notable gainers among liquid option names on June 18th NVDA ADBE LEN ABMD OXY", "url": "https://finnhub.io/api/news?id=a0ceeb938bf465a54261bf45583982fc2430eb7ddfd3d363737ecd54f085cec9"}, {"category": "company", "datetime": 1624004460, "headline": "Friday\u2019s Top Analyst Upgrades and Downgrades: Alaska Air, Biogen, Cirrus Logic, Lennar, Match, Occidental and United Airlines", "id": 68349428, "image": "https://247wallst.com/wp-content/uploads/2020/04/imageForEntry2-Rv3.jpg", "related": "ABMD", "source": "247WallSt", "summary": "Friday\u2019s top analyst upgrades and downgrades included Biogen, Cirrus Logic, Delta Air Lines, Lennar, Match, Occidental Petroleum, Tupperware and United Airlines.", "url": "https://finnhub.io/api/news?id=27d649ce2c4fb53d27049832f28a8f7aa946fdf034040b5a3dc296b88c8dc07b"}, {"category": "company", "datetime": 1623995280, "headline": "Abiomed initiated with a Buy at Deutsche Bank", "id": 68351479, "image": "", "related": "ABMD", "source": "Thefly.com", "summary": "Abiomed initiated with a Buy at Deutsche Bank Deutsche Bank ABMD", "url": "https://finnhub.io/api/news?id=b87a05465039aae26c1b3ed009a1e462344437b504784b78468e61df41b3f9df"}, {"category": "company", "datetime": 1623988920, "headline": "Abiomed confident in near-term business recovery, says Piper Sandler", "id": 68351480, "image": "", "related": "ABMD", "source": "Thefly.com", "summary": "Abiomed confident in near-term business recovery, says Piper Sandler Piper Sandler ABMD", "url": "https://finnhub.io/api/news?id=48c98ed31c4afcd577e46ae24ddcee6100dc1069fbbfec0f9e5c2d9828865e14"}, {"category": "company", "datetime": 1623988560, "headline": "U.S. stocks lower at close of trade; Dow Jones Industrial Average down 1.58% By Investing.com", "id": 68361440, "image": "https://i-invdn-com.investing.com/news/a3d12ec27fa0e3457d56abfdb5654300_L.jpg", "related": "ABMD", "source": "Investing.com", "summary": "U.S. stocks lower at close of trade; Dow Jones Industrial Average down 1.58%", "url": "https://finnhub.io/api/news?id=85a6a229469e47dfec7f092f5e16bcfaff3f887c25029a4e742f9cd0e139a71d"}, {"category": "company", "datetime": 1623947580, "headline": "Abiomed Inc. stock outperforms competitors on strong trading day", "id": 68348467, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. rose 3.07% to $312.61 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index...", "url": "https://finnhub.io/api/news?id=982cca3c3395b786da80d3dd8c4b839d4b38e1f80db9131c90f452ba398bec3b"}, {"category": "company", "datetime": 1623861180, "headline": "Abiomed Inc. stock outperforms market on strong trading day", "id": 68348468, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. inched 0.52% higher to $303.30 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the S&P...", "url": "https://finnhub.io/api/news?id=2dbe75b584cd160f29ccd7118429278f7ad1b05f94acea49683bb127e931f1ec"}, {"category": "company", "datetime": 1623774780, "headline": "Abiomed Inc. stock underperforms Tuesday when compared to competitors", "id": 68348469, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. dropped 0.38% to $301.72 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500...", "url": "https://finnhub.io/api/news?id=936467b635e09d5acc337a791620214d90e22a67bea26d56d30b790fba387991"}, {"category": "company", "datetime": 1623741180, "headline": "Abiomed management to meet virtually with Piper Sandler", "id": 68283539, "image": "", "related": "ABMD", "source": "Thefly.com", "summary": "Abiomed management to meet virtually with Piper Sandler ABMD", "url": "https://finnhub.io/api/news?id=6aa2d20faec8a0c78f9512c333ce49d9b2e07e418bf9ad3d038a8359ab7baf90"}, {"category": "company", "datetime": 1623734091, "headline": "What Does Abiomed, Inc.'s (NASDAQ:ABMD) Share Price Indicate?", "id": 68281098, "image": "https://s.yimg.com/uu/api/res/1.2/8.7wAmlAutGU5iXFvarF9A--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/542f5a72d5758cc977dad831c5295870", "related": "ABMD", "source": "Yahoo", "summary": "Abiomed, Inc. ( NASDAQ:ABMD ) saw a decent share price growth in the teens level on the NASDAQGS over the last few...", "url": "https://finnhub.io/api/news?id=aef9706a3f0e4f9e7b8d34c68b8110c0990b86532d7e7fa3e58006a57bdddd1c"}, {"category": "company", "datetime": 1623688380, "headline": "Abiomed Inc. stock outperforms competitors on strong trading day", "id": 68348470, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. rallied 1.23% to $302.87 Monday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index...", "url": "https://finnhub.io/api/news?id=eca5c1e548a193351b84b29f19f8f595199e3c90525c65fadf115df00ceddbf5"}, {"category": "company", "datetime": 1623658040, "headline": "The Math Shows FXH Can Go To $129", "id": 68372048, "image": "https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?1048961592", "related": "ABMD", "source": "Nasdaq", "summary": "Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itsel", "url": "https://finnhub.io/api/news?id=49b9b95e691166ec81369695b4bca47a8a14fe85be94200b1d85c2ce726b3f7f"}, {"category": "company", "datetime": 1623256380, "headline": "Abiomed Inc. stock outperforms market on strong trading day", "id": 68138093, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. rose 1.61% to $293.82 Wednesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index...", "url": "https://finnhub.io/api/news?id=d9a34e91462597cd91568aead6a1d0277ab0b4902bf3fdec89307cf61ab7cdb0"}, {"category": "company", "datetime": 1623169920, "headline": "Abiomed Inc. stock underperforms Tuesday when compared to competitors", "id": 68138097, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. dropped 0.68% to $289.17 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500...", "url": "https://finnhub.io/api/news?id=2cb5febde9fee2f25b6a72ade41ec455a22e21b692c0e13bff29daf3b323ecbb"}, {"category": "company", "datetime": 1623165929, "headline": "Tuesday Sector Laggards: Utilities, Healthcare", "id": 68355197, "image": "https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?1315584564", "related": "ABMD", "source": "Nasdaq", "summary": "The worst performing sector as of midday Tuesday is the Utilities sector, showing a 0.7% loss.  Within that group, CMS Energy Corp (Symbol: CMS) and American Electric Power Co Inc (Symbol: AEP) are two of the day's laggards, showing a loss of 4.5% and 2.5%, respectively.  Among", "url": "https://finnhub.io/api/news?id=d116ce87efd31e17b2dec6449bf557367bb82a80d815807a47097dae82b2b802"}, {"category": "company", "datetime": 1623152940, "headline": "Tweet suggests Abiomed study trending in right direction, says Piper Sandler", "id": 68072016, "image": "", "related": "ABMD", "source": "Thefly.com", "summary": "Tweet suggests Abiomed study trending in right direction, says Piper Sandler Piper Sandler ABMD", "url": "https://finnhub.io/api/news?id=d6b83dfe8b9740d9c3ab4ba5f5529f30b4de125f420664fa2f2a4e1a77d869ab"}, {"category": "company", "datetime": 1623083580, "headline": "Abiomed Inc. stock outperforms market on strong trading day", "id": 68138099, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. inched 0.57% higher to $291.15 Monday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500...", "url": "https://finnhub.io/api/news?id=1173275c4ed2a2d718f6fd06d2d18c9742b42362f919f315fcad1be6cb0c911c"}, {"category": "company", "datetime": 1622862782, "headline": "Returns On Capital At Abiomed (NASDAQ:ABMD) Have Hit The Brakes", "id": 68372050, "image": "https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?1741535651", "related": "ABMD", "source": "Nasdaq", "summary": "If we want to find a potential multi-bagger, often there are underlying trends that can provide clues.  One common approach is to try and find a company with returns on capital employed (ROCE) that are increasing, in conjunction with a growing amount of capital employed.  Put si", "url": "https://finnhub.io/api/news?id=4b55ec14b37ccf48b519f95f677aa38f5a5c9a28b791db4b692ca20a45c8caef"}, {"category": "company", "datetime": 1622731202, "headline": "Abiomed's (ABMD) preCARDIA Buyout Expands Its Product Portfolio", "id": 68089121, "image": "https://s.yimg.com/uu/api/res/1.2/Bwjibxk8IIsM7dLPsV1mcQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/08380da297340a988e9902fee4e753cb", "related": "ABMD", "source": "Yahoo", "summary": "Abiomed's (ABMD) latest acquisition is expected to improve patient outcome as well as lower the cost of care.", "url": "https://finnhub.io/api/news?id=a57a3b04c6577844f80f8aa5c6ea0f2079e92e0b49a178515b06193be51f0e3d"}, {"category": "company", "datetime": 1622577300, "headline": "Harding Loevner Global Small Companies Equity Q1 2021 Letter", "id": 67961608, "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png", "related": "ABMD", "source": "SeekingAlpha", "summary": "Harding Loevner is an investment manager that invests primarily in publicly traded global equities. We were founded in 1989 by former managers for the Rockefeller family.", "url": "https://finnhub.io/api/news?id=79ef746ad5ba7fd5b820aa809412353e057b27f40f26027dca91017672f4e2c0"}, {"category": "company", "datetime": 1622548980, "headline": "Abiomed Acquires preCARDIA, a Breakthrough Medical Device Company, to Improve Outcomes for Heart Failure Patients", "id": 68089123, "image": "https://s.yimg.com/uu/api/res/1.2/uqCWcg7nJiL22ozfTt4NKg--~B/aD04MTt3PTE0NDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/e5557a8131c08f3bc71ff9aba3b5cfcc", "related": "ABMD", "source": "Yahoo", "summary": "Abiomed (NASDAQ: ABMD) has acquired preCARDIA, developer of a proprietary catheter and controller that will complement Abiomed\u2019s product portfolio to expand options for patients with acute decompensated heart failure (ADHF). The preCARDIA system is uniquely designed to rapidly treat ADHF-related volume overload by effectively reducing cardiac filling pressures and promoting decongestion to improve overall cardiac and renal function.", "url": "https://finnhub.io/api/news?id=0f6de5b76d73802030dab85e3e8f933bec3dc41643c3ff56b91a40baced687bf"}, {"category": "company", "datetime": 1621940400, "headline": "Abiomed to Present at Upcoming Investor Conferences", "id": 68089125, "image": "https://s.yimg.com/uu/api/res/1.2/UE23xCgH.x6OdzvKkpCWWA--~B/aD0xNTQ7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/cc815f714499a1a7aefc6e6464abc68e", "related": "ABMD", "source": "Yahoo", "summary": "Abiomed to present at William Blair\u2019s 41st Annual Growth Stock Conference and the Jefferies Virtual Healthcare Conference.", "url": "https://finnhub.io/api/news?id=0bd5195a61448b949003a2abdd9174a885c02867611834c705522251e4b08a0e"}, {"category": "company", "datetime": 1621937520, "headline": "Sands Capital Cuts Adobe, Amazon", "id": 67919951, "image": "", "related": "ABMD", "source": "GuruFocus", "summary": "GuruFocus Article or News written by Tiziano Frateschi and the topic is about: Firm's largest sales of the 1st quarter", "url": "https://finnhub.io/api/news?id=35a0ac8bc816742ebdf162b70efb740c4bc66acb4885fb9a334a5033a238c8d5"}, {"category": "company", "datetime": 1621926000, "headline": "Abiomed to Present at Upcoming Investor Conferences", "id": 67919952, "image": "", "related": "ABMD", "source": "Business Wire", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.", "url": "https://finnhub.io/api/news?id=128acc855006566abbd055c697ea4130ad657536b660d402d1e7cb6a9dd909bb"}, {"category": "company", "datetime": 1621148952, "headline": "Shareholders Are Thrilled That The Abiomed (NASDAQ:ABMD) Share Price Increased 176%", "id": 67867819, "image": "", "related": "ABMD", "source": "Yahoo", "summary": "It might be of some concern to shareholders to see the Abiomed, Inc. ( NASDAQ:ABMD ) share price down 20% in the last...", "url": "https://finnhub.io/api/news?id=ddcc59113eb1de8dc8bfbbd2d6faa20c79a4b20485234d7875a3c9d9d93b4409"}, {"category": "company", "datetime": 1621009980, "headline": "Abiomed Inc. stock rises Friday, outperforms market", "id": 67852113, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. rose 2.23% to $268.56 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500...", "url": "https://finnhub.io/api/news?id=0f783320a5007172bf3111f846bd475176573d7c1c21981f55098c56c03419e0"}, {"category": "company", "datetime": 1620923580, "headline": "Abiomed Inc. stock falls Thursday, underperforms market", "id": 67852114, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. slid 3.50% to $262.71 Thursday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...", "url": "https://finnhub.io/api/news?id=4c56a9299a94484e8f9ccbce19c7aabc2827873e0dc45c04fc4646d05e667cb6"}, {"category": "company", "datetime": 1620886380, "headline": "Abiomed Stock Is Believed To Be Modestly Undervalued", "id": 67820129, "image": "", "related": "ABMD", "source": "GuruFocus", "summary": "GuruFocus Article or News written by GF Value and the topic is about: ", "url": "https://finnhub.io/api/news?id=aa71c06a82fbd02bf611f3a2122b0c4aaaf22b7e1bd07d9cc7fa5acda0bd282b"}, {"category": "company", "datetime": 1620873540, "headline": "William Blair Investment Management, Llc Buys Charles River Laboratories International Inc, ...", "id": 67808355, "image": "", "related": "ABMD", "source": "GuruFocus", "summary": "GuruFocus Article or News written by insider and the topic is about: ", "url": "https://finnhub.io/api/news?id=546ea5546cff221d025d8bd022e04b46e7a85343b948b6ddd4c0066a8cae4138"}, {"category": "company", "datetime": 1620837180, "headline": "Abiomed Inc. stock underperforms Wednesday when compared to competitors", "id": 67805300, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. shed 2.87% to $272.25 Wednesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index...", "url": "https://finnhub.io/api/news?id=7ee152bdc1e8f61e26e991e3c81c8d4128a88a7b1ba599c746f80948315c91cd"}, {"category": "company", "datetime": 1620820754, "headline": "Relative Strength Alert For ABIOMED", "id": 67780719, "image": "https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?1733389833", "related": "ABMD", "source": "Nasdaq", "summary": "Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful.  One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which m", "url": "https://finnhub.io/api/news?id=969b6ba61dbc20b44474bb1f1e8ee105cbf452a79e09098c0c4598afb91868f5"}, {"category": "company", "datetime": 1620750780, "headline": "Abiomed Inc. stock outperforms market despite losses on the day", "id": 67805301, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. dropped 0.86% to $280.30 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index...", "url": "https://finnhub.io/api/news?id=ea243d0636c325f5ff9f027ebf1a444ed34c488c9f980b1f815d897300ad2530"}, {"category": "company", "datetime": 1620729600, "headline": "Avoid the Dogecoin Crash by Buying These 2 Growth Stocks Instead", "id": 67744100, "image": "", "related": "ABMD", "source": "Yahoo", "summary": "Dogecoin may be breaking its all-time highs every other day, but there's nothing averting a catastrophic fall.", "url": "https://finnhub.io/api/news?id=0e199e31a5077e9d91381db31aaffdd1c01c5df67290fdafe7a35c52f06dcc3f"}, {"category": "company", "datetime": 1620718487, "headline": "Look Under The Hood: QQQJ Has 18% Upside", "id": 67740489, "image": "https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?1357963389", "related": "ABMD", "source": "Nasdaq", "summary": "Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itsel", "url": "https://finnhub.io/api/news?id=483e8bed83791581a304670b3dbc06254a462574cacfc9bce54f1971220576f9"}, {"category": "company", "datetime": 1620715200, "headline": "Avoid the Dogecoin Crash by Buying These 2 Growth Stocks Instead", "id": 67738224, "image": "https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?410538303", "related": "ABMD", "source": "Nasdaq", "summary": "If you want to send someone on a wild goose chase, send them to find a serious investor who's willing to state on the record that Dogecoin (CRYPTO: DOGE) is a surefire long-term investment. Dogecoin may be fun to buy, but it's unlikely be popular forever, and there's next to zero", "url": "https://finnhub.io/api/news?id=bf248652856a5d1903f188aeee3567fe3c5605061327b637e98b1b141199dde0"}, {"category": "company", "datetime": 1620664380, "headline": "Abiomed Inc. stock underperforms Monday when compared to competitors", "id": 67805303, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. slid 4.75% to $282.72 Monday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index...", "url": "https://finnhub.io/api/news?id=7858c9ec0ec67f54f75a2362d101a4b2a57e3ba02e01b078b9f6e7965a13ca04"}, {"category": "company", "datetime": 1620657215, "headline": "Monday Sector Laggards: Technology & Communications, Healthcare", "id": 67718772, "image": "https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?1514938217", "related": "ABMD", "source": "Nasdaq", "summary": "The worst performing sector as of midday Monday is the Technology & Communications sector, showing a 1.3% loss.  Within the sector, Qorvo Inc (Symbol: QRVO) and Monolithic Power Systems Inc (Symbol: MPWR) are two of the day's laggards, showing a loss of 6.8% and 5.9%, respe", "url": "https://finnhub.io/api/news?id=74850d4ae644cdbd7989660e24bee0667fe9e412c2e1e3c6b19223e8f6d14ae1"}, {"category": "company", "datetime": 1620405180, "headline": "Abiomed Inc. stock rises Friday, still underperforms market", "id": 67692925, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. inched 0.37% higher to $296.81 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P...", "url": "https://finnhub.io/api/news?id=d25828ae0da185dba16bbd9f2b3c06f57336447dfc981021544d78e250b1c9b6"}, {"category": "company", "datetime": 1620318780, "headline": "Abiomed Inc. stock falls Thursday, underperforms market", "id": 67692926, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. slid 1.69% to $295.72 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500...", "url": "https://finnhub.io/api/news?id=0ca216b8b36a3c52aa1c4d32e289e6b563b7372a74f1e723a1b057627e11a452"}, {"category": "company", "datetime": 1620293940, "headline": "Abiomed could face new competition from Boston Scientific, says Raymond James", "id": 67626840, "image": "", "related": "ABMD", "source": "Thefly.com", "summary": "Abiomed could face new competition from Boston Scientific, says Raymond James Raymond James BSX ABMD", "url": "https://finnhub.io/api/news?id=d5edecf4dbfc2e21323a67d0f862e3cdcdc6d4928548021d88e3d098caa978be"}, {"category": "company", "datetime": 1620232380, "headline": "Abiomed Inc. stock underperforms Wednesday when compared to competitors", "id": 67692927, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. shed 1.38% to $300.79 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...", "url": "https://finnhub.io/api/news?id=da64bc058466e708421c311dbd2cb21f97d4c27637426c59b26e028e0c03956a"}, {"category": "company", "datetime": 1620213859, "headline": "ABMD Crosses Below Key Moving Average Level", "id": 67606104, "image": "https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?953625636", "related": "ABMD", "source": "Nasdaq", "summary": "In trading on Wednesday, shares of ABIOMED, Inc. (Symbol: ABMD) crossed below their 200 day moving average of $300.26, changing hands as low as $299.76 per share.  ABIOMED, Inc. shares are currently trading down about 1.1% on the day.  The chart below shows the one year perform", "url": "https://finnhub.io/api/news?id=3b699627695a74160cb3996a3edce73e0b904a8ff6b0aed2114146c40476d03c"}, {"category": "company", "datetime": 1620210240, "headline": "ABMD Crosses Below Key Moving Average Level", "id": 67591466, "image": "", "related": "ABMD", "source": "Market News Video", "summary": "In trading on Wednesday, shares of ABIOMED, Inc - (ABMD) crossed below their 200 day moving average of $300.26, changing hands as low as $299.76 per share. - ABMD.", "url": "https://finnhub.io/api/news?id=273b99c34f657adc2ce3d70d47f1aadf0d439aa258f608186f433b59f8466b48"}, {"category": "company", "datetime": 1620145980, "headline": "Abiomed Inc. stock falls Tuesday, underperforms market", "id": 67498823, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. shed 1.18% to $305.00 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones...", "url": "https://finnhub.io/api/news?id=8b6a0b4ced32137c035437cc853308ef85cb5d2f15b58b6f1106f59198c5cbbd"}, {"category": "company", "datetime": 1620134161, "headline": "New Strong Sell Stocks for May 4th", "id": 67452742, "image": "https://s.yimg.com/uu/api/res/1.2/kr_HT6.35NDiR7sMr0eS1g--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4d1fa526b488a2eff982103dbea1e25d", "related": "ABMD", "source": "Yahoo", "summary": "ABMD, CLMT, FLMN, GRUB, and IHG have been added to the Zacks Rank #5 (Strong Sell) List on May 4, 2021", "url": "https://finnhub.io/api/news?id=63b78eb753ec8af7bd19f3b744665141c6cb40fbf8f19a246fb71560ef61bec5"}, {"category": "company", "datetime": 1620128700, "headline": "Abiomed to Shareholders: Patience Please, Growth Is On The Way.", "id": 67446744, "image": "", "related": "ABMD", "source": "Yahoo", "summary": "Despite record revenue for its latest quarter, the medical device maker's shares sank 8% following its earnings release. But its next stage of growth is coming.", "url": "https://finnhub.io/api/news?id=abb75aca2c384d7deef79fc12e0a65441fe0093617fae09fcee3f34b3f2336a8"}, {"category": "company", "datetime": 1620123300, "headline": "The End of the Pandemic Will Mean a Major Boost for These 2 Buy-and-Hold Stalwarts", "id": 67441725, "image": "", "related": "ABMD", "source": "Yahoo", "summary": "It's no secret that in-person medical appointments are hard to come by in the age of COVID-19. But now that the U.S. appears to be getting the pandemic under control, people are eagerly flocking back to the clinic for everything they've put off, from dental cleanings to heart surgery.", "url": "https://finnhub.io/api/news?id=3cdbcea79e903c2e5ab779f1ee01413caaca0781813716a131cd327a3d1badfd"}, {"category": "company", "datetime": 1620114300, "headline": "Abiomed to Shareholders: Patience Please, Growth Is On The Way.", "id": 67446338, "image": "https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?602527034", "related": "ABMD", "source": "Nasdaq", "summary": "Abiomed (NASDAQ: ABMD) reported its fiscal 2021 fourth-quarter earnings last week, with 17% year-over-year revenue growth of $243 million for the quarter. For many mature medical device companies, this would be a fantastic result. Unfortunately, for the full fiscal year, revenue", "url": "https://finnhub.io/api/news?id=a97d882cad2908b5a39c87bfcaa15ecaec4b049d2d75beb649ea09b37167304b"}, {"category": "company", "datetime": 1620108900, "headline": "The End of the Pandemic Will Mean a Major Boost for These 2 Buy-and-Hold Stalwarts", "id": 67442526, "image": "https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?1067594483", "related": "ABMD", "source": "Nasdaq", "summary": "It's no secret that in-person medical appointments are hard to come by in the age of COVID-19. But now that the U.S. appears to be getting the pandemic under control, people are eagerly flocking back to the clinic for everything they've put off, from dental cleanings to heart sur", "url": "https://finnhub.io/api/news?id=df0ccb2b300301d8f074765f0b2841857f7b1bce122f313784cc371723555267"}, {"category": "company", "datetime": 1620059580, "headline": "Abiomed Inc. stock falls Monday, underperforms market", "id": 67498826, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. slipped 3.77% to $308.64 Monday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index...", "url": "https://finnhub.io/api/news?id=561fbbe1de04f630664bc145ae8b871e52726f05c5e064d9f6ad1117b584b0a3"}, {"category": "company", "datetime": 1620014220, "headline": "U.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.70% By Investing.com", "id": 67377924, "image": "https://i-invdn-com.akamaized.net/news/LYNXMPEB4I0NH_L.jpg", "related": "ABMD", "source": "Investing.com", "summary": "U.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.70%", "url": "https://finnhub.io/api/news?id=48723d797b07efff31df6a963e8af80c5be8cd8e09dc82d7ef9cbf1f03d497e0"}, {"category": "company", "datetime": 1619800380, "headline": "Abiomed Inc. stock outperforms competitors despite losses on the day", "id": 67193860, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. sank 0.68% to $320.73 Friday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index...", "url": "https://finnhub.io/api/news?id=4f01b57701f7e75e75ab530d79d088f17633efd01207cfe279145e2efeee0ca8"}, {"category": "company", "datetime": 1619784240, "headline": "The Eaton Vance Fund sells Novartis, Pfizer", "id": 67161585, "image": "", "related": "ABMD", "source": "GuruFocus", "summary": "GuruFocus Article or News written by Tiziano Frateschi and the topic is about: Firm's largest sales of the 1st quarter", "url": "https://finnhub.io/api/news?id=f79fc81125a070f42e5db67d78bba31bb97592a36b768d6754466b34618b58a2"}, {"category": "company", "datetime": 1619780400, "headline": "Validea Peter Lynch Strategy Daily Upgrade Report - 4/30/2021", "id": 67144816, "image": "https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?2061510639", "related": "ABMD", "source": "Nasdaq", "summary": "The following are today's upgrades for Validea's P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relative to earnings growth that also possess strong balance sheets.ABIOMED, INC. (ABMD) is a la", "url": "https://finnhub.io/api/news?id=9fc7297a72bf15df4812fa7a51fa90b99fb17030ce33e2fc6a3a98a5870fa198"}, {"category": "company", "datetime": 1619718185, "headline": "ABIOMED (ABMD) Earnings and Revenues Beat Estimates in Q4", "id": 67133241, "image": "https://s.yimg.com/uu/api/res/1.2/Bwjibxk8IIsM7dLPsV1mcQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/08380da297340a988e9902fee4e753cb", "related": "ABMD", "source": "Yahoo", "summary": "ABIOMED's (ABMD) international and U.S. Impella revenues improve in Q4.", "url": "https://finnhub.io/api/news?id=6126dd8b1df043d1c32f9b71858452421630ac42241cb1c1b04e8e3913c1b7a9"}, {"category": "company", "datetime": 1619717456, "headline": "Abiomed Inc (ABMD) Q4 2021 Earnings Call Transcript", "id": 67133242, "image": "https://s.yimg.com/uu/api/res/1.2/zmj.74VZmDKFyMQXCAbujg--~B/aD0xNDk0O3c9MTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/motleyfool.com/e48e86dda35543079ee2080fd9208b73", "related": "ABMD", "source": "Yahoo", "summary": "ABMD earnings call for the period ending March 31, 2021.", "url": "https://finnhub.io/api/news?id=a0ff8a10e59b0b47cf6570252a169bdb37a1b859c3f372c7700c0ffc4ad24108"}, {"category": "company", "datetime": 1619713980, "headline": "Abiomed Inc. stock underperforms Thursday when compared to competitors", "id": 67135000, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. slid 8.04% to $322.94 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500...", "url": "https://finnhub.io/api/news?id=8e11040b1230f3536964a77010174e4e686b56a3e3f783e4da2dca65213672ff"}, {"category": "company", "datetime": 1619706755, "headline": "Thursday Sector Laggards: Healthcare, Technology & Communications", "id": 67122571, "image": "https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?235033591", "related": "ABMD", "source": "Nasdaq", "summary": "The worst performing sector as of midday Thursday is the Healthcare sector, showing a 0.8% loss.  Within the sector, ABIOMED, Inc. (Symbol: ABMD) and Hologic Inc (Symbol: HOLX) are two large stocks that are lagging, showing a loss of 8.0% and 7.8%, respectively.  Among healthca", "url": "https://finnhub.io/api/news?id=b301416ecd85f7c97b7d0860e3f10285d8e698dffc8999dc588e431ddbf109ab"}, {"category": "company", "datetime": 1619705440, "headline": "Abiomed's (ABMD) CEO Mike Minogue on Q4 2021 Results - Earnings Call Transcript", "id": 67117855, "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png", "related": "ABMD", "source": "SeekingAlpha", "summary": "Abiomed, Inc. (NASDAQ:ABMD) Q4 2021 Earnings Conference Call April 29, 2021 8:00 AM ET Company Participants Todd Trapp \u2013 Vice President and Chief Financial Officer Mike Minogue \u2013 Chairman,...", "url": "https://finnhub.io/api/news?id=e96c35ec2b24185a48264e1692f1b48e777a8a83d903fcbdc6c2d73fdd715419"}, {"category": "company", "datetime": 1619703056, "headline": "Abiomed Inc (ABMD) Q4 2021 Earnings Call Transcript", "id": 67124926, "image": "https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?1453792229", "related": "ABMD", "source": "Nasdaq", "summary": "Image source: The Motley Fool.", "url": "https://finnhub.io/api/news?id=f7c6bd27e1d43c4b3cb054c833affa7b4c1b5e2c4acf447380669bc454217635"}, {"category": "company", "datetime": 1619700312, "headline": "Abiomed (ABMD) Q4 Earnings and Revenues Surpass Estimates", "id": 67112228, "image": "https://s.yimg.com/uu/api/res/1.2/9naTdeJlVMX28sdlDpLdrQ--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ac90b3d74679f6d01a122aa033d8a9a4", "related": "ABMD", "source": "Yahoo", "summary": "Abiomed (ABMD) delivered earnings and revenue surprises of 12.73% and 4.72%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?", "url": "https://finnhub.io/api/news?id=ca541f9e8525bcff891cc34b9d6706052441ee19b7b905428679d1195dd25d45"}, {"category": "company", "datetime": 1619699940, "headline": "Abiomed earnings selloff a buying opportunity, says Piper Sandler", "id": 67118609, "image": "", "related": "ABMD", "source": "Thefly.com", "summary": "Abiomed earnings selloff a buying opportunity, says Piper Sandler Piper Sandler ABMD", "url": "https://finnhub.io/api/news?id=96724dace516f3019918168c191358e0a139fb8e5a7f21b2c1439ef6e7ba0920"}, {"category": "company", "datetime": 1619694614, "headline": "Abiomed, Inc. 2021 Q4 - Results - Earnings Call Presentation", "id": 67113598, "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png", "related": "ABMD", "source": "SeekingAlpha", "summary": "The following slide deck was published by Abiomed, Inc. in conjunction with their 2021 Q4 earnings call.", "url": "https://finnhub.io/api/news?id=0c88265cfec326e57781032b3c4f4df01ec22743dc3fdf6bce90501288dab384"}, {"category": "company", "datetime": 1619694000, "headline": "Abiomed Announces Record Revenue of $241 Million, up 17% Year Over Year, With 26.0% Operating Margin", "id": 67112229, "image": "https://s.yimg.com/uu/api/res/1.2/0B0zCa4aUjfBl4rrebhdFw--~B/aD0xNTQ7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/ff148e3d38a838153b30ad5fdf2612a3", "related": "ABMD", "source": "Yahoo", "summary": "Abiomed announces record revenue of $241 million , up 17% year over year, with 26.0% operating margin.", "url": "https://finnhub.io/api/news?id=eeb413a841dc96d0c7f478a6e20fcb14a451c85d721358ecade0ee74508824a7"}, {"category": "company", "datetime": 1619689500, "headline": "ABIOMED, Inc. to Host Earnings Call", "id": 67112230, "image": "https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png", "related": "ABMD", "source": "Yahoo", "summary": "NEW YORK, NY / ACCESSWIRE / April 29, 2021 / ABIOMED, Inc. (NASDAQ:ABMD) will be discussing their earnings results in their 2021 Fourth Quarter Earnings call to be held on April 29, 2021 at 8:00 AM Eastern Time.", "url": "https://finnhub.io/api/news?id=3fc5656fa86ea48a998eae49c88845c23c456538b78b9fc558a721067b631199"}, {"category": "company", "datetime": 1619684100, "headline": "The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx", "id": 67114627, "image": "https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/nerve-cell-2213009_1920_25.jpg", "related": "ABMD", "source": "Benzinga", "summary": "Here's a roundup of top developments in the biotech space over the last 24 hours:\nScaling The Peaks\n(Biotech Stocks Hitting 52-week Highs April 28)\n\nAxonics, Inc. (NASDAQ:...", "url": "https://finnhub.io/api/news?id=6806a6eb1696b3877747d836ffe30d3c896546e7a9bcd241efeee5c7e9857e8f"}, {"category": "company", "datetime": 1619682240, "headline": "Abiomed: Fiscal Q4 Earnings Snapshot", "id": 67113814, "image": "", "related": "ABMD", "source": "Associated Press, The", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.", "url": "https://finnhub.io/api/news?id=edef04637a99abad60483677fcc7fb5b42a5e84b35d2c6f175bc8f919ebd5981"}, {"category": "company", "datetime": 1619680606, "headline": "Abiomed Inc. Q4 Earnings Climb", "id": 67111570, "image": "https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?1317008283", "related": "ABMD", "source": "Nasdaq", "summary": "(RTTNews) - Abiomed Inc. (ABMD) announced a profit for its fourth quarter that climbed from the same period last year.The company's bottom line totaled $56.86 million, or $1.24 per share.  This compares with $31.80 million, or $0.70 per share, in last year's fourth quarter.", "url": "https://finnhub.io/api/news?id=050420aa83d770a1998bcc5941b4a22f4b52283725a1a92daae17dc470066868"}, {"category": "company", "datetime": 1619679615, "headline": "Abiomed Q4 21 Earnings Conference Call At 8:00 AM ET", "id": 67111571, "image": "https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?897255751", "related": "ABMD", "source": "Nasdaq", "summary": "(RTTNews) - Abiomed Inc. (ABMD) will host a conference call at 8:00 AM ET on April 29, 2021, to discuss Q4 21 earnings results.To access the live webcast, log on to https://edge.media-server.com/mmc/p/u4c589ep", "url": "https://finnhub.io/api/news?id=da28ffab2003975f9dfb17003d48885a98280ab997d23e3acc1f284e74b0fc52"}, {"category": "company", "datetime": 1619679600, "headline": "Abiomed Announces Record Revenue of $241 Million, up 17% Year Over Year, With 26.0% Operating Margin", "id": 67113815, "image": "", "related": "ABMD", "source": "Business Wire", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.", "url": "https://finnhub.io/api/news?id=06f1c6689d399f1a7416fe828e8421d22a51e644318cf4f961382e7b6ae869b8"}, {"category": "company", "datetime": 1619678040, "headline": "Abiomed sees FY22 revenue $990M-$1.03B, consensus $998.13M", "id": 67113816, "image": "", "related": "ABMD", "source": "Thefly.com", "summary": "Abiomed sees FY22 revenue $990M-$1.03B, consensus $998.13M ABMD", "url": "https://finnhub.io/api/news?id=d326878794fc095feb1d3b921ed279e64a83765d10122b6b4f0b18e8733eea1c"}, {"category": "company", "datetime": 1619677860, "headline": "Abiomed reports Q4 EPS $1.24, consensus $1.10", "id": 67113817, "image": "", "related": "ABMD", "source": "Thefly.com", "summary": "Abiomed reports Q4 EPS $1.24, consensus $1.10 ABMD", "url": "https://finnhub.io/api/news?id=f71e9545859bad448725d25247dddeea9ec9e2751dbd656936b3d37529851f48"}, {"category": "company", "datetime": 1619659920, "headline": "Thursday Sector Laggards: Healthcare, Technology & Communications", "id": 67120093, "image": "", "related": "ABMD", "source": "Market News Video", "summary": "", "url": "https://finnhub.io/api/news?id=c98d233a8d98fbbe7e798a3b4f364fb01d23b2ad532625530e09952b18cd82fd"}, {"category": "company", "datetime": 1619639820, "headline": "Final Results from the National Cardiogenic Shock Initiative (NCSI) Study Demonstrate the Benefit of Early Cardiac Unloading with Impella", "id": 67003240, "image": "https://s.yimg.com/uu/api/res/1.2/mRRz4K8Dgru2bTMKrOu5kQ--~B/aD0yOTk7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/6a70cd85b317ef070a1feda94a23a214", "related": "ABMD", "source": "Yahoo", "summary": "The final results of the physician-led National Cardiogenic Shock Initiative (NCSI) Study demonstrate a 71% survival to discharge with greater than 90% native heart recovery when best practices are used, including placement of an Impella heart pump prior to revascularization (PCI). The study evaluated the outcomes of 406 consecutive patients who presented with acute myocardial infarction cardiogenic shock (AMICS) at 80 participating sites throughout the United States. The study shows a protocol-based approach to increasing survival rates in cardiogenic shock is reproducible in both academic and community hospital settings. Results were presented today by Babar Basir, DO, director of the acute mechanical circulatory support program at Henry Ford Hospital and co-principal investigator of the study, at the 2021 Society of Cardiovascular Angiography & Interventions (SCAI) Scientific Sessions.", "url": "https://finnhub.io/api/news?id=b1c756407a123a332b294f8be20abc8b87267687284c75e423bb536b6db484d8"}, {"category": "company", "datetime": 1619627580, "headline": "Abiomed Inc. stock underperforms Wednesday when compared to competitors despite daily gains", "id": 67025622, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. rose 3.09% to $351.17 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index...", "url": "https://finnhub.io/api/news?id=02a4751ee293b582097e002355fa82ace3e588944e56d64ee4eb219a9bef94b7"}, {"category": "company", "datetime": 1619625420, "headline": "Final Results from the National Cardiogenic Shock Initiative (NCSI) Study Demonstrate the Benefit of Early Cardiac Unloading with Impella", "id": 67007282, "image": "", "related": "ABMD", "source": "Business Wire", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.", "url": "https://finnhub.io/api/news?id=8659c132a5639b7aef6353434e103115f289ed69e473e975c6adeaa0ff01562b"}, {"category": "company", "datetime": 1619611380, "headline": "Dr. Paula A. Johnson Joins Abiomed Board of Directors", "id": 66936482, "image": "https://s.yimg.com/uu/api/res/1.2/pa3uLX3xjqIjWxnHDhVu_w--~B/aD00ODA7dz0zODQ7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/8bb6e1ae0b46ae870bab7c954912bc68", "related": "ABMD", "source": "Yahoo", "summary": "Dr. Paula Johnson joins the Abiomed Board of Directors", "url": "https://finnhub.io/api/news?id=a170ab3128b173ec49f815cda608f28fccf39d6caffec756403a0c5015aedb89"}, {"category": "company", "datetime": 1619596980, "headline": "Dr. Paula A. Johnson Joins Abiomed Board of Directors", "id": 66911814, "image": "", "related": "ABMD", "source": "Business Wire", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.", "url": "https://finnhub.io/api/news?id=ee0e9aeb259d9cf37436911b2ba8f9c9e8f930cf353ef08465b857fda6a8f27a"}, {"category": "company", "datetime": 1619588340, "headline": "Newfound Research LLC Buys JPMorgan U.S. Quality Factor ETF, BTC iShares MSCI USA Min Vol ...", "id": 67042310, "image": "", "related": "ABMD", "source": "GuruFocus", "summary": "GuruFocus Article or News written by insider and the topic is about: ", "url": "https://finnhub.io/api/news?id=4138a4c3c05ae0743f08fae5d2d656104c44adbf96c09ccb980940347d909499"}, {"category": "company", "datetime": 1619541180, "headline": "Abiomed Inc. stock underperforms Tuesday when compared to competitors", "id": 66762716, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. shed 2.17% to $340.63 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones...", "url": "https://finnhub.io/api/news?id=6d590bb6be241f4a14ff277221754ff659f451ad0544c463d6b82a79220eb2b1"}, {"category": "company", "datetime": 1619454780, "headline": "Abiomed Inc. stock outperforms competitors despite losses on the day", "id": 66762721, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. slumped 0.81% to $348.20 Monday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index...", "url": "https://finnhub.io/api/news?id=008cdad15e85793d0b8b7383016348b45b83e2ed99f9994b2cb8ae2ff8bb79f0"}, {"category": "company", "datetime": 1619383727, "headline": "Is ABMD Stock A Buy or Sell?", "id": 66554775, "image": "https://s.yimg.com/uu/api/res/1.2/iV9XnhDcz9n6EeKEHCxH_Q--~B/aD02MDA7dz00NzM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/991824deb0f1e14ba51a47933aa13a23", "related": "ABMD", "source": "Yahoo", "summary": "Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of September. At Insider Monkey, we follow nearly 900 active hedge funds and notable investors and by analyzing their 13F filings, we can determine the stocks that they are [\u2026]", "url": "https://finnhub.io/api/news?id=9ea6a373df4cc62f6edbc01aaf2421816f8d41f2ad330c6c1c929aac4c539f02"}, {"category": "company", "datetime": 1619191503, "headline": "ABIOMED (ABMD) to Report Q4 Earnings: What's in the Cards?", "id": 66554778, "image": "https://s.yimg.com/uu/api/res/1.2/wTHMFcASXFw2GoAQpQr9tw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/3b6072b30ddd43fb75a7496ced0a8833", "related": "ABMD", "source": "Yahoo", "summary": "Strong momentum of ABIOMED's (ABMD) Impella product line, both in Europe and Japan, is expected to have continued in the fiscal fourth quarter as well.", "url": "https://finnhub.io/api/news?id=f37f40e90f0558579eaa2939e617163a84ae90d35d12572b7fdf332e201f1cd2"}, {"category": "company", "datetime": 1619109184, "headline": "Abiomed (ABMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release", "id": 66554779, "image": "https://s.yimg.com/uu/api/res/1.2/t6.OdXEVKQihFo9otNenfg--~B/aD01NjU7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4f1a8d86cead9f96536efb147945dcc9", "related": "ABMD", "source": "Yahoo", "summary": "Abiomed (ABMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.", "url": "https://finnhub.io/api/news?id=507708399ffcaf01170d0c73551e3a0bc53148df645f77778c8752fc599a4491"}, {"category": "company", "datetime": 1619109180, "headline": "Abiomed Inc. stock underperforms Thursday when compared to competitors despite daily gains", "id": 66199109, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. inched 0.22% higher to $343.40 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the S&P...", "url": "https://finnhub.io/api/news?id=7304e0d85302cade18af4548d5532f5e09fcb64adbe75d63e11dd4f5b471735b"}, {"category": "company", "datetime": 1619030372, "headline": "Abiomed: Valuation Drivers Justify The Premium Over Peers", "id": 66189453, "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1255404968/medium_image_1255404968.jpg", "related": "ABMD", "source": "SeekingAlpha", "summary": "Abiomed shares continue their positive outlook, driven by sales momentum in the Impella 5.0 & 5.5 platforms.", "url": "https://finnhub.io/api/news?id=ec8b0aec2f33906e74ee5686cc4148a03e0218d79a91366e60d3350fdb0176f9"}, {"category": "company", "datetime": 1619022780, "headline": "Abiomed Inc. stock outperforms competitors on strong trading day", "id": 66199111, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. advanced 3.80% to $342.64 Wednesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500...", "url": "https://finnhub.io/api/news?id=b8112a49742483ab229f0e1e9ee4d809eecaea8784f42505c4cac0fc95d93c8c"}, {"category": "company", "datetime": 1618936380, "headline": "Abiomed Inc. stock outperforms market on strong trading day", "id": 66199112, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. inched 0.21% higher to $330.10 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500...", "url": "https://finnhub.io/api/news?id=907f1246b94d1833d699338d801800484da07bcdf66ce1343b34b6fb299b167a"}, {"category": "company", "datetime": 1618849980, "headline": "Abiomed Inc. stock outperforms market despite losses on the day", "id": 66199114, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. dropped 0.34% to $329.42 Monday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index...", "url": "https://finnhub.io/api/news?id=f0ac7a19d958502c65a0ab7cfa36c20c60f0aeb3b454adec6838bcf12a0bfa1a"}, {"category": "company", "datetime": 1618590720, "headline": "Abiomed Inc. stock falls Friday, underperforms market", "id": 66163798, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. shed 2.09% to $330.53 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500...", "url": "https://finnhub.io/api/news?id=cf01678d5e743697c086e78fbb2141bda82149c801a6687533c058fea95f37dd"}, {"category": "company", "datetime": 1618554224, "headline": "Is Abiomed, Inc.'s(NASDAQ:ABMD) Recent Stock Performance Tethered To Its Strong Fundamentals?", "id": 66554782, "image": "https://s.yimg.com/uu/api/res/1.2/8.7wAmlAutGU5iXFvarF9A--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/542f5a72d5758cc977dad831c5295870", "related": "ABMD", "source": "Yahoo", "summary": "Abiomed's (NASDAQ:ABMD) stock is up by a considerable 9.4% over the past month. Given the company's impressive...", "url": "https://finnhub.io/api/news?id=a199e24e68fcaa26e1f3c78bea3150effa9d71d0ff2efdbd9f82a20d2755b830"}, {"category": "company", "datetime": 1618504380, "headline": "Abiomed Inc. stock outperforms market on strong trading day", "id": 66163799, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. rose 2.11% to $337.59 Thursday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index...", "url": "https://finnhub.io/api/news?id=8c22550a4c97cde5f5ed400afaf9b7367ed1048050497d3268a83fbbb0a37a66"}, {"category": "company", "datetime": 1618503840, "headline": "UnitedHealth, Abiomed rise; Delta, Virgin Galactic fall", "id": 66267520, "image": "", "related": "ABMD", "source": "Associated Press, The", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.", "url": "https://finnhub.io/api/news?id=d5a15b8a84bb183f48124361c55b75c4885b3401340fe4a2b7398617f84a4dd6"}, {"category": "company", "datetime": 1618488180, "headline": "First Patient Enrolled in PROTECT IV Randomized Controlled Trial of Impella", "id": 66554785, "image": "https://s.yimg.com/uu/api/res/1.2/Z8zjGQpH0vGfeqaCQBCYAg--~B/aD0yNzA7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/b694d94d08fbab97b3b0039d51bbb582", "related": "ABMD", "source": "Yahoo", "summary": "Abiomed (NASDAQ:ABMD) announced today that the first patient has been enrolled in PROTECT IV, a large, prospective, multi-center randomized controlled trial (RCT) that is designed to provide the level of clinical evidence needed to achieve a Class I guideline recommendation for Impella in high-risk percutaneous coronary intervention (HRPCI). The first patient was enrolled at Ascension St. John Hospital in Detroit by Dr. Ted Schreiber, chief of cardiology at Ascension St. John Macomb-Oakland Hospital and Dr. Amir Kaki, interventional cardiologist and director of mechanical circulatory support at Ascension St. John Hospital.", "url": "https://finnhub.io/api/news?id=0a6b1366053053a14ccd2e2613eaffa4043df59148332f75766630b57e4ba5a8"}, {"category": "company", "datetime": 1618473780, "headline": "First Patient Enrolled in PROTECT IV Randomized Controlled Trial of Impella", "id": 66338068, "image": "", "related": "ABMD", "source": "Business Wire", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.", "url": "https://finnhub.io/api/news?id=db321c6a31fb8c3129efbd71aee7810a61fba3c45831ae3f72e3593f41ba30a7"}, {"category": "company", "datetime": 1618470780, "headline": "Abiomed says1st patient enrolled in PROTECT IV RCT of Impella", "id": 66338069, "image": "", "related": "ABMD", "source": "Thefly.com", "summary": "Abiomed says1st patient enrolled in PROTECT IV RCT of Impella ABMD", "url": "https://finnhub.io/api/news?id=24f7e20c89a2df01049c1bb8c5d202b178200a8b5c74637dd5e74b8c1c639225"}, {"category": "company", "datetime": 1618417980, "headline": "Abiomed Inc. stock underperforms Wednesday when compared to competitors despite daily gains", "id": 66146226, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. inched 0.19% higher to $330.60 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow...", "url": "https://finnhub.io/api/news?id=ceebadc835a14656afa80ce3ee2df7417df112644788a9324e37745b05a0f508"}, {"category": "company", "datetime": 1618331580, "headline": "Abiomed Inc. stock underperforms Tuesday when compared to competitors", "id": 66143117, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. slipped 0.94% to $329.97 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500...", "url": "https://finnhub.io/api/news?id=453edfeab2d277a3ed02b7abd837945cd6e6dec8d2f0c5e63edb684d84eb4f18"}, {"category": "company", "datetime": 1618306740, "headline": "Chicago Capital, LLC Buys Lithia Motors Inc, Abiomed Inc, Ligand Pharmaceuticals Inc, Sells ...", "id": 66289124, "image": "https://static.gurufocus.com/photos/gurus/guru_logo_square.jpg", "related": "ABMD", "source": "GuruFocus", "summary": "Chicago Capital, LLC Buys Lithia Motors Inc, Abiomed Inc, Ligand Pharmaceuticals Inc, Sells RealPage Inc, Carvana Co, BlackLine Inc, Stocks: LAD,ABMD,LGND,NFLX,TRU,SPY,TRIP,PLNT,PLTR,BKNG,ESG, release date:Apr 13, 2021", "url": "https://finnhub.io/api/news?id=bf2c04fe4c9d1043973b4af3933d9e0ed61d3732d50da08bb6d7e181ce00c21a"}, {"category": "company", "datetime": 1618245180, "headline": "Abiomed Inc. stock underperforms Monday when compared to competitors", "id": 66143118, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. slumped 0.21% to $333.11 Monday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500...", "url": "https://finnhub.io/api/news?id=45b280ef4836ce775be3c50912b6328139269e78890ca9a5c12ad400980c84e1"}, {"category": "company", "datetime": 1618048800, "headline": "3 Overlooked Healthcare Stocks to Buy Right Now", "id": 66554787, "image": "https://s.yimg.com/uu/api/res/1.2/w3XnfB_QInmvMxtDPfb3Sg--~B/aD05MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/c25bd712d4334d8bf443bfa765bee97e", "related": "ABMD", "source": "Yahoo", "summary": "Here, I'll talk about three overlooked healthcare stocks to buy now for big reward potential well into the future.  Intuitive Surgical (NASDAQ: ISRG) has slipped about 6% since the start of the year.  This leader in robotic surgery holds more than 80% of the global market, a report from Informa Pharma Intelligence shows.", "url": "https://finnhub.io/api/news?id=ad9e18e493fa14dc992f17474fae9422cd7c49b4d005e531c41dec245bde2235"}, {"category": "company", "datetime": 1617985920, "headline": "Abiomed Inc. stock underperforms Friday when compared to competitors despite daily gains", "id": 66112443, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. advanced 1.23% to $333.81 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...", "url": "https://finnhub.io/api/news?id=fd95ebf43a2cdcce3a7309501e12baab5a2fe10816858beebd47e80d05bf969a"}, {"category": "company", "datetime": 1617899580, "headline": "Abiomed Inc. stock rises Thursday, outperforms market", "id": 66109216, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. rallied 2.85% to $329.75 Thursday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...", "url": "https://finnhub.io/api/news?id=dd4517c53e4d1902c4f081fc55b43abb55a2b126eaa2c85aaac035d952424136"}, {"category": "company", "datetime": 1617879600, "headline": "Abiomed Fourth Quarter Fiscal 2021 Earnings and Conference Call Notification", "id": 66554789, "image": "https://s.yimg.com/uu/api/res/1.2/ymYFoxGkjFb80O4VlQh5Ug--~B/aD0xNTQ7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/d9fa5414e4e4ff1b73131c3426a0d177", "related": "ABMD", "source": "Yahoo", "summary": "Abiomed announces that on Thursday, April 29, 2021 the Company will release financial results for the fourth quarter of fiscal 2021.", "url": "https://finnhub.io/api/news?id=722473fcdcc6390e28e294a4ca721cc5261594bd9f54534fd5f20acb766a0bb7"}, {"category": "company", "datetime": 1617869580, "headline": "Abiomed Stock Appears To Be Fairly Valued", "id": 66338071, "image": "https://static.gurufocus.com/photos/gurus/guru_logo_square.jpg", "related": "ABMD", "source": "GuruFocus", "summary": "Abiomed Stock Appears To Be Fairly Valued, Stocks: ABMD, release date:Apr 08, 2021", "url": "https://finnhub.io/api/news?id=099922aebf936cf58998f39f88a0a450afcde2e4b669afd63356f32a76560ece"}, {"category": "company", "datetime": 1617865200, "headline": "Abiomed Fourth Quarter Fiscal 2021 Earnings and Conference Call Notification", "id": 66338072, "image": "", "related": "ABMD", "source": "Business Wire", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.", "url": "https://finnhub.io/api/news?id=b29697e4039cd837ddf9b9423cd923440e3bc90d1fb1dd09fb17dcc64c0b6ae6"}, {"category": "company", "datetime": 1617813180, "headline": "Abiomed Inc. stock falls Wednesday, underperforms market", "id": 66109217, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. dropped 0.93% to $320.62 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...", "url": "https://finnhub.io/api/news?id=1c93e70a7f3160952c46802afcf5cc7531492e5881125d07814f72fba66897fa"}, {"category": "company", "datetime": 1617726780, "headline": "Abiomed Inc. stock rises Tuesday, outperforms market", "id": 66109218, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. inched 0.66% higher to $323.62 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P...", "url": "https://finnhub.io/api/news?id=f57f7a8cc751bbbd372a9a706a70e3ba00503d6774255bc50673859d89b12f4c"}, {"category": "company", "datetime": 1617640380, "headline": "Abiomed Inc. stock outperforms competitors on strong trading day", "id": 66077778, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. rallied 1.95% to $321.50 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...", "url": "https://finnhub.io/api/news?id=7d2e77d2da29a7ffc5d7d5d92f6eafe3c2c0ab63f3340309e5d277f071509af4"}, {"category": "company", "datetime": 1617528281, "headline": "RMR Wealth Builders Has $260,000 Stock Holdings in Abiomed, Inc. (NASDAQ:ABMD)", "id": 66054403, "image": "https://www.marketbeat.com/logos/abiomed-logo.gif", "related": "ABMD", "source": "https://www.thelincolnianonline.com", "summary": "RMR Wealth Builders reduced its stake in Abiomed, Inc. (NASDAQ:ABMD) by 26.7% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 803 shares of the medical equipment provider\u2019s stock after selling 293 shares during the period. RMR Wealth Builders\u2019 holdings in Abiomed were worth [\u2026]", "url": "https://finnhub.io/api/news?id=ce2fb4735b876447dab9f0479b31ea211bcf2596226af5637ba3938783c95d5d"}, {"category": "company", "datetime": 1617446400, "headline": "Buy These 3 Breakout Healthcare Stocks if There's a Sell-Off or Correction", "id": 66554792, "image": "https://s.yimg.com/uu/api/res/1.2/.D3Ex4qd0JjcxU0yIP8JKg--~B/aD05MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/8b590217db5fc157909e60c7e6bbcaa1", "related": "ABMD", "source": "Yahoo", "summary": "Seeing a wall of red numbers on your brokerage account is usually a frightening experience, but it doesn't necessarily mean that you're a bad investor.  In this vein, I've been watching a group of three healthcare stocks that are currently on the pricey side.  STAAR Surgical Company (NASDAQ: STAA) makes exactly that: implantable lenses for ocular surgery.", "url": "https://finnhub.io/api/news?id=49f52c071aae6f518c2f57b121f9803bdad262a22ed2bbd014cce239c7c7bbb7"}, {"category": "company", "datetime": 1617274620, "headline": "Better Buy for the Next 10 Years: Abiomed vs. Guardant Heath", "id": 66554793, "image": "https://s.yimg.com/uu/api/res/1.2/YKwdcwHJs2SihziNAFcdrA--~B/aD05MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/56791a3d40737a177a8f077127c3c322", "related": "ABMD", "source": "Yahoo", "summary": "Abiomed (NASDAQ: ABMD) and Guardant Health (NASDAQ: GH) both sport market caps just north of $13 billion, but these companies represent very different ways to invest in healthcare stocks for the next decade.  Abiomed is the maker of Impella, a temporarily implanted device meant to help protect the heart when it's been damaged or during complex procedures.  Guardant Health, meanwhile, utilizes a blood test to perform a liquid biopsy to determine whether a patient has cancer, and if so, what treatment regimens would be best.", "url": "https://finnhub.io/api/news?id=3f0daaf0f62211ea2f874adc7f9db7abfd93a402f4da5af2f0623e07d1f35fbb"}, {"category": "company", "datetime": 1617208380, "headline": "Abiomed Inc. stock outperforms competitors on strong trading day", "id": 66011339, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. advanced 2.86% to $318.73 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500...", "url": "https://finnhub.io/api/news?id=a28ad739d75c9bfc241b48aa31f90ee9881e70b694c53fdcf77765d01e1b7a8a"}, {"category": "company", "datetime": 1617189431, "headline": "Zacks Industry Outlook Highlights: Natus Medical, IDEXX Laboratories, Hologic, Thermo Fisher Scientific and Abiomed", "id": 66532418, "image": "https://s.yimg.com/uu/api/res/1.2/f_ivn8Bjpou.vwuiQ0Xriw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/67d55099b4ab8c0c454774738660eba8", "related": "ABMD", "source": "Yahoo", "summary": "Zacks Industry Outlook Highlights: Natus Medical, IDEXX Laboratories, Hologic, Thermo Fisher Scientific and Abiomed", "url": "https://finnhub.io/api/news?id=c5f897f903c3074ccd1890fb204ad27b86dffb16d96af52b506b17ab7374ad47"}, {"category": "company", "datetime": 1617121980, "headline": "Abiomed Inc. stock rises Tuesday, outperforms market", "id": 65987554, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. rose 1.34% to $309.88 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index...", "url": "https://finnhub.io/api/news?id=ed6a4d015b01d45d2cfd32843c8ab66c37ee516e58e5e22b99663822105ea3cc"}, {"category": "company", "datetime": 1616776380, "headline": "Abiomed Inc. stock outperforms market on strong trading day", "id": 65278538, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. advanced 2.47% to $301.40 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P 500...", "url": "https://finnhub.io/api/news?id=5f6a2f1eddf12f97f22ec09d7482a324d3f60b64033858f984bb541c7e2d6772"}, {"category": "company", "datetime": 1616689980, "headline": "Abiomed Inc. stock falls Thursday, underperforms market", "id": 65278539, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. sank 0.02% to $294.14 Thursday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...", "url": "https://finnhub.io/api/news?id=af5eb62e4695fd0594f6bc5c43a342bf82f0fb1756b352a59b7fa4bacb01294a"}, {"category": "company", "datetime": 1616603580, "headline": "Abiomed Inc. stock falls Wednesday, underperforms market", "id": 64835290, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. slid 1.48% to $294.21 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500...", "url": "https://finnhub.io/api/news?id=191692808cb75ec4cb2923ff972e3dc3a56b6acf656fecc8443576bd2b316a09"}, {"category": "company", "datetime": 1616517180, "headline": "Abiomed Inc. stock falls Tuesday, underperforms market", "id": 64813811, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. shed 2.46% to $298.62 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index...", "url": "https://finnhub.io/api/news?id=c4bad076f5707181438d9f48c8acc2211f3b0fbf7b8dbfaab8f7b00873013623"}, {"category": "company", "datetime": 1616430780, "headline": "Abiomed Inc. stock outperforms market on strong trading day", "id": 64795475, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. rose 2.12% to $306.16 Monday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index...", "url": "https://finnhub.io/api/news?id=988dec53b8924a240ebdcedf0c8fc109437502d262218ef0217abf9fa7c2f8a3"}, {"category": "company", "datetime": 1616326620, "headline": "This Company Will Fix the Hidden COVID Danger to Come", "id": 66554797, "image": "https://s.yimg.com/uu/api/res/1.2/ZOTQHv2HpSvZD.aS0FuB0g--~B/aD05MzQ7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/dd58c1fd15a8704466e31996e4eb1a9e", "related": "ABMD", "source": "Yahoo", "summary": "While much ado has rightfully been made of the COVID public health disaster, we haven't seen a lot of long-term forward-looking analysis -- few prognosticators seem focused on skating to where the puck is going.  Throughout COVID, I read a whole lot about the possibilities of investing in the vaccine (Moderna, Pfizer, Johnson & Johnson), ventilators (Resmed), and treatments (Gilead) -- but I didn't hear many cogent arguments focused around what are sure to be the longer-term public health implications of COVID-19.  A July 2020 study done in Frankfurt, Germany, of patients who had recovered from COVID showed that 60% had ongoing heart problems after recovery, independent of their pre-existing conditions.", "url": "https://finnhub.io/api/news?id=7073c607479ec776aa9b9d66a796025dc04a3fe1c2969ac724481c65bb2d492a"}, {"category": "company", "datetime": 1616171580, "headline": "Abiomed Inc. stock outperforms competitors on strong trading day", "id": 64764470, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. inched 0.32% higher to $299.81 Friday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500...", "url": "https://finnhub.io/api/news?id=429aa8631e62c61aca0cc48238e819197f82d2eeae66c1001fde79f4e5b96cfb"}, {"category": "company", "datetime": 1616085180, "headline": "Abiomed Inc. stock falls Thursday, underperforms market", "id": 64740081, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. slipped 1.90% to $298.86 Thursday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500...", "url": "https://finnhub.io/api/news?id=aeecafe847fa141648793896bef93b984409299a1f35e435e1f601cfa1fc6be3"}, {"category": "company", "datetime": 1615998780, "headline": "Abiomed Inc. stock underperforms Wednesday when compared to competitors", "id": 64717713, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. slipped 1.31% to $304.66 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P...", "url": "https://finnhub.io/api/news?id=1feb4809d3e58556cc78b4f33ac6c2c053baecef8f97d3156563bfc9fd8b9fbe"}, {"category": "company", "datetime": 1615912380, "headline": "Abiomed Inc. stock outperforms market on strong trading day", "id": 64694853, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. inched 0.49% higher to $308.69 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the S&P...", "url": "https://finnhub.io/api/news?id=81fd2e3942a87351e3de8194d7aeaf6bbf480dff6727f2e60c04275863d05052"}, {"category": "company", "datetime": 1615891920, "headline": "Abbott confirms to Bloomberg suspension of trial enrollment", "id": 66338073, "image": "", "related": "ABMD", "source": "Thefly.com", "summary": "Abbott confirms to Bloomberg suspension of trial enrollment ABT ABMD", "url": "https://finnhub.io/api/news?id=d3ff3d00a557659298e07a36103b858843b43b9b3edff55faa89951d105dd669"}, {"category": "company", "datetime": 1615889640, "headline": "Abbott study challenging Abiomed`s Impella halted, says Piper Sandler", "id": 66338074, "image": "", "related": "ABMD", "source": "Thefly.com", "summary": "Abbott study challenging Abiomed's Impella halted, says Piper Sandler Piper Sandler ABMD ABT", "url": "https://finnhub.io/api/news?id=b35c602805322ee1ff35bb715bcf1c55f01659733647a85961d3a1381c81312f"}, {"category": "company", "datetime": 1615889580, "headline": "Abiomed up 1% after Clinicaltrial.gov shows Abbott study halt", "id": 66338075, "image": "", "related": "ABMD", "source": "Thefly.com", "summary": "Abiomed up 1% after Clinicaltrial.gov shows Abbott study halt ABMD ABT", "url": "https://finnhub.io/api/news?id=98bb4fb395134102eef2d4fd81041a39db8c591907a6570a2a8e05c47fd5fd3e"}, {"category": "company", "datetime": 1615889520, "headline": "Abbott study challenging Abiomed`s Impalla halted, says Piper Sandler", "id": 66338076, "image": "", "related": "ABMD", "source": "Thefly.com", "summary": "The Fly is a leading digital publisher of real-time financial news. The Fly team scours all sources of company news and delivers short-form stories consisting of only market moving content.", "url": "https://finnhub.io/api/news?id=de94556d4e84eb83d3e23102f247b57f6ede65f48b51f3ebdf141c3b7b029942"}, {"category": "company", "datetime": 1615568280, "headline": "Abiomed Inc. stock falls Friday, underperforms market", "id": 64644350, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. shed 0.27% to $303.55 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500...", "url": "https://finnhub.io/api/news?id=445031dc4735999b15fb9eafb3009fc9e1206d0eb1a2faccea632d0ed1117d6b"}, {"category": "company", "datetime": 1615481880, "headline": "Abiomed Inc. stock rises Thursday, outperforms market", "id": 64618767, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. rallied 2.73% to $304.37 Thursday, on what proved to be an all-around great trading session for the stock market, with the S&P 500...", "url": "https://finnhub.io/api/news?id=31a97c389289af773368b3047fda91c0c9579ffbe62c662c42db6f5ec3c8a368"}, {"category": "company", "datetime": 1615480804, "headline": "CMD or ABMD: Which Is the Better Value Stock Right Now?", "id": 66554799, "image": "https://s.yimg.com/uu/api/res/1.2/Fj4TPQveJWuth16WIsEVAw--~B/aD01OTQ7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/46ebfcbff417ac1bbde85ad33fa0d4be", "related": "ABMD", "source": "Yahoo", "summary": "CMD vs. ABMD: Which Stock Is the Better Value Option?", "url": "https://finnhub.io/api/news?id=bb2052f61e2ceeea06a68acd31466d4ca76dbe6d1c92ef3767d679210f663422"}, {"category": "company", "datetime": 1615395480, "headline": "Abiomed Inc. stock falls Wednesday, underperforms market", "id": 64588726, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. slid 0.18% to $296.28 Wednesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index...", "url": "https://finnhub.io/api/news?id=fd00b2e9c3158200d3d4005d225c30d1f338da441879215c86cbda42363ed6be"}, {"category": "company", "datetime": 1615374000, "headline": "Could Abiomed Be a Millionaire-Maker Stock?", "id": 66554801, "image": "https://s.yimg.com/uu/api/res/1.2/DuGPmBJS_oGQh5YTcv2yCg--~B/aD05MzQ7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/8919d0e28c4e29f521304ed211e78d83", "related": "ABMD", "source": "Yahoo", "summary": "Abiomed (NASDAQ: ABMD) shares have tripled in value over the past five years.  The U.S. Food and Drug Administration has authorized its pumps for the treatment of some hospitalized coronavirus patients.  In more good news, the company reported record revenue in the most recent quarter.", "url": "https://finnhub.io/api/news?id=0a51b8d24c1db7b46f8258bd4dbc4ecb31d23ece7626836935c4642646d51d39"}, {"category": "company", "datetime": 1615309080, "headline": "Abiomed Inc. stock rises Tuesday, outperforms market", "id": 64555962, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. rallied 3.81% to $296.80 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500...", "url": "https://finnhub.io/api/news?id=4b5fd4e2671d5268ecba535ee80431791fdffe2c2f06789469a0aee9afb77e1c"}, {"category": "company", "datetime": 1615300392, "headline": "Tuesday Sector Leaders: Technology & Communications, Healthcare", "id": 64663739, "image": "https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?97366384", "related": "ABMD", "source": "Nasdaq", "summary": "Looking at the sectors faring best as of midday Tuesday, shares of Technology & Communications companies are outperforming other sectors, up 3.5%.  Within that group, Enphase Energy Inc. (Symbol: ENPH) and Monolithic Power Systems Inc (Symbol: MPWR) are two large stocks lea", "url": "https://finnhub.io/api/news?id=98f4aa3dc319340e2c3a473418071dada832d49434551175ca6b1017eb2b62de"}, {"category": "company", "datetime": 1615222680, "headline": "Abiomed Inc. stock underperforms Monday when compared to competitors", "id": 64537329, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. slipped 5.08% to $285.92 Monday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones...", "url": "https://finnhub.io/api/news?id=f4383210d0da33111029fe3439b875fab95c543fca5fe205b9ee211d14370b02"}, {"category": "company", "datetime": 1615150973, "headline": "Align Your Portfolio For Growth With Align Technology", "id": 64519526, "image": "https://static3.seekingalpha.com/assets/og_image_192-59bfd51c9fe6af025b2f9f96c807e46f8e2f06c5ae787b15bf1423e6c676d4db.png", "related": "ABMD", "source": "SeekingAlpha", "summary": "Fast-growing Align Technology has a premium product thanks to its intellectual property in orthodontic treatment.", "url": "https://finnhub.io/api/news?id=abbfdd43feb07a3bc83985a1a2f97bfca0daefc5257535864dacfee038663362"}, {"category": "company", "datetime": 1614963480, "headline": "Abiomed Inc. stock rises Friday, still underperforms market", "id": 64493335, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. rallied 1.89% to $301.22 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...", "url": "https://finnhub.io/api/news?id=6ead62d6bbc1292f13cd1c40855faa1063fd391ccc2cad5a1f815738c24b7e35"}, {"category": "company", "datetime": 1614940620, "headline": "ABIOMED Breaks Below 200-Day Moving Average - Notable for ABMD", "id": 66338077, "image": "", "related": "ABMD", "source": "Market News Video", "summary": "In trading on Friday, shares of ABIOMED, Inc - (ABMD) crossed below their 200 day moving average of $284.77, changing hands as low as $282.23 per share. - ABMD.", "url": "https://finnhub.io/api/news?id=d1616b2e0dce02bf2884126b0ba98d0bd1793d0e96105582534fd5dcce8527fe"}, {"category": "company", "datetime": 1614902400, "headline": "Resumen: MEDCERT autoriza el uso del procedimiento de acceso \u00fanico con las vainas introductoras Impella CP en Europa", "id": 64487493, "image": "https://mms.businesswire.com/media/20210305005465/es/863186/23/Single_Access.jpg", "related": "ABMD", "source": "businesswire", "summary": "Tras consultar con MEDCERT GmbH, su organismo notificado, Abiomed va a poner en marcha en Europa el procedimiento de entrada \u00fanica Impella CP con vain", "url": "https://finnhub.io/api/news?id=fdc0e477101b2af2104e36f3e221c87dfcaa5d0638ee586eb985c16b8294a350"}, {"category": "company", "datetime": 1614895080, "headline": "Abiomed Inc. stock falls Thursday, underperforms market", "id": 64467627, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. slipped 3.89% to $295.63 Thursday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500...", "url": "https://finnhub.io/api/news?id=7dbe25dc3373b4c05b341d05de147a2c2b5b2a5cd3eef4f8ee98898d1d8279b7"}, {"category": "company", "datetime": 1614866400, "headline": "MEDCERT Enables the Use of the Single Access Procedure with Impella CP Introducer Sheaths in Europe", "id": 66554804, "image": "https://s.yimg.com/uu/api/res/1.2/3FmUXd8.Og8HS2TsSl_yRQ--~B/aD0yNTM7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/c2d984164ccddbf0b4e2c77783d194f8", "related": "ABMD", "source": "Yahoo", "summary": "Following consultation with its notified body, MEDCERT GmbH, Abiomed is introducing the single access procedure with Impella CP introducer sheaths for the treatment of heart disease in Europe.", "url": "https://finnhub.io/api/news?id=fc84ea576404a69e587e3b4b8fbcc672b7d9c0324980dc6ff4f1d766ee6d38fa"}, {"category": "company", "datetime": 1614848400, "headline": "MEDCERT Enables the Use of the Single Access Procedure with Impella CP Introducer Sheaths in Europe", "id": 66338079, "image": "", "related": "ABMD", "source": "Business Wire", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.", "url": "https://finnhub.io/api/news?id=a5186d0f7d0906016a8794cbc9da2f13ef78876083e5e40f0bbae8314d433465"}, {"category": "company", "datetime": 1614816000, "headline": "MEDCERT autorise l'utilisation de la proc\u00e9dure d'acc\u00e8s unique des gaines d'introduction Impella CP en Europe", "id": 64466535, "image": "https://mms.businesswire.com/media/20210304006116/fr/863186/23/Single_Access.jpg", "related": "ABMD", "source": "businesswire", "summary": "Apr\u00e8s consultation de son organisme notifi\u00e9 - MEDCERT GmbH - Abiomed lance la proc\u00e9dure d'acc\u00e8s unique des gaines d'insertion Impella CP pour le trait", "url": "https://finnhub.io/api/news?id=b8cafd5f267c70138135741e0141f6bfbad19717a55abad1da26a4dd0cd9bd61"}, {"category": "company", "datetime": 1614816000, "headline": "MEDCERT autorise l'utilisation de la proc\u00e9dure d'acc\u00e8s unique des gaines d'introduction Impella CP en Europe", "id": 64466533, "image": "https://mms.businesswire.com/media/20210304006116/fr/863186/23/Single_Access.jpg", "related": "ABMD", "source": "businesswire", "summary": "Apr\u00e8s consultation de son organisme notifi\u00e9 - MEDCERT GmbH - Abiomed lance la proc\u00e9dure d'acc\u00e8s unique des gaines d'insertion Impella CP pour le trait", "url": "https://finnhub.io/api/news?id=fac66b1ec3e88e1663c680585bb80a2e370deca82cc4d79666a8ffd3da49af81"}, {"category": "company", "datetime": 1614816000, "headline": "MEDCERT autorise l'utilisation de la proc\u00e9dure d'acc\u00e8s unique des gaines d'introduction Impella CP en Europe", "id": 64466447, "image": "https://mms.businesswire.com/media/20210304006116/fr/863186/23/Single_Access.jpg", "related": "ABMD", "source": "businesswire", "summary": "Apr\u00e8s consultation de son organisme notifi\u00e9 - MEDCERT GmbH - Abiomed lance la proc\u00e9dure d'acc\u00e8s unique des gaines d'insertion Impella CP pour le trait", "url": "https://finnhub.io/api/news?id=b80c3d132e0759349e2402a2efff959265dcf38122b1c817831d8a4fee60a7be"}, {"category": "company", "datetime": 1614816000, "headline": "Riassunto: MEDCERT autorizza l'uso della procedura di accesso singolo con le guaine introduttive Impella CP in Europa", "id": 64465764, "image": "https://mms.businesswire.com/media/20210304006036/it/863186/23/Single_Access.jpg", "related": "ABMD", "source": "businesswire", "summary": "A seguito della consultazione con il suo organismo notificato, MEDCERT GmbH, Abiomed sta introducendo la procedura di accesso singolo con guaine intro", "url": "https://finnhub.io/api/news?id=0d437579d829f412f452a2c66703ce9701bb75ba02a12bd650e9413b0873069b"}, {"category": "company", "datetime": 1614816000, "headline": "Samenvatting: MEDCERT maakt het gebruik van de Single Access Procedure met Impella CP Introducer Sheaths in Europa mogelijk", "id": 64462098, "image": "https://mms.businesswire.com/media/20210304005939/nl/863186/23/Single_Access.jpg", "related": "ABMD", "source": "businesswire", "summary": "Na overleg met haar aangemelde instantie, MEDCERT GmbH, introduceert Abiomed de single access-procedure met Impella CP-introducerhulzen voor de behand", "url": "https://finnhub.io/api/news?id=0c8a752014bc19217a900d4b5b63220606ca7d61c2749289fe117bae12379450"}, {"category": "company", "datetime": 1614816000, "headline": "MEDCERT erm\u00f6glicht in Europa die Anwendung des Single-Access Verfahrens mit Impella CP Einf\u00fchrschleusen", "id": 64451892, "image": "https://mms.businesswire.com/media/20210304005575/de/863186/23/Single_Access.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed f\u00fchrt nach R\u00fccksprache mit seiner Benannten Stelle MEDCERT GmbH bei der Behandlung von Herzerkrankungen ab sofort auch in Europa das Single-Ac", "url": "https://finnhub.io/api/news?id=f70e745518752e31510de79216d81da14d50417bb5744fcdeb8d4f8dffe1c7fd"}, {"category": "company", "datetime": 1614816000, "headline": "MEDCERT Enables the Use of the Single Access Procedure with Impella CP Introducer Sheaths in Europe", "id": 64451891, "image": "https://mms.businesswire.com/media/20210304005331/en/863186/23/Single_Access.jpg", "related": "ABMD", "source": "businesswire", "summary": "Following consultation with its notified body, MEDCERT GmbH, Abiomed is introducing the single access procedure with Impella CP introducer sheaths for", "url": "https://finnhub.io/api/news?id=99b4d130b5e6209915da371f25e058c8e63db9ad56276add6447bddf89de0ea0"}, {"category": "company", "datetime": 1614790680, "headline": "Abiomed Inc. stock falls Wednesday, underperforms market", "id": 64439987, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. slid 5.44% to $307.60 Wednesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index...", "url": "https://finnhub.io/api/news?id=7d2696b172d301fd0add267d412be0398d9f4278c7bbaf449d427a58e55143f5"}, {"category": "company", "datetime": 1614704280, "headline": "Abiomed Inc. stock outperforms market on strong trading day", "id": 64401411, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. inched 0.32% higher to $325.31 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500...", "url": "https://finnhub.io/api/news?id=e21b91162b1bcf3e3de9db3c22f05c5d54743e7f9da8e0715378b6410f61fc9a"}, {"category": "company", "datetime": 1614659175, "headline": "What Do The Returns On Capital At Abiomed (NASDAQ:ABMD) Tell Us?", "id": 66554807, "image": "https://s.yimg.com/uu/api/res/1.2/8.7wAmlAutGU5iXFvarF9A--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/542f5a72d5758cc977dad831c5295870", "related": "ABMD", "source": "Yahoo", "summary": "There are a few key trends to look for if we want to identify the next multi-bagger. Firstly, we'd want to identify a...", "url": "https://finnhub.io/api/news?id=a196cc6a2381b84370e22771da2dd80ae2376d0346e0027fcd7dd921ac6b35d2"}, {"category": "company", "datetime": 1614617880, "headline": "Abiomed Inc. stock underperforms Monday when compared to competitors", "id": 64364676, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. dropped 0.09% to $324.26 Monday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index...", "url": "https://finnhub.io/api/news?id=a19a96e5be110c3caec1ee01f5b5133b8b7613f8bb77600b56044ca2b0deadbe"}, {"category": "company", "datetime": 1614443404, "headline": "Abiomed (ABMD) Down 8.6% Since Last Earnings Report: Can It Rebound?", "id": 66554808, "image": "https://s.yimg.com/uu/api/res/1.2/QOfludHza1dTKV8R6Coeiw--~B/aD02MDE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/48ad4265c55e3ba7a1fb9148d6e717d9", "related": "ABMD", "source": "Yahoo", "summary": "Abiomed (ABMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.", "url": "https://finnhub.io/api/news?id=17741c841cd4c14374152e2e1cc10d09334de5f3f5ca3cc4cc623bb08d5e7414"}, {"category": "company", "datetime": 1614358680, "headline": "Abiomed Inc. stock outperforms market on strong trading day", "id": 64319850, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. rallied 1.27% to $324.55 Friday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index...", "url": "https://finnhub.io/api/news?id=24dcd70eb501eacaa5a9f78fa728e7a9d1b8b878ceb986940f336de96288d16a"}, {"category": "company", "datetime": 1614272280, "headline": "Abiomed Inc. stock outperforms market despite losses on the day", "id": 64319851, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. shed 1.02% to $320.47 Thursday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index...", "url": "https://finnhub.io/api/news?id=35da157a649c6e5704df505ad837303607570584dccfd7b5e28d2b10d7d79c31"}, {"category": "company", "datetime": 1614185880, "headline": "Abiomed Inc. stock rises Wednesday, still underperforms market", "id": 64158640, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. inched 0.65% higher to $323.78 Wednesday, on what proved to be an all-around great trading session for the stock market, with the S&P...", "url": "https://finnhub.io/api/news?id=06ed6d29c302dea3f515167508f2d756a1be6ac318575be25fe98a54f6b79085"}, {"category": "company", "datetime": 1614099480, "headline": "Abiomed Inc. stock outperforms competitors despite losses on the day", "id": 64158672, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. sank 0.33% to $321.69 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...", "url": "https://finnhub.io/api/news?id=c99edd265df4c9c9d08bcc3a5ad107be9ed76825244773dbbdc1c65cde16270d"}, {"category": "company", "datetime": 1614013080, "headline": "Abiomed Inc. stock underperforms Monday when compared to competitors", "id": 63852539, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. slipped 2.78% to $322.75 Monday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones...", "url": "https://finnhub.io/api/news?id=8e7b577aeb82682927568ba7227b7203d8c5266796adcce63f112b9c01dc06fc"}, {"category": "company", "datetime": 1613753880, "headline": "Abiomed Inc. stock outperforms competitors on strong trading day", "id": 63705754, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. advanced 3.07% to $331.97 Friday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones...", "url": "https://finnhub.io/api/news?id=64d0da3a411b38e22fbc425826be41f0c6ea665449187a030188ba4cedcdd8f1"}, {"category": "company", "datetime": 1613667480, "headline": "Abiomed Inc. stock outperforms market on strong trading day", "id": 63671371, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. advanced 1.83% to $322.08 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500...", "url": "https://finnhub.io/api/news?id=7441d9066ba565f8189a42cd5c8132e4356bc506a24e39eab0b410ed80b10193"}, {"category": "company", "datetime": 1613642400, "headline": "Validea Peter Lynch Strategy Daily Upgrade Report - 2/18/2021", "id": 63791018, "image": "https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?1045707089", "related": "ABMD", "source": "Nasdaq", "summary": "The following are today's upgrades for Validea's P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relative to earnings growth that also possess strong balance sheets.ELLINGTON RESIDENTIAL MORTGA", "url": "https://finnhub.io/api/news?id=692f30f1933a4a1298446e900cf5d0cec5e612da448dcbb6740bd05b6a1e18c9"}, {"category": "company", "datetime": 1613606400, "headline": "Abiomed beruft Dr. Myron Rolle in das Board of Directors", "id": 63666174, "image": "https://mms.businesswire.com/media/20210218005874/de/859430/23/MYRON_ROLLE_Headshot_%281%29.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ: ABMD) gibt die Berufung von Myron Rolle, MD, in das Board of Directors von Abiomed mit sofortiger Wirkung bekannt. Dr. Rolle wird als", "url": "https://finnhub.io/api/news?id=48e6f93a63fefb2948d9bec5947391a46a43dc7b40741e0b378e5088d5cf6cf9"}, {"category": "company", "datetime": 1613606400, "headline": "Abiomed beruft Dr. Myron Rolle in das Board of Directors", "id": 63666150, "image": "https://mms.businesswire.com/media/20210218005874/de/859430/23/MYRON_ROLLE_Headshot_%281%29.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ: ABMD) gibt die Berufung von Myron Rolle, MD, in das Board of Directors von Abiomed mit sofortiger Wirkung bekannt. Dr. Rolle wird als", "url": "https://finnhub.io/api/news?id=c5c514b631a11d31376a9914bd229add86687b9e673b23e623845d54c5b4769a"}, {"category": "company", "datetime": 1613606400, "headline": "Resumen: Abiomed anuncia el nombramiento del Dr. Myron Rolle como miembro del Consejo de Administraci\u00f3n", "id": 63666141, "image": "https://mms.businesswire.com/media/20210218005880/es/859430/23/MYRON_ROLLE_Headshot_%281%29.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ: ABMD) anuncia el nombramiento de Myron Rolle, MD, como miembro del Consejo De Administraci\u00f3n de la empresa, con efecto inmediato. El", "url": "https://finnhub.io/api/news?id=5e3a6a7e1f92e9ca71aacbdf189671a5de285ba30f42c7f0b386c6f499640fbd"}, {"category": "company", "datetime": 1613606400, "headline": "Resumen: Abiomed anuncia el nombramiento del Dr. Myron Rolle como miembro del Consejo de Administraci\u00f3n", "id": 63666140, "image": "https://mms.businesswire.com/media/20210218005880/es/859430/23/MYRON_ROLLE_Headshot_%281%29.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ: ABMD) anuncia el nombramiento de Myron Rolle, MD, como miembro del Consejo De Administraci\u00f3n de la empresa, con efecto inmediato. El", "url": "https://finnhub.io/api/news?id=4c85acd549dbdb0cb227bf8139211de796ceebaabe7fd53585cffc3730db8fb4"}, {"category": "company", "datetime": 1613606400, "headline": "Abiomed beruft Dr. Myron Rolle in das Board of Directors", "id": 63666094, "image": "https://mms.businesswire.com/media/20210218005874/de/859430/23/MYRON_ROLLE_Headshot_%281%29.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ: ABMD) gibt die Berufung von Myron Rolle, MD, in das Board of Directors von Abiomed mit sofortiger Wirkung bekannt. Dr. Rolle wird als", "url": "https://finnhub.io/api/news?id=2cae750a30bad915e11c2064fa2c433ad68d0406f2fbc39e6048b2a464943667"}, {"category": "company", "datetime": 1613606400, "headline": "Resumen: Abiomed anuncia el nombramiento del Dr. Myron Rolle como miembro del Consejo de Administraci\u00f3n", "id": 63666093, "image": "https://mms.businesswire.com/media/20210218005880/es/859430/23/MYRON_ROLLE_Headshot_%281%29.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ: ABMD) anuncia el nombramiento de Myron Rolle, MD, como miembro del Consejo De Administraci\u00f3n de la empresa, con efecto inmediato. El", "url": "https://finnhub.io/api/news?id=0ffa32eda90a938ec96608582e64a9d9740b7beb5652bc7eac13c99e6edb464c"}, {"category": "company", "datetime": 1613588521, "headline": "Abiomed\u00a0: annonce la nomination du docteur Myron Rolle au conseil d'administration | Zone bourse", "id": 64454074, "image": "https://www.zonebourse.com/images/twitter_ZB_fdblanc.png", "related": "ABMD", "source": "https://www.zonebourse.com", "summary": "", "url": "https://finnhub.io/api/news?id=f0613b8c1d30b03eaf658f6f2e7ac4e05bcf296fb78d4fbc78d26e3bec26af0b"}, {"category": "company", "datetime": 1613588521, "headline": "Abiomed : annonce la nomination du docteur Myron Rolle au conseil d'administration | Zone bourse", "id": 63718119, "image": "https://www.zonebourse.com/images/twitter_ZB_fdgris.png", "related": "ABMD", "source": "https://www.zonebourse.com", "summary": "", "url": "https://finnhub.io/api/news?id=9213d00357f82cc6e1bb90386453a856edbc986f48bd8be7d131cdd6f0aa2135"}, {"category": "company", "datetime": 1613581080, "headline": "Abiomed Inc. stock falls Wednesday, underperforms market", "id": 63629144, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. shed 2.01% to $316.30 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones...", "url": "https://finnhub.io/api/news?id=c384e31345f939425e32db4a4f4775e50e9b91b6e6fe8d19463f3a38fab4e0ea"}, {"category": "company", "datetime": 1613566980, "headline": "Abiomed Announces Appointment of Dr. Myron Rolle to Board of Directors", "id": 66554810, "image": "https://s.yimg.com/uu/api/res/1.2/uZFoIzI_dPHTGqLUM0A3Kw--~B/aD0zMjA7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/53ee923e7bf89bbd07d4067ef06c62be", "related": "ABMD", "source": "Yahoo", "summary": "Abiomed announces the appointment of Myron Rolle, MD, to the Abiomed Board of Directors.", "url": "https://finnhub.io/api/news?id=c22c4fdb3a13dc56c1ac3002792fe3c2c71a054681a1dec08b95d60402f5ec3a"}, {"category": "company", "datetime": 1613563200, "headline": "Abiomed to Present at Upcoming Investor Conferences", "id": 66554812, "image": "https://s.yimg.com/uu/api/res/1.2/xmOIfqJFzrOZ4W6AHVC0EQ--~B/aD0xNTQ7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/56ced4bcd23821e24b28f9ce5f685ffa", "related": "ABMD", "source": "Yahoo", "summary": "Abiomed to present at upcoming investor conferences.", "url": "https://finnhub.io/api/news?id=6664df9c086ca7b1d164bb38bb25b93baa31426f9996a632dd206a462677e168"}, {"category": "company", "datetime": 1613520000, "headline": "Riassunto: Abiomed annuncia la nomina del Dott. Myron Rolle a membro del consiglio di amministrazione", "id": 63626982, "image": "https://mms.businesswire.com/media/20210217005980/it/859430/23/MYRON_ROLLE_Headshot_%281%29.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ: ABMD) annuncia la nomina di Myron Rolle, MD, a membro del consiglio di amministrazione dell'azienda, con effetto immediato. Il Dott.", "url": "https://finnhub.io/api/news?id=4e5744cd8ca95387e273b7db0fdb38eb68d478e64f0a73063ac2e1883f48c3ac"}, {"category": "company", "datetime": 1613520000, "headline": "Abiomed annonce la nomination du docteur Myron Rolle au conseil d\u2019administration", "id": 63622593, "image": "https://mms.businesswire.com/media/20210217005876/fr/859430/23/MYRON_ROLLE_Headshot_%281%29.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ : ABMD) annonce la nomination avec effet imm\u00e9diat de Myron Rolle, docteur en m\u00e9decine, au conseil d\u2019administration d\u2019Abiomed. Le docte", "url": "https://finnhub.io/api/news?id=7f264c7aec79a6887b697ff014b1aa809b58f2755f965643e04b2e949fa77560"}, {"category": "company", "datetime": 1613520000, "headline": "Abiomed kondigt de benoeming van Dr. Myron Rolle aan als lid van de Raad van Bestuur", "id": 63617263, "image": "https://mms.businesswire.com/media/20210217005697/nl/859430/23/MYRON_ROLLE_Headshot_%281%29.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ: ABMD) kondigt de benoeming aan van Myron Rolle, MD, in de Raad van Bestuur van Abiomed, met onmiddellijke ingang. Dr. Rolle zal diene", "url": "https://finnhub.io/api/news?id=9748d9ce2844949eaccf238ecfd96ef2d049686cc8ab3b62937ebf46d1c459a9"}, {"category": "company", "datetime": 1613520000, "headline": "Abiomed Announces Appointment of Dr. Myron Rolle to Board of Directors", "id": 63612648, "image": "https://mms.businesswire.com/media/20210217005546/en/859430/23/MYRON_ROLLE_Headshot_%281%29.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed announces the appointment of Myron Rolle, MD, to the Abiomed Board of Directors.", "url": "https://finnhub.io/api/news?id=b8b2e696a777405743d9dfc8917d61c10b7a0b34ac1c12df0f5668b2788943a2"}, {"category": "company", "datetime": 1613520000, "headline": "Abiomed Announces Appointment of Dr. Myron Rolle to Board of Directors", "id": 63612646, "image": "https://mms.businesswire.com/media/20210217005546/en/859430/23/MYRON_ROLLE_Headshot_%281%29.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed announces the appointment of Myron Rolle, MD, to the Abiomed Board of Directors.", "url": "https://finnhub.io/api/news?id=7480f828523ade5d0d41f7814a18ee92301fb7c4dcc5992d8c1524bbed66500c"}, {"category": "company", "datetime": 1613520000, "headline": "Abiomed Announces Appointment of Dr. Myron Rolle to Board of Directors", "id": 63612397, "image": "https://mms.businesswire.com/media/20210217005546/en/859430/23/MYRON_ROLLE_Headshot_%281%29.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed announces the appointment of Myron Rolle, MD, to the Abiomed Board of Directors.", "url": "https://finnhub.io/api/news?id=cac1d358091668f69c287341961f55c0552fd36c7f4d59984cbf15553f8a9952"}, {"category": "company", "datetime": 1613494680, "headline": "Abiomed Inc. stock falls Tuesday, underperforms market", "id": 63593327, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. slipped 1.70% to $322.78 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones...", "url": "https://finnhub.io/api/news?id=556ceb3261c1f5fd96fb3549fb475630d98f8888371345b9a72ae07f63394305"}, {"category": "company", "datetime": 1613149080, "headline": "Abiomed Inc. stock rises Friday, outperforms market", "id": 63530369, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. advanced 1.68% to $328.36 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P 500...", "url": "https://finnhub.io/api/news?id=2db3f44cb876bed8aea848adbc929cee4b9c7e831a05ae5bf3591caee60c8cb8"}, {"category": "company", "datetime": 1613062680, "headline": "Abiomed Inc. stock falls Thursday, underperforms market", "id": 63509132, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. slid 0.49% to $322.93 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index...", "url": "https://finnhub.io/api/news?id=60ad36ea232733e0dc1891b84216f25eb95e42a15f97f3c9b4939d709feb1cba"}, {"category": "company", "datetime": 1613062024, "headline": "Why You Should Retain Abiomed (ABMD) Stock in Your Portfolio", "id": 66554814, "image": "https://s.yimg.com/uu/api/res/1.2/KF.RcOL3NCis8EjppApmOg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/13810238994cd44cc10997bfcd271168", "related": "ABMD", "source": "Yahoo", "summary": "Investor confidence is high in Abiomed (ABMD) stock, courtesy of its solid prospects.", "url": "https://finnhub.io/api/news?id=b2017deca5b89585ac158a4f836d62d25f891004e76011e6fcbeeb984cd1d967"}, {"category": "company", "datetime": 1612976280, "headline": "Abiomed Inc. stock outperforms market on strong trading day", "id": 63477239, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. inched 0.01% higher to $324.51 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow...", "url": "https://finnhub.io/api/news?id=59952709f5aad877fb608e0d154ea79352d2763fb91113a9230bcc05fdaea041"}, {"category": "company", "datetime": 1612889880, "headline": "Abiomed Inc. stock falls Tuesday, underperforms market", "id": 63370021, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. slid 0.42% to $324.48 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index...", "url": "https://finnhub.io/api/news?id=1a683bfdb3ca17a76b3743f6c939d9a1c8e491f347c5808025ad31dee681d124"}, {"category": "company", "datetime": 1612803480, "headline": "Abiomed Inc. stock falls Monday, underperforms market", "id": 63063640, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. slipped 0.61% to $325.86 Monday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500...", "url": "https://finnhub.io/api/news?id=519e244f291da143d7c83bc7508deaae684bc6476128ef5a83e3bb52ea6c12b7"}, {"category": "company", "datetime": 1612544280, "headline": "Abiomed Inc. stock outperforms competitors on strong trading day", "id": 63044614, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. inched 0.95% higher to $327.85 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P 500...", "url": "https://finnhub.io/api/news?id=a60c708ff86c0fe1e2a1468e7c001b54bf5b8ef7a31b75c0663a87ad9f5c5ef2"}, {"category": "company", "datetime": 1612457940, "headline": "Abiomed Inc. stock falls Thursday, underperforms market", "id": 63044615, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. dropped 0.44% to $324.78 Thursday, on what proved to be an all-around great trading session for the stock market, with the S&P 500...", "url": "https://finnhub.io/api/news?id=f43d8353e50a3b4f10156d64abda42558707a0de9b93548237d94d10074f452f"}, {"category": "company", "datetime": 1612442820, "headline": "Where to Invest $10,000 Right Now", "id": 66554816, "image": "https://s.yimg.com/uu/api/res/1.2/5fI8YtAKUzFZZw1xjnYtJg--~B/aD0xMDAxO3c9MTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/motleyfool.com/7fbe8fa5ad2cbfaf8de749260070bdb8", "related": "ABMD", "source": "Yahoo", "summary": "Abiomed's (NASDAQ: ABMD) heart pumps assist or take over the pumping function to allow the heart to rest.  The ventricular assist device market, at a compound annual growth rate of 20%, may reach $3.5 billion by 2027, according to a Global Industry Analysts report.  Abiomed's revenue and general financial health are another plus.", "url": "https://finnhub.io/api/news?id=7df4a23cbbe03c5c4da51053aa57d17f868cbe03acf1dc6ed0b5f92330e1b74e"}, {"category": "company", "datetime": 1612424820, "headline": "Where to Invest $10,000 Right Now", "id": 63475813, "image": "https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?928036285", "related": "ABMD", "source": "Nasdaq", "summary": "The S&P 500 slipped 1.1% in January to finish the first month of the year in the doldrums. And the coronavirus pandemic seems far from over. But these two elements shouldn't discourage us from investing in stocks that have proven themselves over the long term -- and fared wel", "url": "https://finnhub.io/api/news?id=91a7ad22661c0e9aa25801a619dd44c6e15232264c2eb4a109b2424b234e8b7e"}, {"category": "company", "datetime": 1612371540, "headline": "Abiomed Inc. stock falls Wednesday, underperforms market", "id": 62685290, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. shed 6.21% to $326.23 Wednesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index...", "url": "https://finnhub.io/api/news?id=6fd4fdb588dff09db062ea969ef204e4713aa3adf13edc7869ddbe2f38f3a9d2"}, {"category": "company", "datetime": 1612362993, "headline": "Wednesday Sector Laggards: Healthcare, Utilities", "id": 63475814, "image": "https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?607997791", "related": "ABMD", "source": "Nasdaq", "summary": "Looking at the sectors faring worst as of midday Wednesday, shares of Healthcare companies are underperforming other sectors, showing a 0.5% loss.  Within that group, PerkinElmer, Inc. (Symbol: PKI) and ABIOMED, Inc. (Symbol: ABMD) are two large stocks that are lagging, showing", "url": "https://finnhub.io/api/news?id=c625b5797b5e5b82e4fa14f3987cb7094fc7a0072cb560abb299d6af93c30843"}, {"category": "company", "datetime": 1612285080, "headline": "Abiomed Inc. stock underperforms Tuesday when compared to competitors despite daily gains", "id": 62662053, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. rallied 1.75% to $347.84 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500...", "url": "https://finnhub.io/api/news?id=d6b4e68d7616c018991f0c7ced8e707e045df38ea7ceba98bf59fbf90c2beb59"}, {"category": "company", "datetime": 1612224000, "headline": "Aramark Sets New Climate Goal, Commits to Reducing Greenhouse Gas Emissions by 15% by the End Of 2025", "id": 62647271, "image": "https://mms.businesswire.com/media/20210202005275/en/856253/23/People_Planet_Graphic_Final_Updated_revGL.jpg", "related": "ABMD", "source": "businesswire", "summary": "Just one year after introducing its sustainability plan, Be Well. Do Well., Aramark (NYSE: ARMK), the leading U.S.-based provider of food, facilities", "url": "https://finnhub.io/api/news?id=448f6a245f24e21fa0fd0ab09b543b335d1b1b56559c7774c30971ec1b844525"}, {"category": "company", "datetime": 1612224000, "headline": "Aramark Sets New Climate Goal, Commits to Reducing Greenhouse Gas Emissions by 15% by the End Of 2025", "id": 62647270, "image": "https://mms.businesswire.com/media/20210202005275/en/856253/23/People_Planet_Graphic_Final_Updated_revGL.jpg", "related": "ABMD", "source": "businesswire", "summary": "Just one year after introducing its sustainability plan, Be Well. Do Well., Aramark (NYSE: ARMK), the leading U.S.-based provider of food, facilities", "url": "https://finnhub.io/api/news?id=9ac91283c9df9b5a6c0b8033c80a274d406a16bd88e1742b948c6a6ca515be41"}, {"category": "company", "datetime": 1612224000, "headline": "Aramark Sets New Climate Goal, Commits to Reducing Greenhouse Gas Emissions by 15% by the End Of 2025", "id": 62647251, "image": "https://mms.businesswire.com/media/20210202005275/en/856253/23/People_Planet_Graphic_Final_Updated_revGL.jpg", "related": "ABMD", "source": "businesswire", "summary": "Just one year after introducing its sustainability plan, Be Well. Do Well., Aramark (NYSE: ARMK), the leading U.S.-based provider of food, facilities", "url": "https://finnhub.io/api/news?id=eaa4cce8255485a8818fc03104add794847b62ff111d62ecb29e4ef2bbd51dbb"}, {"category": "company", "datetime": 1612198680, "headline": "Abiomed Inc. stock underperforms Monday when compared to competitors", "id": 62637522, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. shed 1.83% to $341.86 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index...", "url": "https://finnhub.io/api/news?id=4702999e3fabfab1aa91552edd7dde50fde22aea75029a13e62705b27fb9d0a2"}, {"category": "company", "datetime": 1612137600, "headline": "Cardiac Insight Comments on Medicare Administrative Contractor Novitas Rate Publication", "id": 62634287, "image": "https://mms.businesswire.com/media/20210201005891/en/856159/23/CI_logo.jpg", "related": "ABMD", "source": "businesswire", "summary": "Cardiac Insight, Inc. comments on the recent reimbursement rates published by Medicare Administrative Contractor Novitas Solutions.", "url": "https://finnhub.io/api/news?id=c371810ad2027c33eba1f87c1ac3a96c29e6ecbadccc40101364887ce2bbb8f7"}, {"category": "company", "datetime": 1612137600, "headline": "Worldwide Wireless ECG Devices Industry to 2025 - Declining Cost of Wireless Technologies is Driving Growth - ResearchAndMarkets.com", "id": 62630504, "image": "https://mms.businesswire.com/media/20210201005743/en/371054/23/ResearchAndMarkets_800px.jpg", "related": "ABMD", "source": "businesswire", "summary": "The", "url": "https://finnhub.io/api/news?id=a0a5ec13dfe10cf07cbc57e8b2895aadac6a7466f68479793d64d1459b0a5dbc"}, {"category": "company", "datetime": 1612137600, "headline": "Resumen: Gran ensayo cl\u00ednico presentado en STS 2021 revela una tasa de supervivencia del 79 % tras el uso de Impella 5.5 con SmartAssist", "id": 62630460, "image": "https://mms.businesswire.com/media/20210201005696/es/855170/23/Impella_Heart.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ: ABMD) anuncia que un gran estudio con 356 pacientes tratados con Impella 5.5 con SmartAssist en 16 centros de EE. UU. y Alemania ha r", "url": "https://finnhub.io/api/news?id=7e35e7f85545b8da9fb8b29e9a01758372b6cc09194448e86ae32b7e84ae5a00"}, {"category": "company", "datetime": 1612137600, "headline": "Resumen: Gran ensayo cl\u00ednico presentado en STS 2021 revela una tasa de supervivencia del 79 % tras el uso de Impella 5.5 con SmartAssist", "id": 62630458, "image": "https://mms.businesswire.com/media/20210201005696/es/855170/23/Impella_Heart.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ: ABMD) anuncia que un gran estudio con 356 pacientes tratados con Impella 5.5 con SmartAssist en 16 centros de EE. UU. y Alemania ha r", "url": "https://finnhub.io/api/news?id=c3688595642014f847077061de242df427a02f3421ac689f1eef2154574efa80"}, {"category": "company", "datetime": 1612137600, "headline": "Resumen: Gran ensayo cl\u00ednico presentado en STS 2021 revela una tasa de supervivencia del 79 % tras el uso de Impella 5.5 con SmartAssist", "id": 62630456, "image": "https://mms.businesswire.com/media/20210201005696/es/855170/23/Impella_Heart.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ: ABMD) anuncia que un gran estudio con 356 pacientes tratados con Impella 5.5 con SmartAssist en 16 centros de EE. UU. y Alemania ha r", "url": "https://finnhub.io/api/news?id=009cffeba796b0cd92a7f577f44675e4a6474c589b378945b3f43df27251528b"}, {"category": "company", "datetime": 1612137600, "headline": "Resumen: Gran ensayo cl\u00ednico presentado en STS 2021 revela una tasa de supervivencia del 79 % tras el uso de Impella 5.5 con SmartAssist", "id": 62630432, "image": "https://mms.businesswire.com/media/20210201005696/es/855170/23/Impella_Heart.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ: ABMD) anuncia que un gran estudio con 356 pacientes tratados con Impella 5.5 con SmartAssist en 16 centros de EE. UU. y Alemania ha r", "url": "https://finnhub.io/api/news?id=c50e3d2395d26675afc3fb18bed4477d27ee446c04e48458b66fc8df39d7dce5"}, {"category": "company", "datetime": 1612137600, "headline": "Global Cardiac Pacemakers Market (2020 to 2025) - Growth, Trends, and Forecasts - ResearchAndMarkets.com", "id": 62624222, "image": "https://mms.businesswire.com/media/20210201005547/en/371054/23/ResearchAndMarkets_800px.jpg", "related": "ABMD", "source": "businesswire", "summary": "The", "url": "https://finnhub.io/api/news?id=5b034d693d11191f38dc35d39b3b19eb9dd7f17849aeeae14f60c7d6ae582c13"}, {"category": "company", "datetime": 1612137600, "headline": "Auf der STS-Jahrestagung vorgestellte umfangreiche klinische Studie zeigt \u00dcberlebensrate von 79 % bei Behandlung mit Impella 5.5 mit SmartAssist Herzpumpe", "id": 62623769, "image": "https://mms.businesswire.com/media/20210201005530/de/855170/23/Impella_Heart.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ: ABMD) hat die Ergebnisse aus einer umfangreichen klinischen Studie mit 356 Patienten vorgestellt, die an 16 US-amerikanischen und deu", "url": "https://finnhub.io/api/news?id=88412851916e66067fd542154d561d22b150984576fa5286b4e4cc934ebe7bd6"}, {"category": "company", "datetime": 1612137600, "headline": "Auf der STS-Jahrestagung vorgestellte umfangreiche klinische Studie zeigt \u00dcberlebensrate von 79 % bei Behandlung mit Impella 5.5 mit SmartAssist Herzpumpe", "id": 62623767, "image": "https://mms.businesswire.com/media/20210201005530/de/855170/23/Impella_Heart.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ: ABMD) hat die Ergebnisse aus einer umfangreichen klinischen Studie mit 356 Patienten vorgestellt, die an 16 US-amerikanischen und deu", "url": "https://finnhub.io/api/news?id=c73c2a81b27a0cc1b3603cd98f9e2710cfb2204db4781bfb5887557e9f5f0826"}, {"category": "company", "datetime": 1612137600, "headline": "Auf der STS-Jahrestagung vorgestellte umfangreiche klinische Studie zeigt \u00dcberlebensrate von 79 % bei Behandlung mit Impella 5.5 mit SmartAssist Herzpumpe", "id": 62623766, "image": "https://mms.businesswire.com/media/20210201005530/de/855170/23/Impella_Heart.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ: ABMD) hat die Ergebnisse aus einer umfangreichen klinischen Studie mit 356 Patienten vorgestellt, die an 16 US-amerikanischen und deu", "url": "https://finnhub.io/api/news?id=a253e6d5ef1044cce38e16b19d17880bc6675370497ba95120d64e5f9a51f039"}, {"category": "company", "datetime": 1612137600, "headline": "Auf der STS-Jahrestagung vorgestellte umfangreiche klinische Studie zeigt \u00dcberlebensrate von 79 % bei Behandlung mit Impella 5.5 mit SmartAssist Herzpumpe", "id": 62622937, "image": "https://mms.businesswire.com/media/20210201005530/de/855170/23/Impella_Heart.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ: ABMD) hat die Ergebnisse aus einer umfangreichen klinischen Studie mit 356 Patienten vorgestellt, die an 16 US-amerikanischen und deu", "url": "https://finnhub.io/api/news?id=545bcbd020c9252225ca76022cdaeb9ed1e977c24f4885639ca9b89ca304eac0"}, {"category": "company", "datetime": 1612078231, "headline": "UK charity shops hope donation surge will help cover lockdown losses", "id": 62616989, "image": "https://i.guim.co.uk/img/media/e5732385000ab2e58864b736d2a3891023bdf409/36_42_2488_1494/master/2488.jpg?width=1200&height=630&quality=85&auto=format&fit=crop&overlay-align=bottom%2Cleft&overlay-width=100p&overlay-base64=L2ltZy9zdGF0aWMvb3ZlcmxheXMvdG8tZGVmYXVsdC5wbmc&enable=upscale&s=f4df31e23d31c51858cd290087dd829e", "related": "ABMD", "source": "The Guardian", "summary": "Closed stores have cost charities more than \u00a328m a month, but once Covid restrictions are eased bosses hope for a spring boost", "url": "https://finnhub.io/api/news?id=ff26ce0cc10466b1c11f4f7b0a9839ce12a4261c4e6feb12d0a452614d3392ef"}, {"category": "company", "datetime": 1612054900, "headline": "Abiomed, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions", "id": 63475815, "image": "https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?613823093", "related": "ABMD", "source": "Nasdaq", "summary": "Abiomed, Inc. (NASDAQ:ABMD) just released its quarterly report and things are looking bullish.      It was overall a positive result, with revenues beating expectations by 2.4% to hit US$232m. Abiomed also reported a statutory profit of US$1.35, which was an impressive 20% above", "url": "https://finnhub.io/api/news?id=ce93f9f770ab5faede67268fd712479b357e207edc51ef87262248f99c35e595"}, {"category": "company", "datetime": 1611964800, "headline": "Une vaste \u00e9tude clinique pr\u00e9sent\u00e9e lors de la r\u00e9union annuelle 2021 de la Society of Thoracic Surgeons (STS) conclut que l'utilisation de la pompe cardiaque Impella 5.5 avec SmartAssist est associ\u00e9e \u00e0 un taux de survie de 79%", "id": 62609381, "image": "https://mms.businesswire.com/media/20210129005650/fr/855170/23/Impella_Heart.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ: ABMD) annonce qu'une vaste \u00e9tude r\u00e9unissant 356 patients trait\u00e9s avec la pompe cardiaque Impella 5.5 avec SmartAssist dans 16 centres", "url": "https://finnhub.io/api/news?id=fecfdf78452c95062340c820aac146e509644b7e51e8067e5076073d78faecd6"}, {"category": "company", "datetime": 1611964800, "headline": "Une vaste \u00e9tude clinique pr\u00e9sent\u00e9e lors de la r\u00e9union annuelle 2021 de la Society of Thoracic Surgeons (STS) conclut que l'utilisation de la pompe cardiaque Impella 5.5 avec SmartAssist est associ\u00e9e \u00e0 un taux de survie de 79%", "id": 62609379, "image": "https://mms.businesswire.com/media/20210129005650/fr/855170/23/Impella_Heart.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ: ABMD) annonce qu'une vaste \u00e9tude r\u00e9unissant 356 patients trait\u00e9s avec la pompe cardiaque Impella 5.5 avec SmartAssist dans 16 centres", "url": "https://finnhub.io/api/news?id=ff6f4c295b1a294445d881d0280779c8552951ea30b9b7d91ff604f0b477ef6e"}, {"category": "company", "datetime": 1611964800, "headline": "Une vaste \u00e9tude clinique pr\u00e9sent\u00e9e lors de la r\u00e9union annuelle 2021 de la Society of Thoracic Surgeons (STS) conclut que l'utilisation de la pompe cardiaque Impella 5.5 avec SmartAssist est associ\u00e9e \u00e0 un taux de survie de 79%", "id": 62609377, "image": "https://mms.businesswire.com/media/20210129005650/fr/855170/23/Impella_Heart.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ: ABMD) annonce qu'une vaste \u00e9tude r\u00e9unissant 356 patients trait\u00e9s avec la pompe cardiaque Impella 5.5 avec SmartAssist dans 16 centres", "url": "https://finnhub.io/api/news?id=40041022f389423ae0e35a3c15bfdb8a2ad56e085af6cbf444f274b8cc45cfdc"}, {"category": "company", "datetime": 1611964800, "headline": "Une vaste \u00e9tude clinique pr\u00e9sent\u00e9e lors de la r\u00e9union annuelle 2021 de la Society of Thoracic Surgeons (STS) conclut que l'utilisation de la pompe cardiaque Impella 5.5 avec SmartAssist est associ\u00e9e \u00e0 un taux de survie de 79%", "id": 62609150, "image": "https://mms.businesswire.com/media/20210129005650/fr/855170/23/Impella_Heart.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ: ABMD) annonce qu'une vaste \u00e9tude r\u00e9unissant 356 patients trait\u00e9s avec la pompe cardiaque Impella 5.5 avec SmartAssist dans 16 centres", "url": "https://finnhub.io/api/news?id=9cbf99982b0576cc89dba5a7efacd5d6b9b84a85c975b5df7933b7b3c4a0607e"}, {"category": "company", "datetime": 1611939480, "headline": "Abiomed Inc. stock falls Friday, underperforms market", "id": 62607197, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. shed 1.94% to $348.25 Friday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index...", "url": "https://finnhub.io/api/news?id=9e4b2a94bfcc9d11cb5a6c583720c617252ac639df3471ec1f8db4764c75bb80"}, {"category": "company", "datetime": 1611878400, "headline": "The Daily Biotech Pulse: Novavax Vaccine Readout, Clinical Hold On Bellicum Study Lifted, Lilly Earnings, NLS Pharma IPO", "id": 62600631, "image": "https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/medicine-1309148_1920_306.jpg", "related": "ABMD", "source": "benzinga", "summary": "Here's a roundup of top developments in the biotech space over the last 24 hours.\nScaling The Peaks\n(Biotech Stocks Hitting 52-week Highs Jan. 28)\n\nAbbott Laboratories (NYSE:...", "url": "https://finnhub.io/api/news?id=c120b27070687e58d8f319636fa7de15e80c6524a7f606e0dd8b07fdc035d1b6"}, {"category": "company", "datetime": 1611878400, "headline": "Riassunto: Un ampio studio clinico presentato all'STS 2021 rivela un tasso di sopravvivenza del 79% con Impella 5.5 con SmartAssist", "id": 62607978, "image": "https://mms.businesswire.com/media/20210129005636/it/855170/23/Impella_Heart.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ: ABMD) annuncia che un ampio studio condotto su 356 pazienti trattati con Impella 5.5 con SmartAssist presso 16 centri negli USA e in", "url": "https://finnhub.io/api/news?id=5bc08313628b0a1f2205b64cbe33e9fabd1efa7e4916417d5628f2905cdccdcf"}, {"category": "company", "datetime": 1611878400, "headline": "Riassunto: Un ampio studio clinico presentato all'STS 2021 rivela un tasso di sopravvivenza del 79% con Impella 5.5 con SmartAssist", "id": 62607977, "image": "https://mms.businesswire.com/media/20210129005636/it/855170/23/Impella_Heart.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ: ABMD) annuncia che un ampio studio condotto su 356 pazienti trattati con Impella 5.5 con SmartAssist presso 16 centri negli USA e in", "url": "https://finnhub.io/api/news?id=9dff36c798fadb08884ce9c70b89821be1abbe85a66c1f0a4bc69978893892e7"}, {"category": "company", "datetime": 1611878400, "headline": "Riassunto: Un ampio studio clinico presentato all'STS 2021 rivela un tasso di sopravvivenza del 79% con Impella 5.5 con SmartAssist", "id": 62607976, "image": "https://mms.businesswire.com/media/20210129005636/it/855170/23/Impella_Heart.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ: ABMD) annuncia che un ampio studio condotto su 356 pazienti trattati con Impella 5.5 con SmartAssist presso 16 centri negli USA e in", "url": "https://finnhub.io/api/news?id=5c052a7912f57ab546448f2d0d45f395f9e46a2db9f2921e97d26cb80053278b"}, {"category": "company", "datetime": 1611878400, "headline": "Riassunto: Un ampio studio clinico presentato all'STS 2021 rivela un tasso di sopravvivenza del 79% con Impella 5.5 con SmartAssist", "id": 62607751, "image": "https://mms.businesswire.com/media/20210129005636/it/855170/23/Impella_Heart.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ: ABMD) annuncia che un ampio studio condotto su 356 pazienti trattati con Impella 5.5 con SmartAssist presso 16 centri negli USA e in", "url": "https://finnhub.io/api/news?id=e9686f8bf2c909d5007606fda923fcf1d48ab82e46294f8b609c34023768a8ba"}, {"category": "company", "datetime": 1611878400, "headline": "Samenvatting: Grote klinische studie gepresenteerd op STS 2021 vindt 79% overlevingspercentage met Impella 5.5 met SmartAssist", "id": 62602601, "image": "https://mms.businesswire.com/media/20210129005516/nl/855170/23/Impella_Heart.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ: ABMD) kondigt een grote studie aan onder 356 pati\u00ebnten die werden behandeld met Impella 5.5 met SmartAssist in 16 Amerikaanse en Duit", "url": "https://finnhub.io/api/news?id=c4101f0b8c701a5e530cc9638a6b2d8446581d2d86f823aa9c3a3e997fe6ac46"}, {"category": "company", "datetime": 1611878400, "headline": "Global Cardiac Monitoring Market (2020 to 2025) - Growth, Trends, and Forecasts - ResearchAndMarkets.com", "id": 62596506, "image": "https://mms.businesswire.com/media/20210129005347/en/371054/23/ResearchAndMarkets_800px.jpg", "related": "ABMD", "source": "businesswire", "summary": "The", "url": "https://finnhub.io/api/news?id=33a4b997477d3137f99e682aee07a2558e365b795b281ef45e40808190923fbf"}, {"category": "company", "datetime": 1611878400, "headline": "Large Clinical Study Presented at STS 2021 Finds 79% Survival Rate with Impella 5.5 with SmartAssist", "id": 62596493, "image": "https://mms.businesswire.com/media/20210129005016/en/855170/23/Impella_Heart.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ: ABMD) announces a large study of 356 patients treated with Impella 5.5 with SmartAssist at 16 U.S. and German centers found a 79% sur", "url": "https://finnhub.io/api/news?id=d6967ba64b9b758e30928d6508f6be84e6ba50cf69c5d217891fac668e34a1fe"}, {"category": "company", "datetime": 1611878400, "headline": "Large Clinical Study Presented at STS 2021 Finds 79% Survival Rate with Impella 5.5 with SmartAssist", "id": 62596491, "image": "https://mms.businesswire.com/media/20210129005016/en/855170/23/Impella_Heart.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ: ABMD) announces a large study of 356 patients treated with Impella 5.5 with SmartAssist at 16 U.S. and German centers found a 79% sur", "url": "https://finnhub.io/api/news?id=09422b9740179ea9382df4f869d5278176d50f8fdb7ed20033ac9beb52d02743"}, {"category": "company", "datetime": 1611878400, "headline": "Large Clinical Study Presented at STS 2021 Finds 79% Survival Rate with Impella 5.5 with SmartAssist", "id": 62596489, "image": "https://mms.businesswire.com/media/20210129005016/en/855170/23/Impella_Heart.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ: ABMD) announces a large study of 356 patients treated with Impella 5.5 with SmartAssist at 16 U.S. and German centers found a 79% sur", "url": "https://finnhub.io/api/news?id=fc0b9badef512f12f7e4c72d3d6e34dabb940cb53e6a04e679a9f06f5bdafb10"}, {"category": "company", "datetime": 1611878400, "headline": "Large Clinical Study Presented at STS 2021 Finds 79% Survival Rate with Impella 5.5 with SmartAssist", "id": 62596254, "image": "https://mms.businesswire.com/media/20210129005016/en/855170/23/Impella_Heart.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ: ABMD) announces a large study of 356 patients treated with Impella 5.5 with SmartAssist at 16 U.S. and German centers found a 79% sur", "url": "https://finnhub.io/api/news?id=efce4f465713a39ec330290e08f3b75a948bb42539a125556bc4f4403b23dd22"}, {"category": "company", "datetime": 1611853080, "headline": "Abiomed Inc. stock outperforms market on strong trading day", "id": 62586579, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. rose 8.07% to $355.13 Thursday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...", "url": "https://finnhub.io/api/news?id=10404767caee579b01dd732ccba3a1bf0412b828d73e7de337ac32495f647bef"}, {"category": "company", "datetime": 1611849331, "headline": "Health Care Sector Update for 01/28/2021: UBER,EYPT,ABMD,VCYT", "id": 63471717, "image": "https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?415570854", "related": "ABMD", "source": "Nasdaq", "summary": "Health care stocks were ending mostly higher this afternoon, with the NYSE Health Care Index rising 2.0% while the SPDR Health Care Select Sector ETF also was up 1.9%.The Nasdaq Biotechnology index was climbing 0.6%.", "url": "https://finnhub.io/api/news?id=078b4d00941d50972819e41f05357f38c5145247937e32b97d89795bc23faf13"}, {"category": "company", "datetime": 1611847214, "headline": "Abiomed, Inc. (ABMD) Q3 2021 Earnings Call Transcript | AlphaStreet", "id": 62580145, "image": "https://cdn.news.alphastreet.com/wp-content/uploads/2020/09/Transcript-thumbnail.jpg", "related": "ABMD", "source": "https://news.alphastreet.com", "summary": "Abiomed, Inc. (NASDAQ: ABMD) Q3 2021 earnings call dated Jan. 28, 2021", "url": "https://finnhub.io/api/news?id=81a41c8fe1601c2077166f292d3aca48392d96a09d9f16f8e8aeda4279d61ba9"}, {"category": "company", "datetime": 1611842077, "headline": "Health Care Sector Update for 01/28/2021: EYPT,ABMD,VCYT", "id": 63471720, "image": "https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?698202894", "related": "ABMD", "source": "Nasdaq", "summary": "Health care stocks were mostly higher this afternoon, with the NYSE Health Care Index rising 2.0% while the SPDR Health Care Select Sector ETF also was up 2.2%.The Nasdaq Biotechnology index was climbing 1.2%.", "url": "https://finnhub.io/api/news?id=4a1318294fd6c5beb94ebb31c26777a4743cd86f693a2ed26976d177aac56847"}, {"category": "company", "datetime": 1611841860, "headline": "Why Abiomed Stock Popped Today", "id": 63475818, "image": "https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?1584821370", "related": "ABMD", "source": "Nasdaq", "summary": "What happened?On Thursday morning, medical devices specialist Abiomed (NASDAQ: ABMD) released its financial reports for the third quarter of its fiscal year 2021, which ended on Dec. 31, 2020. Investors seem to be happy with the company's performance during this quarter: Abiomed'", "url": "https://finnhub.io/api/news?id=1158db01060134d66b4b79f4588c8866793a8b6093bb5814c1eb9f87f0ba6555"}, {"category": "company", "datetime": 1611840669, "headline": "Abiomed Inc (ABMD) Q3 2021 Earnings Call Transcript", "id": 63475819, "image": "https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?1758737758", "related": "ABMD", "source": "Nasdaq", "summary": "Image source: The Motley Fool.", "url": "https://finnhub.io/api/news?id=f98bcdbfa77db1cc2a6adc00b58a8ad6d8058b85ae3ff696dc20f82d44573240"}, {"category": "company", "datetime": 1611831600, "headline": "Quebec researchers find possible coronavirus treatment, but some remain skeptical", "id": 62589159, "image": "https://www.theglobeandmail.com/resizer/atTS3GLuNLcxdHCGOykTM8jplP4=/1200x0/filters:quality(80)/cloudfront-us-east-1.images.arcpublishing.com/tgam/6XVQCHNESJKZNKGLMYGZOZG7DM.jpg", "related": "ABMD", "source": "https://www.theglobeandmail.com", "summary": "The data from a clinical trial has yet to be peer reviewed and some experts say more proof is needed", "url": "https://finnhub.io/api/news?id=41cb13f3069c9b8953f138bf2217c91cc638a477f40475dc37c6f99ccfffb50d"}, {"category": "company", "datetime": 1611831001, "headline": "S&P 500 Movers: LUMN, AAL", "id": 64133774, "image": "https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?772314320", "related": "ABMD", "source": "Nasdaq", "summary": "In early trading on Thursday, shares of American Airlines Group topped the list of the day's best performing components of the S&P 500 index, trading up 21.6%.  Year to date, American Airlines Group registers a 27.6% gain.", "url": "https://finnhub.io/api/news?id=e89192f5debc1692795f95f71edabd28bac00fc77438ccb93c12a562c74d4dca"}, {"category": "company", "datetime": 1611829560, "headline": "Stocks That Hit 52-Week Highs On Thursday", "id": 62590620, "image": "https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/sites/all/themes/bz2/images/bz-icon.png", "related": "ABMD", "source": "Benzinga", "summary": "\u00a0\n\u00a0\nOn Thursday morning, 92 companies achieved new highs for the year.\nInteresting Highlights:\n\nAbbott Laboratories (NYSE:ABT) was the largest company by market cap to...", "url": "https://finnhub.io/api/news?id=6e3e2520e41fac52e30973079b4754d47238027ab603e75f5bb347612c5c971c"}, {"category": "company", "datetime": 1611820980, "headline": "The Daily Biotech Pulse: Decision Day For Amgen, Zymeworks Sinks On Data, Ortho Clinical Diagnostics IPO", "id": 62572729, "image": "https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/nerve-cell-2213009_1920_19.jpg", "related": "ABMD", "source": "Benzinga", "summary": "Here's a roundup of top developments in the biotech space over the last 24 hours:\nScaling The Peaks\n(Biotech Stocks Hitting 52-week Highs Jan. 27)\n\nAbbott Laboratories (NYSE:...", "url": "https://finnhub.io/api/news?id=be6aa801127354ddbd0493cf90c45ee345d4fd5bdc28b08d0c7d058698f8c9dc"}, {"category": "company", "datetime": 1611818448, "headline": "Abiomed Inc. Q3 Income Retreats", "id": 63475820, "image": "https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?102124331", "related": "ABMD", "source": "Nasdaq", "summary": "(RTTNews) - Abiomed Inc. (ABMD) released earnings for third quarter that declined from the same period last year.The company's earnings came in at $61.87 million, or $1.35 per share.  This compares with $69.22 million, or $1.51 per share, in last year's third quarter.", "url": "https://finnhub.io/api/news?id=bcb79663c70f70170be6d85afd3c5fbadf9814c0a66c18e8e8b3440ee679ec57"}, {"category": "company", "datetime": 1611806820, "headline": "Earnings Scheduled For January 28, 2021", "id": 62572570, "image": "https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/earnings_scheduled_1790.png", "related": "ABMD", "source": "Benzinga", "summary": "\u00a0\nCompanies Reporting Before The Bell\n\u2022 OSI Systems (NASDAQ:OSIS) is expected to report quarterly earnings at $1.14 per share on revenue of $272.66 million.\n\u2022 GATX...", "url": "https://finnhub.io/api/news?id=4604d5303c559ddfb01d01d2814c871fb0c38d5192b94e68e24d747f1ef79af3"}, {"category": "company", "datetime": 1611792000, "headline": "Abiomed: Q3 Earnings Insights", "id": 62578687, "image": "https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/sites/all/themes/bz2/images/bz-icon.png", "related": "ABMD", "source": "benzinga", "summary": "Shares of Abiomed (NASDAQ:ABMD) were unchanged after the company reported Q3 results.\nQuarterly Results\nEarnings per share rose 20.54% year over year to $1.35, which beat...", "url": "https://finnhub.io/api/news?id=2474b5f668bf383c17d9939eaab9b1638b57544a82a501171ddd7987619b63f8"}, {"category": "company", "datetime": 1611792000, "headline": "The Daily Biotech Pulse: Decision Day For Amgen, Zymeworks Sinks On Data, Ortho Clinical Diagnostics IPO", "id": 62577225, "image": "https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/nerve-cell-2213009_1920_19.jpg", "related": "ABMD", "source": "benzinga", "summary": "Here's a roundup of top developments in the biotech space over the last 24 hours:\nScaling The Peaks\n(Biotech Stocks Hitting 52-week Highs Jan. 27)\n\nAbbott Laboratories (NYSE:...", "url": "https://finnhub.io/api/news?id=58699c55fd905e36ec493479e02e0544dc2e9ccdd82401f3889f9a6a0d19a0fc"}, {"category": "company", "datetime": 1611792000, "headline": "Abiomed: Q3 Earnings Insights", "id": 62575976, "image": "https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/sites/all/themes/bz2/images/bz-icon.png", "related": "ABMD", "source": "benzinga", "summary": "Shares of Abiomed (NASDAQ:ABMD) were unchanged after the company reported Q3 results.\nQuarterly Results\nEarnings per share rose 20.54% year over year to $1.35, which beat...", "url": "https://finnhub.io/api/news?id=2c42f3c8a897cdb0b98ef05ad5ebb977f05b0e71dc5a38d3a01df0d25eb9fc49"}, {"category": "company", "datetime": 1611766680, "headline": "Abiomed Inc. stock underperforms Wednesday when compared to competitors", "id": 62564813, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. slid 3.61% to $328.60 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500...", "url": "https://finnhub.io/api/news?id=f68c74499986952af58b9fb697ccd83f98909a8e1cdba51662e881d58b30ee7c"}, {"category": "company", "datetime": 1611680280, "headline": "Abiomed Inc. stock underperforms Tuesday when compared to competitors", "id": 62533960, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. shed 2.13% to $340.89 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index...", "url": "https://finnhub.io/api/news?id=63f044dfc3065e123105c905eee6c3fc5bc5eff17e80de82bb4bda37dc290a03"}, {"category": "company", "datetime": 1611593880, "headline": "Abiomed Inc. stock rises Monday, still underperforms market", "id": 62506346, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. inched 0.12% higher to $348.32 Monday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500...", "url": "https://finnhub.io/api/news?id=a8d7bd35e567ca407075fdca8b53990985130cb34aa93076f9eb7b82934bc35a"}, {"category": "company", "datetime": 1611532800, "headline": "MagSafe and medical devices: Apple says keep them \u2018a safe distance away\u2019", "id": 62539508, "image": "https://images.idgesg.net/images/article/2020/10/iphone-12-magsafe-100862047-large.3x2.jpg", "related": "ABMD", "source": "https://www.macworld.com", "summary": "Apple posted a support document noting that magnetic interference is possible with medical devices, and that users should consult with their doctor.", "url": "https://finnhub.io/api/news?id=ecbc85ac8f6b5346eefc2669dfc8e46bdf209c8f8bf185634ea528e3d77c582d"}, {"category": "company", "datetime": 1611453600, "headline": "Rule Breaker Investing: 5 Stocks Rolled Up at Random", "id": 63487033, "image": "https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?583932915", "related": "ABMD", "source": "Nasdaq", "summary": "Surely it's not possible to beat the market with a random roll of the dice! But what if we're dicing in a universe of great companies? What if we're randomizing Rule Breakers? In this episode of Rule Breaker Investing, Motley Fool co-founder David Gardner is eager to find this ou", "url": "https://finnhub.io/api/news?id=c27fc9548a17d34f946bb85ad56def21fbef2aaa17f8a6099502812754ec1502"}, {"category": "company", "datetime": 1611360000, "headline": "The Week Ahead In Biotech (Jan 24-30): J&J, Lilly to Kickstart Big Pharma Earnings, Amgen FDA Decision and More", "id": 62538890, "image": "https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/syringe-1884758_1920_36_1.jpg", "related": "ABMD", "source": "benzinga", "summary": "Biopharma stocks advanced yet again in the week ended Jan. 22, with the change of guard at the White House generating broader market strength.\nEli Lilly And Co (NYSE: LLY) was the...", "url": "https://finnhub.io/api/news?id=e9967f226ee7bde531f3307ba27a47d655f6b8ebe0be6f1a8b583576c77807c7"}, {"category": "company", "datetime": 1611334680, "headline": "Abiomed Inc. stock falls Friday, still outperforms market", "id": 62484427, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. slumped 0.19% to $347.90 Friday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index...", "url": "https://finnhub.io/api/news?id=729a0eca21c2ff7e9860fd96eee64501b30d56dab53fb14f2e2d55a681af235d"}, {"category": "company", "datetime": 1611248280, "headline": "Abiomed Inc. stock outperforms market on strong trading day", "id": 62462562, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. inched 0.20% higher to $348.56 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the S&P...", "url": "https://finnhub.io/api/news?id=9a79e69f3569c328039ec4ab5f7df0c27b26cdea58f6df22ca91066521f0b941"}, {"category": "company", "datetime": 1611216300, "headline": "The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer Inovio Announces $150M Follow-On Offering, Boston Scientific Goes Shopping", "id": 62462025, "image": "https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/brain-1787622_1920_57.jpg", "related": "ABMD", "source": "Benzinga", "summary": "Here's a roundup of top developments in the biotech space over the last 24 hours:\nScaling The Peaks\n(Biotech Stocks Hitting 52-week Highs Jan. 20)\n\n10X Genomics Inc\u00a0(...", "url": "https://finnhub.io/api/news?id=bad94e59b438779c4109208792a323663eb68e8f793e9d1f3eb2d037b83b2434"}, {"category": "company", "datetime": 1611161880, "headline": "Abiomed Inc. stock outperforms competitors on strong trading day", "id": 62442422, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. advanced 3.44% to $347.87 Wednesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500...", "url": "https://finnhub.io/api/news?id=ceac42b81d1c160f752c735e5a6e77b964e320b09afb63235ac0287eea6d4a0d"}, {"category": "company", "datetime": 1611127920, "headline": "The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study", "id": 62462137, "image": "https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/medicine-1309148_1920_301.jpg", "related": "ABMD", "source": "Benzinga", "summary": "Here's a roundup of top developments in the biotech space over the last 24 hours.\nScaling The Peaks\n(Biotech Stocks Hitting 52-week Highs Jan. 19)\n\n4D Molecular Therapeutics...", "url": "https://finnhub.io/api/news?id=76fe8eec73d4c09a9a7a5ccd8a4b1144513a9ae5e6d9d6c670501ab185939fb1"}, {"category": "company", "datetime": 1611075180, "headline": "Abiomed Inc. stock rises Tuesday, outperforms market", "id": 62406256, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. rose 2.00% to $336.30 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500...", "url": "https://finnhub.io/api/news?id=42dec1df18b01067c342f8b2780ee90d574cdd8fd45485bd4eadc22e0fea3a35"}, {"category": "company", "datetime": 1611014400, "headline": "Impulse Dynamics anuncia primeiro paciente com insufici\u00eancia card\u00edaca tratado com terapia CCM (MCC - Modula\u00e7\u00e3o de Contratilidade Card\u00edaca) no Brasil", "id": 62390307, "image": "https://mms.businesswire.com/media/20210119005191/pt/780141/23/19-09-25_ID_Coporate_Logo_gray.jpg", "related": "ABMD", "source": "businesswire", "summary": "A Impulse Dynamics, empresa dedicada a ajudar profissionais de sa\u00fade a melhorar as vidas de pessoas com insufici\u00eancia card\u00edaca, anunciou hoje que o pr", "url": "https://finnhub.io/api/news?id=380afa865903429c503686941f7aae78c3188034fdded5f06727a7acbedb448e"}, {"category": "company", "datetime": 1610877600, "headline": "Validea's Top Five Healthcare Stocks Based On David Dreman - 1/17/2021", "id": 63475821, "image": "https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?769180629", "related": "ABMD", "source": "Nasdaq", "summary": "The following are the top rated Healthcare stocks according to Validea's Contrarian Investor model based on the published strategy of David Dreman. This contrarian strategy finds the most unpopular mid- and large-cap stocks in the market and looks for improving fundamentals.CATAL", "url": "https://finnhub.io/api/news?id=3616aa1d403cac6551475eb98288289136ff08324e1764460a97466daccbac31"}, {"category": "company", "datetime": 1610735340, "headline": "Abiomed Inc. stock outperforms market on strong trading day", "id": 62376303, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. rallied 3.58% to $329.69 Friday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index...", "url": "https://finnhub.io/api/news?id=5b2ae15fed318240c0a953f8d7c71d01e4ec781fde2f6ad5ea2be02358b39ca9"}, {"category": "company", "datetime": 1610721238, "headline": "Friday Sector Leaders: Utilities, Healthcare", "id": 63475822, "image": "https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?2131162664", "related": "ABMD", "source": "Nasdaq", "summary": "In afternoon trading on Friday, Utilities stocks are the best performing sector, higher by 1.0%.  Within that group, NiSource Inc.  (Symbol: NI) and CenterPoint Energy, Inc (Symbol: CNP) are two large stocks leading the way, showing a gain of 4.3% and 2.9%, respectively.  Among", "url": "https://finnhub.io/api/news?id=d49e5e0390e1ec8d86277270ff35f5e42808e49e472f29c85e5deb3bd9baa19b"}, {"category": "company", "datetime": 1610704800, "headline": "Validea Peter Lynch Strategy Daily Upgrade Report - 1/15/2021", "id": 63604505, "image": "https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?589303316", "related": "ABMD", "source": "Nasdaq", "summary": "The following are today's upgrades for Validea's P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relative to earnings growth that also possess strong balance sheets.MAGYAR TELEKOM TAVKOZLESI NY", "url": "https://finnhub.io/api/news?id=8a089340fe2d5740d8718f65f29885ac2f6677c4512fec56fea19b7f82cafd45"}, {"category": "company", "datetime": 1610648940, "headline": "Abiomed Inc. stock underperforms Thursday when compared to competitors", "id": 62350397, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. slipped 1.67% to $318.31 Thursday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500...", "url": "https://finnhub.io/api/news?id=b7aae92636fec57df829f756f84f82a1bec41be237ffa7ba8dbe30601d9d169d"}, {"category": "company", "datetime": 1610562600, "headline": "Abiomed Inc. stock falls Wednesday, underperforms market", "id": 62330102, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. slipped 0.30% to $323.71 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500...", "url": "https://finnhub.io/api/news?id=f06ccb400bf7ebcf294ccad9c1d7e26b7c8bf01ae153aff4e952d08a879bf44e"}, {"category": "company", "datetime": 1610476140, "headline": "Abiomed Inc. stock rises Tuesday, still underperforms market", "id": 62300312, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. inched 0.02% higher to $324.67 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P...", "url": "https://finnhub.io/api/news?id=f0ad3dc97c8882c16dbfaefcf0b380b4b1f3e7083ec6d422a43baadafb3777f0"}, {"category": "company", "datetime": 1610389800, "headline": "Abiomed Inc. stock outperforms competitors on strong trading day", "id": 62269481, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. inched 0.16% higher to $324.59 Monday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500...", "url": "https://finnhub.io/api/news?id=fb2cf2fd727d095db64cd8f52273bbf9913eecd4cadc41d8f21502b3912e07f6"}, {"category": "company", "datetime": 1610130540, "headline": "Abiomed Inc. stock rises Friday, still underperforms market", "id": 62235276, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. inched 0.15% higher to $324.06 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P...", "url": "https://finnhub.io/api/news?id=f80cf4b61ce3d268b2f249d63bf8ffa97e7f9bfb4cb98abdfccc2e70e19dc595"}, {"category": "company", "datetime": 1610064000, "headline": "Abiomed setzt die St\u00e4rkung seines geistigen Eigentums fort und h\u00e4lt nun bereits Rechte an \u00fcber 1.000 Patenten", "id": 62226401, "image": "https://mms.businesswire.com/media/20210108005347/de/722993/23/AbioLogo_TAGLINE_COLOR.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ: ABMD) gibt bekannt, dass das Unternehmen \u00fcber mehr als 1.000 Patente und 850 angemeldete Patente weltweit verf\u00fcgt. Das robuste Portfo", "url": "https://finnhub.io/api/news?id=77b342a1e1a5ba8d54fdc2c8bcb1f0849832e8bfc9c9824a8db042636bd9f925"}, {"category": "company", "datetime": 1610044200, "headline": "Abiomed Inc. stock rises Thursday, still underperforms market", "id": 62214719, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. inched 0.61% higher to $323.56 Thursday, on what proved to be an all-around positive trading session for the stock market, with the...", "url": "https://finnhub.io/api/news?id=8f06cfb64eecc16ed32d5ee92ef665dfe5ffb42925b35fdad0f6f465a8fc692d"}, {"category": "company", "datetime": 1609977600, "headline": "Riassunto: Abiomed continua a rafforzare la sua propriet\u00e0 intellettuale, ora detiene pi\u00f9 di 1.000 brevetti", "id": 62201991, "image": "https://mms.businesswire.com/media/20210107005721/it/722993/23/AbioLogo_TAGLINE_COLOR.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ: ABMD) annuncia di aver superato pi\u00f9 di 1.000 brevetti in tutto il mondo, con oltre 850 ulteriori brevetti in corso di registrazione.", "url": "https://finnhub.io/api/news?id=25f21b3633c9fa8588413b8f543280a5dd76a353895218d4e21fd52327c5a95d"}, {"category": "company", "datetime": 1609977600, "headline": "Samenvatting: Abiomed blijft haar intellectuele eigendom versterken en bezit nu meer dan 1.000 patenten", "id": 62198208, "image": "https://mms.businesswire.com/media/20210107005660/nl/722993/23/AbioLogo_TAGLINE_COLOR.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ: ABMD) kondigt aan dat het wereldwijd meer dan 1.000 patenten heeft overtroffen, met meer dan 850 aangevraagde patenten. Abiomeds robu", "url": "https://finnhub.io/api/news?id=40165ef50d6bd770c78c18676693b23cf2364604ccdc8b8dfbefc623a8ea3448"}, {"category": "company", "datetime": 1609977600, "headline": "Abiomed continue de renforcer sa propri\u00e9t\u00e9 intellectuelle et d\u00e9tient \u00e0 pr\u00e9sent plus de 1 000 brevets", "id": 62198205, "image": "https://mms.businesswire.com/media/20210107005665/fr/722993/23/AbioLogo_TAGLINE_COLOR.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ : ABMD) annonce avoir d\u00e9pass\u00e9 le cap des 1 000 brevets au niveau mondial, et compte plus de 850 brevets en instance suppl\u00e9mentaires. L", "url": "https://finnhub.io/api/news?id=43a456e43b2da6dbcfc45b748a5e93213079f2d0342f5992b2ed923bcf7eba3f"}, {"category": "company", "datetime": 1609977600, "headline": "Abiomed Continues to Strengthen its Intellectual Property, Now Holds More Than 1,000 Patents", "id": 62193098, "image": "https://mms.businesswire.com/media/20210107005146/en/722993/23/AbioLogo_TAGLINE_COLOR.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ: ABMD) announces it has surpassed more than 1,000 patents worldwide, with more than 850 additional patents pending. Abiomed\u2019s robust i", "url": "https://finnhub.io/api/news?id=86f868eb30c3c3ca55711435a482ae4bd0337bf8c2de3d84c4db5f8a61d9f324"}, {"category": "company", "datetime": 1609957740, "headline": "Abiomed Inc. stock falls Wednesday, underperforms market", "id": 62182567, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. shed 0.31% to $321.61 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...", "url": "https://finnhub.io/api/news?id=87b9421ed82caa54f63db390489662ad3a30c20bf04efd3327634200713cae28"}, {"category": "company", "datetime": 1609871400, "headline": "Abiomed Inc. stock outperforms market on strong trading day", "id": 62155024, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. rallied 1.85% to $322.60 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...", "url": "https://finnhub.io/api/news?id=709c56c62b74dfd6dbeadbd75ed8f98ae2114606f505c76025fbf78edb78a603"}, {"category": "company", "datetime": 1609835880, "headline": "The Daily Biotech Pulse: Moderna Coronavirus Vaccine Receives Third Regulatory Nod, Gritstone Rallies On Hedge Fund Stake, aTyr's COVID-19 Drug Data", "id": 62154228, "image": "https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/red-blood-cells-3188223_1920_18.jpg", "related": "ABMD", "source": "Benzinga", "summary": "Here's a roundup of top developments in the biotech space over the last 24 hours:\nScaling The Peaks\n(Biotech Stocks Hitting 52-week Highs Jan. 4)\n\nABIOMED, Inc. (NASDAQ: ABMD...", "url": "https://finnhub.io/api/news?id=1d2f2353b8b1d9b4b90e155aa00aea037197901b783a8ef63a0a94ee25682c2b"}, {"category": "company", "datetime": 1609784760, "headline": "Abiomed Inc. stock falls Monday, underperforms market", "id": 62135817, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. slid 2.30% to $316.73 Monday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index...", "url": "https://finnhub.io/api/news?id=fb1ba30e6ca0153af3fd47317ff4294495921e279d4a0370fd227204f1a19b15"}, {"category": "company", "datetime": 1609765020, "headline": "Stocks That Hit 52-Week Highs On Monday", "id": 62135288, "image": "https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/sites/all/themes/bz2/images/bz-icon.png", "related": "ABMD", "source": "Benzinga", "summary": "\u00a0\nDuring Monday's morning session, 286 stocks hit new 52-week highs.\nAreas of Interest:\n\nThe company with the largest market cap to set a new 52-week high was Tesla (...", "url": "https://finnhub.io/api/news?id=7e294fb973473add652290afef1d64bb4821daf6562b0c7a2d728c83fa053b4f"}, {"category": "company", "datetime": 1609565443, "headline": "Andrew J. Greenfield Sells 5,000 Shares of Abiomed, Inc. (NASDAQ:ABMD) Stock", "id": 62102377, "image": "https://www.marketbeat.com/logos/abiomed-logo.gif", "related": "ABMD", "source": "https://www.thelincolnianonline.com", "summary": "Abiomed, Inc. (NASDAQ:ABMD) VP Andrew J. Greenfield sold 5,000 shares of the firm\u2019s stock in a transaction that occurred on Tuesday, December 29th. The shares were sold at an average price of $321.00, for a total value of $1,605,000.00. Following the completion of the transaction, the vice president now owns 26,930 shares of the company\u2019s [\u2026]", "url": "https://finnhub.io/api/news?id=e81ac582ab6f44ac1207de7f40e7414531e1cd338d88befd5f6fcf524fdc8963"}, {"category": "company", "datetime": 1609439340, "headline": "Abiomed Inc. stock rises Thursday, still underperforms market", "id": 62081895, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. inched 0.09% higher to $324.20 Thursday, on what proved to be an all-around great trading session for the stock market, with the S&P...", "url": "https://finnhub.io/api/news?id=1bf63abf7fb4aa4bc9bb4fb2b4de7c1eed91c4554c7fd36d5bd1a9cc711cd06a"}, {"category": "company", "datetime": 1609352940, "headline": "Abiomed Inc. stock outperforms market on strong trading day", "id": 62061521, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. inched 0.93% higher to $323.92 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the...", "url": "https://finnhub.io/api/news?id=514a4f757c1aec52b281dbc20e4fc7c0006c7db8524a8f24d9f5605c697fe719"}, {"category": "company", "datetime": 1609323660, "headline": "Stocks That Hit 52-Week Highs On Wednesday", "id": 62060976, "image": "https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/sites/all/themes/bz2/images/bz-icon.png", "related": "ABMD", "source": "Benzinga", "summary": "\u00a0\nWednesday morning saw 123 companies set new 52-week highs.\nAreas of Significance:\n\nThe largest company by market cap to break to a new 52-week high was Taiwan Semiconductor...", "url": "https://finnhub.io/api/news?id=ae9136bd883a2f0939df6ddc7d2ccd5a379a657146985c2fe8ea9f70588d9994"}, {"category": "company", "datetime": 1609315680, "headline": "The Daily Biotech Pulse: Osmotica Faces Second FDA Rejection, UK Conditionally Approves AstraZeneca's Vaccine Candidate, Hepion NASH Data", "id": 62060980, "image": "https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/dna-24559_1280_26.png", "related": "ABMD", "source": "Benzinga", "summary": "Here's a roundup of top developments in the biotech space over the last 24 hours:\nScaling The Peaks\n(Biotech Stocks Hitting 52-week Highs Dec. 29)\n\nABIOMED, Inc. (NASDAQ: ABMD...", "url": "https://finnhub.io/api/news?id=29f90a1ebf37e89dae203d78ca4ae8be3c4cd0f6b8bad8d3331b5dab56dc98fb"}, {"category": "company", "datetime": 1609266600, "headline": "Abiomed Inc. stock outperforms competitors on strong trading day", "id": 62041554, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. rallied 2.56% to $320.93 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index...", "url": "https://finnhub.io/api/news?id=a005be01972883c19ac48d27bfd23b506b5c5e1c3f0521df501358ed330dda0a"}, {"category": "company", "datetime": 1609256369, "headline": "Tuesday Sector Leaders: Healthcare, Utilities", "id": 62044902, "image": "https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?622864065", "related": "ABMD", "source": "Nasdaq", "summary": "Looking at the sectors faring best as of midday Tuesday, shares of Healthcare companies are outperforming other sectors, not showing much of a loss.  Within that group, ABIOMED, Inc. (Symbol: ABMD) and Zimmer Biomet Holdings Inc (Symbol: ZBH) are two large stocks leading the wa", "url": "https://finnhub.io/api/news?id=fe2435a787bae365d2e2cb8af7a7cf637d9831a0ea2980fe5744c7fb207e551d"}, {"category": "company", "datetime": 1609255200, "headline": "These are the best performing Nasdaq and S&P 500 stocks of 2020", "id": 62032952, "image": "https://s.marketwatch.com/public/resources/images/MW-IX074_tesla__ZG_20201228113827.jpg", "related": "ABMD", "source": "MarketWatch", "summary": "COVID-19 has rewarded companies at the cutting edge of mobility and remote working.", "url": "https://finnhub.io/api/news?id=88cb9befaa833b8fed137f76c4c2e332025cb96bc92458b5a1032a6d2ae0340d"}, {"category": "company", "datetime": 1609241236, "headline": "BUZZ-U.S. STOCKS ON THE MOVE-Amphastar Pharma, Snap, Aprea Therapeutics", "id": 62039916, "image": "https://www.nasdaq.com/sites/acquia.prod/files/2020-11-09T194226Z_892677665_RC2VZJ9Q6HBA_RTRMADP_2_USA-STOCKS.JPG?1577077819", "related": "ABMD", "source": "Nasdaq", "summary": "A compilation of the most active stocks on U.S. exchanges. For faster updates on individual market-movers, Eikon users please use search string \"STXBZ US\" and Thomson One users please search \"RT/STXBZ US\".", "url": "https://finnhub.io/api/news?id=b4ad623c4a8653f35ff9c8e1be1c3938e13efd869559a0fffeb8725eba502fa4"}, {"category": "company", "datetime": 1609239987, "headline": "S&P 500 Movers: LB, ABMD", "id": 62039978, "image": "https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?1796165826", "related": "ABMD", "source": "Nasdaq", "summary": "In early trading on Tuesday, shares of ABIOMED, topped the list of the day's best performing components of the S&P 500 index, trading up 2.7%.  Year to date, ABIOMED, registers a 88.4% gain.", "url": "https://finnhub.io/api/news?id=80fd47e38b796ebf3cd282131946cea2391d7d064c67f64e1a436973cbde1036"}, {"category": "company", "datetime": 1609237920, "headline": "Stocks That Hit 52-Week Highs On Tuesday", "id": 62040135, "image": "https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/sites/all/themes/bz2/images/bz-icon.png", "related": "ABMD", "source": "Benzinga", "summary": "\u00a0\nThis morning 110 companies set new 52-week highs.\nInteresting Facts:\n\nApple (NASDAQ: AAPL) was the company with the largest market cap to set a new 52-week high.\nNew...", "url": "https://finnhub.io/api/news?id=43bcff740e81dc1851ab9c1c7f825e63d649fe8eae96ffa08c998f22f5fc75d0"}, {"category": "company", "datetime": 1609180140, "headline": "Abiomed Inc. stock rises Monday, outperforms market", "id": 62023735, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. advanced 3.13% to $312.91 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...", "url": "https://finnhub.io/api/news?id=70490cb63633b959b87867e06e0a07cf3afa9a9bb317dad7923bbc9706ec00cd"}, {"category": "company", "datetime": 1608852600, "headline": "Abiomed Inc. stock falls Thursday, underperforms market", "id": 61999262, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. sank 0.21% to $303.41 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500...", "url": "https://finnhub.io/api/news?id=423f1cf54ae759350cfa923fc6130bc4b78983962f4c502b1cd4d90f7cd6146c"}, {"category": "company", "datetime": 1608748140, "headline": "Abiomed Inc. stock outperforms competitors on strong trading day", "id": 61951866, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. inched 0.57% higher to $304.05 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the...", "url": "https://finnhub.io/api/news?id=8c0706b08535b38a9bb2bc830f741584adf8e0ca81f86cb46bc7ad9114e8edff"}, {"category": "company", "datetime": 1608661800, "headline": "Abiomed Inc. stock outperforms competitors on strong trading day", "id": 61835791, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. advanced 2.20% to $302.33 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500...", "url": "https://finnhub.io/api/news?id=08030652300da8214d40eda39fa3f263a1cf7e15d08734aec4bd409b7ff6f0e1"}, {"category": "company", "datetime": 1608575400, "headline": "Abiomed Inc. stock outperforms competitors on strong trading day", "id": 61812912, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. inched 0.82% higher to $295.81 Monday, on what proved to be an all-around mixed trading session for the stock market, with the Dow...", "url": "https://finnhub.io/api/news?id=23af7f86d5dd091d251439e39a07f223c56050b250b6f17200572f5b992c9732"}, {"category": "company", "datetime": 1608508800, "headline": "Riassunto: I primi pazienti, compreso un paziente COVID-19, trattati con la tecnologia innovativa ECMO di Abiomed", "id": 61808426, "image": "https://mms.businesswire.com/media/20201221005692/it/848312/23/First_Patient_Ambulating.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ: ABMD) annuncia il trattamento dei primi due pazienti al mondo con Abiomed Breethe OXY-1 System, un sistema compatto di bypass cardiop", "url": "https://finnhub.io/api/news?id=749d50d39c46495d65170ef1b342d53225bd5f35a2f98ea3fa8fb7a8172d4503"}, {"category": "company", "datetime": 1608508800, "headline": "Deux premi\u00e8res patientes, dont une atteinte de la COVID-19, ont \u00e9t\u00e9 trait\u00e9es avec ECMO, la technologie innovante d\u2019Abiomed", "id": 61808390, "image": "https://mms.businesswire.com/media/20201221005680/fr/848312/23/First_Patient_Ambulating.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ: ABMD) annonce que, pour la premi\u00e8re fois au monde, deux patientes ont \u00e9t\u00e9 trait\u00e9es avec l'Abiomed Breethe OXY-1 , un syst\u00e8me de ponta", "url": "https://finnhub.io/api/news?id=b0216e306abba8db7b37f073e9441751512647b3da278b2d65a9881f3b11ca9d"}, {"category": "company", "datetime": 1608508800, "headline": "Deux premi\u00e8res patientes, dont une atteinte de la COVID-19, ont \u00e9t\u00e9 trait\u00e9es avec ECMO, la technologie innovante d\u2019Abiomed", "id": 61808389, "image": "https://mms.businesswire.com/media/20201221005680/fr/848312/23/First_Patient_Ambulating.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ: ABMD) annonce que, pour la premi\u00e8re fois au monde, deux patientes ont \u00e9t\u00e9 trait\u00e9es avec l'Abiomed Breethe OXY-1 , un syst\u00e8me de ponta", "url": "https://finnhub.io/api/news?id=23dea1ace8e5fa3b31d2d1bd55461efdeffc705599fb2fb71c23c763ae78c7cd"}, {"category": "company", "datetime": 1608508800, "headline": "Deux premi\u00e8res patientes, dont une atteinte de la COVID-19, ont \u00e9t\u00e9 trait\u00e9es avec ECMO, la technologie innovante d\u2019Abiomed", "id": 61808388, "image": "https://mms.businesswire.com/media/20201221005680/fr/848312/23/First_Patient_Ambulating.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ: ABMD) annonce que, pour la premi\u00e8re fois au monde, deux patientes ont \u00e9t\u00e9 trait\u00e9es avec l'Abiomed Breethe OXY-1 , un syst\u00e8me de ponta", "url": "https://finnhub.io/api/news?id=190b39a672864dd82e9bf9965eb0c6c68510322b8d78213ca92914fe19317898"}, {"category": "company", "datetime": 1608508800, "headline": "Deux premi\u00e8res patientes, dont une atteinte de la COVID-19, ont \u00e9t\u00e9 trait\u00e9es avec ECMO, la technologie innovante d\u2019Abiomed", "id": 61808333, "image": "https://mms.businesswire.com/media/20201221005680/fr/848312/23/First_Patient_Ambulating.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ: ABMD) annonce que, pour la premi\u00e8re fois au monde, deux patientes ont \u00e9t\u00e9 trait\u00e9es avec l'Abiomed Breethe OXY-1 , un syst\u00e8me de ponta", "url": "https://finnhub.io/api/news?id=5aa4f2017b3b8d139e46db98ca7fb52b768a360c55199dda9166e353a1a96909"}, {"category": "company", "datetime": 1608508800, "headline": "Resumen: Los primeros pacientes, incluido un paciente de COVID-19, tratados con la innovadora tecnolog\u00eda ECMO de Abiomed", "id": 61804754, "image": "https://mms.businesswire.com/media/20201221005524/es/848312/23/First_Patient_Ambulating.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ: ABMD) ha anunciado que los dos primeros pacientes en el mundo han sido tratados con el sistema Abiomed Breethe OXY-1, un sistema de b", "url": "https://finnhub.io/api/news?id=ead68b712339cb7e21b5c02a1b5673a11323a9271bf2a813de4b9b9711cdc672"}, {"category": "company", "datetime": 1608508800, "headline": "Samenvatting: Eerste pati\u00ebnten, waaronder een COVID-19-pati\u00ebnt, behandeld met de innovatieve ECMO-technologie van Abiomed", "id": 61804752, "image": "https://mms.businesswire.com/media/20201221005521/nl/848312/23/First_Patient_Ambulating.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ: ABMD) kondigt aan dat de eerste twee pati\u00ebnten ter wereld zijn behandeld met het Abiomed Breethe OXY-1-systeem, een compact cardiopul", "url": "https://finnhub.io/api/news?id=570bbde46ef6802c3b04c1875bb6bd08b86dac87757c056e2537435c1dbba5cd"}, {"category": "company", "datetime": 1608508800, "headline": "Samenvatting: Eerste pati\u00ebnten, waaronder een COVID-19-pati\u00ebnt, behandeld met de innovatieve ECMO-technologie van Abiomed", "id": 61804751, "image": "https://mms.businesswire.com/media/20201221005521/nl/848312/23/First_Patient_Ambulating.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ: ABMD) kondigt aan dat de eerste twee pati\u00ebnten ter wereld zijn behandeld met het Abiomed Breethe OXY-1-systeem, een compact cardiopul", "url": "https://finnhub.io/api/news?id=bd7ff6e593d458819919aa2f7f431a0eb8d11666907164c2d6fb90f4e9604c84"}, {"category": "company", "datetime": 1608508800, "headline": "Samenvatting: Eerste pati\u00ebnten, waaronder een COVID-19-pati\u00ebnt, behandeld met de innovatieve ECMO-technologie van Abiomed", "id": 61804750, "image": "https://mms.businesswire.com/media/20201221005521/nl/848312/23/First_Patient_Ambulating.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ: ABMD) kondigt aan dat de eerste twee pati\u00ebnten ter wereld zijn behandeld met het Abiomed Breethe OXY-1-systeem, een compact cardiopul", "url": "https://finnhub.io/api/news?id=6c882ebc62c11f28246272f5be962640bea0201c0e74c73ac10e06d1ddb1a82e"}, {"category": "company", "datetime": 1608508800, "headline": "Samenvatting: Eerste pati\u00ebnten, waaronder een COVID-19-pati\u00ebnt, behandeld met de innovatieve ECMO-technologie van Abiomed", "id": 61804740, "image": "https://mms.businesswire.com/media/20201221005521/nl/848312/23/First_Patient_Ambulating.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ: ABMD) kondigt aan dat de eerste twee pati\u00ebnten ter wereld zijn behandeld met het Abiomed Breethe OXY-1-systeem, een compact cardiopul", "url": "https://finnhub.io/api/news?id=94cff3da913ff21fb3d1a706aeeff0e69d19bf2cb5226185345fd0a2577e3fce"}, {"category": "company", "datetime": 1608508800, "headline": "First Patients, Including a COVID-19 Patient, Treated with Abiomed\u2019s Innovative ECMO Technology", "id": 61803375, "image": "https://mms.businesswire.com/media/20201221005403/en/848312/23/First_Patient_Ambulating.jpg", "related": "ABMD", "source": "businesswire", "summary": "The first two patients in the world have been treated with the Abiomed Breethe OXY-1 System, including a COVID-19 patient in respiratory failure.", "url": "https://finnhub.io/api/news?id=254ce248e07c865f51120ba0a085bde998e3536f87951d393966faa0b4d4a9c6"}, {"category": "company", "datetime": 1608508800, "headline": "First Patients, Including a COVID-19 Patient, Treated with Abiomed\u2019s Innovative ECMO Technology", "id": 61803374, "image": "https://mms.businesswire.com/media/20201221005403/en/848312/23/First_Patient_Ambulating.jpg", "related": "ABMD", "source": "businesswire", "summary": "The first two patients in the world have been treated with the Abiomed Breethe OXY-1 System, including a COVID-19 patient in respiratory failure.", "url": "https://finnhub.io/api/news?id=b77c5040f08f65381e2342be3629fd58d58e4c82e63487968b64fc2116a79a30"}, {"category": "company", "datetime": 1608508800, "headline": "First Patients, Including a COVID-19 Patient, Treated with Abiomed\u2019s Innovative ECMO Technology", "id": 61803373, "image": "https://mms.businesswire.com/media/20201221005403/en/848312/23/First_Patient_Ambulating.jpg", "related": "ABMD", "source": "businesswire", "summary": "The first two patients in the world have been treated with the Abiomed Breethe OXY-1 System, including a COVID-19 patient in respiratory failure.", "url": "https://finnhub.io/api/news?id=011c77d556bd19938043fd18ba14c7caf9553e3fa949c2de318561669639f7bd"}, {"category": "company", "datetime": 1608508800, "headline": "First Patients, Including a COVID-19 Patient, Treated with Abiomed\u2019s Innovative ECMO Technology", "id": 61803260, "image": "https://mms.businesswire.com/media/20201221005403/en/848312/23/First_Patient_Ambulating.jpg", "related": "ABMD", "source": "businesswire", "summary": "The first two patients in the world have been treated with the Abiomed Breethe OXY-1 System, including a COVID-19 patient in respiratory failure.", "url": "https://finnhub.io/api/news?id=a7376bf6372faa9c31e02632dcd38f416381af58fc233b06f22217085a5e5f9b"}, {"category": "company", "datetime": 1608316320, "headline": "Abiomed Inc. stock outperforms market on strong trading day", "id": 61792805, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. advanced 4.04% to $293.39 Friday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500...", "url": "https://finnhub.io/api/news?id=ab0261a471ddc336491d9b4aa78ea1497dcf5089a90c333c31b0d9877a65c787"}, {"category": "company", "datetime": 1608229740, "headline": "Abiomed Inc. stock rises Thursday, outperforms market", "id": 61777840, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. advanced 2.86% to $281.99 Thursday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...", "url": "https://finnhub.io/api/news?id=180d3ab5ad4c04d0738842567c55bce6bcccaf59d33e7263dbd6b665c950a242"}, {"category": "company", "datetime": 1608187846, "headline": "Brinker Capital Investments LLC Takes $2.72 Million Position in Abiomed, Inc. (NASDAQ:ABMD)", "id": 61773122, "image": "https://www.marketbeat.com/logos/abiomed-logo.gif", "related": "ABMD", "source": "https://www.thelincolnianonline.com", "summary": "Brinker Capital Investments LLC bought a new stake in shares of Abiomed, Inc. (NASDAQ:ABMD) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 9,810 shares of the medical equipment provider\u2019s stock, valued at approximately $2,718,000. Other large investors also recently made changes [\u2026]", "url": "https://finnhub.io/api/news?id=01f52cec9e9d682737c2f5100d1a2b54d2cae299a4bb6c7275dc04f57e96b862"}, {"category": "company", "datetime": 1608143400, "headline": "Abiomed Inc. stock underperforms Wednesday when compared to competitors", "id": 61764296, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. slipped 0.44% to $274.14 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500...", "url": "https://finnhub.io/api/news?id=3f11ffccf6593c358242bac6e44669a9bb5e5688c45e6a094db506eedf88c544"}, {"category": "company", "datetime": 1608076800, "headline": "Zwei Meilensteine auf dem Weg zu kleineren Zug\u00e4ngen mit Impella erreicht", "id": 61755640, "image": "https://mms.businesswire.com/media/20201216005701/de/846808/23/Picture1.jpg", "related": "ABMD", "source": "businesswire", "summary": "Wie Abiomed (NASDAQ: ABMD) mitteilte, hat das Unternehmen bei der Entwicklung von kleineren Zug\u00e4ngen f\u00fcr die Impella-Herzpumpe zwei Meilensteine errei", "url": "https://finnhub.io/api/news?id=e09aef16a0cdc83d1d320b3ee10a4a55d03fbfc44808c640ac0dffe6fccb871e"}, {"category": "company", "datetime": 1608075300, "headline": "Abiomed Inc. stock outperforms market on strong trading day", "id": 61750946, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. rallied 2.89% to $275.36 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500...", "url": "https://finnhub.io/api/news?id=f12a59e01f9780ae8dd1f3c60fd0abc284c61b248e525a7640b108f23b848e8f"}, {"category": "company", "datetime": 1608046636, "headline": "Noteworthy Tuesday Option Activity: ABMD, RUN, TEAM", "id": 61751605, "image": "https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?681203202", "related": "ABMD", "source": "Nasdaq", "summary": "Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in ABIOMED, Inc. (Symbol: ABMD), where a total volume of 995 contracts has been traded thus far today, a contract volume which is representative of approximately 9", "url": "https://finnhub.io/api/news?id=3f5d46cb455ac03c74081e92cb9d7b6fb36a6029a34e7f9bbc42f432a563b091"}, {"category": "company", "datetime": 1607990400, "headline": "Deux \u00e9tapes franchies vers l'acc\u00e8s aux petits al\u00e9sages avec le dispositif Impella", "id": 61750529, "image": "https://mms.businesswire.com/media/20201215006162/fr/846808/23/Picture1.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ : ABMD) annonce la r\u00e9alisation de deux \u00e9tapes importantes dans le d\u00e9veloppement de l'acc\u00e8s aux petits al\u00e9sages avec la pompe cardiaque", "url": "https://finnhub.io/api/news?id=8729dbb72ae104dd335733c2577440cdb1effffdfcf0dbae877839950a21c09e"}, {"category": "company", "datetime": 1607990400, "headline": "Riassunto: Conseguiti due risultati importanti verso l'accesso di dimensioni ridotte con Impella", "id": 61750445, "image": "https://mms.businesswire.com/media/20201215006147/it/846808/23/Picture1.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ: ABMD) annuncia di aver ottenuto due risultati importanti nello sviluppo dell'accesso di dimensioni ridotte per la pompa cardiaca Impe", "url": "https://finnhub.io/api/news?id=5819cf55261c6fef78f317f3150996ce763433dbc3d12088ef52d8e51d5b1aa7"}, {"category": "company", "datetime": 1607990400, "headline": "Riassunto: Conseguiti due risultati importanti verso l'accesso di dimensioni ridotte con Impella", "id": 61750442, "image": "https://mms.businesswire.com/media/20201215006147/it/846808/23/Picture1.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ: ABMD) annuncia di aver ottenuto due risultati importanti nello sviluppo dell'accesso di dimensioni ridotte per la pompa cardiaca Impe", "url": "https://finnhub.io/api/news?id=1d5740c09d6c0ee3fefed6ef422411d52162aec3ab31cb13190e233456bf75bb"}, {"category": "company", "datetime": 1607990400, "headline": "Riassunto: Conseguiti due risultati importanti verso l'accesso di dimensioni ridotte con Impella", "id": 61750440, "image": "https://mms.businesswire.com/media/20201215006147/it/846808/23/Picture1.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ: ABMD) annuncia di aver ottenuto due risultati importanti nello sviluppo dell'accesso di dimensioni ridotte per la pompa cardiaca Impe", "url": "https://finnhub.io/api/news?id=b8f00ed1c46201eae50d395f1e062beb0682aa2ad5d4fff70f04ddc54d725eea"}, {"category": "company", "datetime": 1607990400, "headline": "Riassunto: Conseguiti due risultati importanti verso l'accesso di dimensioni ridotte con Impella", "id": 61750429, "image": "https://mms.businesswire.com/media/20201215006147/it/846808/23/Picture1.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ: ABMD) annuncia di aver ottenuto due risultati importanti nello sviluppo dell'accesso di dimensioni ridotte per la pompa cardiaca Impe", "url": "https://finnhub.io/api/news?id=ea8cbe4f68c5c2c9f19c0426afa4874d9c4117339f3f1794d2da57ba020c41b8"}, {"category": "company", "datetime": 1607990400, "headline": "Samenvatting: Twee mijlpalen behaald in de richting van toegang tot kleine boringen met Impella", "id": 61747790, "image": "https://mms.businesswire.com/media/20201215005833/nl/846808/23/Picture1.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ: ABMD) kondigt de verwezenlijking aan van twee mijlpalen in de ontwikkeling van toegang voor kleine boringen voor de Impella-hartpomp.", "url": "https://finnhub.io/api/news?id=71694495a6e2502694bff7858f1d54d567acbd12b9f1fa8098f09d1c7e569d9b"}, {"category": "company", "datetime": 1607990400, "headline": "Two Milestones Achieved Toward Small Bore Access with Impella", "id": 61743877, "image": "https://mms.businesswire.com/media/20201215005395/en/846808/23/Picture1.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ: ABMD) announces the achievement of two milestones in the development of small bore access for the Impella heart pump. The Impella ECP", "url": "https://finnhub.io/api/news?id=3f9a27df281571a35178f6cba190aacb5f864f44f58c8aca4a6ac2cf5cf83b84"}, {"category": "company", "datetime": 1607990400, "headline": "Two Milestones Achieved Toward Small Bore Access with Impella", "id": 61743875, "image": "https://mms.businesswire.com/media/20201215005395/en/846808/23/Picture1.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ: ABMD) announces the achievement of two milestones in the development of small bore access for the Impella heart pump. The Impella ECP", "url": "https://finnhub.io/api/news?id=a38dee98aca94c0fa1e69a80c7b34e40340570741163ad1efadd709b7187e0c1"}, {"category": "company", "datetime": 1607990400, "headline": "Two Milestones Achieved Toward Small Bore Access with Impella", "id": 61743873, "image": "https://mms.businesswire.com/media/20201215005395/en/846808/23/Picture1.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ: ABMD) announces the achievement of two milestones in the development of small bore access for the Impella heart pump. The Impella ECP", "url": "https://finnhub.io/api/news?id=561b9b4925d85ef507394bbb1c366dc4548e3aa3ddf4c5ae77a66914c844d242"}, {"category": "company", "datetime": 1607990400, "headline": "Two Milestones Achieved Toward Small Bore Access with Impella", "id": 61743859, "image": "https://mms.businesswire.com/media/20201215005395/en/846808/23/Picture1.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ: ABMD) announces the achievement of two milestones in the development of small bore access for the Impella heart pump. The Impella ECP", "url": "https://finnhub.io/api/news?id=285d15d31b6b71a3e02fbfa13efa8ec5a436621c9b21b61fd26e1d74a10288b2"}, {"category": "company", "datetime": 1607711400, "headline": "Abiomed Inc. stock underperforms Friday when compared to competitors", "id": 61718111, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. slipped 3.54% to $258.45 Friday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones...", "url": "https://finnhub.io/api/news?id=c5aae80b6bff333d01e857ccccca10a72b971c48f34f84c85505fc39ee2cec57"}, {"category": "company", "datetime": 1607697198, "headline": "Friday Sector Laggards: Energy, Healthcare", "id": 61718188, "image": "https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?2104241477", "related": "ABMD", "source": "Nasdaq", "summary": "Looking at the sectors faring worst as of midday Friday, shares of Energy companies are underperforming other sectors, showing a 2.1% loss.  Within that group, Cabot Oil & Gas Corp. (Symbol: COG) and TechnipFMC plc (Symbol: FTI) are two large stocks that are lagging, showin", "url": "https://finnhub.io/api/news?id=327205b0d559aa9b923949990b0e55df066bdfc2534555ab878cd6e94c93401e"}, {"category": "company", "datetime": 1607685565, "headline": "BUZZ-U.S. STOCKS ON THE MOVE-Sonoma Pharma, Walt Disney, NantHealth, Sellas Life Sciences", "id": 61710565, "image": "https://www.nasdaq.com/sites/acquia.prod/files/2020-11-24T225937Z_621074520_RC2Y9K9ISLAQ_RTRMADP_2_USA-STOCKS.JPG?920657974", "related": "ABMD", "source": "Nasdaq", "summary": "A compilation of the most active stocks on U.S. exchanges. For faster updates on individual market-movers, Eikon users please use search string \"STXBZ US\" and Thomson One users please search \"RT/STXBZ US\".", "url": "https://finnhub.io/api/news?id=2f410449b2733594a8ecd721468a40dc426019045fa33a289a036a4cedfad3ef"}, {"category": "company", "datetime": 1607643000, "headline": "Abiomed Inc. stock rises Thursday, outperforms market", "id": 61697625, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. inched 0.67% higher to $267.93 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the S&P...", "url": "https://finnhub.io/api/news?id=89b9cf237426ef55caf21ba6d1c1c936898bbfc14ad20ec2f3fbc1da4d25835e"}, {"category": "company", "datetime": 1607538540, "headline": "Abiomed Inc. stock underperforms Wednesday when compared to competitors", "id": 61678576, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. shed 2.74% to $266.15 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index...", "url": "https://finnhub.io/api/news?id=d434cb5f56101268f8f21a16fd92e805e6ade96927dde4f83486d0108b450a73"}, {"category": "company", "datetime": 1607470140, "headline": "Abiomed Inc. stock outperforms market on strong trading day", "id": 61664331, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. inched 0.65% higher to $273.64 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the...", "url": "https://finnhub.io/api/news?id=4c4619b6effc17fddbe267fd7a8e092205ce3ac7ce1d1a3f83a8e1145bdd61ef"}, {"category": "company", "datetime": 1607365740, "headline": "Abiomed Inc. stock falls Monday, underperforms market", "id": 61649676, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. dropped 0.27% to $271.88 Monday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500...", "url": "https://finnhub.io/api/news?id=06371110873b7fdda1316921d3222afb190ae606ab49de5e6a031f266a0ea888"}, {"category": "company", "datetime": 1607106660, "headline": "Abiomed Inc. stock rises Friday, outperforms market", "id": 61615481, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. advanced 2.16% to $272.61 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500...", "url": "https://finnhub.io/api/news?id=faee5eebaef9665b72be550f79575dd9f27d1ff130b8e45904e146b5751d7a39"}, {"category": "company", "datetime": 1607020260, "headline": "Abiomed Inc. stock rises Thursday, outperforms market", "id": 61596358, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. inched 0.60% higher to $266.84 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the Dow...", "url": "https://finnhub.io/api/news?id=0dcf6810f2778dde4ea151910238a765460dc2dacf352c959765de03a7dd6e10"}, {"category": "company", "datetime": 1606933860, "headline": "Abiomed Inc. stock underperforms Wednesday when compared to competitors", "id": 61574920, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. slid 1.10% to $265.25 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...", "url": "https://finnhub.io/api/news?id=69533ab178ba57fcb216cd6e17d92493ea40322cb1cbbc50c38c4f44300d8dee"}, {"category": "company", "datetime": 1606847460, "headline": "Abiomed Inc. stock falls Tuesday, underperforms market", "id": 61566221, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. shed 2.15% to $268.21 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500...", "url": "https://finnhub.io/api/news?id=6c340a4e755b258795387b59fc8041931ac526c3baad36dde91dec7cf9ba35a7"}, {"category": "company", "datetime": 1606818108, "headline": "S&P 500 Movers: MKC, AIV", "id": 61557073, "image": "https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?1171917608", "related": "ABMD", "source": "Nasdaq", "summary": "", "url": "https://finnhub.io/api/news?id=62f744cde9a4c81d150cbbee28c22871d6c13a8f9363824da27d6f4450255f95"}, {"category": "company", "datetime": 1606761060, "headline": "Abiomed Inc. stock rises Monday, outperforms market", "id": 61549084, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. inched 0.81% higher to $274.10 Monday, on what proved to be an all-around dismal trading session for the stock market, with the S&P...", "url": "https://finnhub.io/api/news?id=cbfe5c052e26d231f5ec66bc60367632f9a22f6430acec6aebf01b7ac2f3862c"}, {"category": "company", "datetime": 1606629892, "headline": "Abiomed, Inc. (NASDAQ:ABMD) Shares Bought by BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp", "id": 61528336, "image": "https://www.marketbeat.com/logos/abiomed-logo.gif", "related": "ABMD", "source": "https://www.thelincolnianonline.com", "summary": "BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp grew its holdings in shares of Abiomed, Inc. (NASDAQ:ABMD) by 8.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 7,798 shares of the medical equipment provider\u2019s stock after buying an additional 577 shares during [\u2026]", "url": "https://finnhub.io/api/news?id=e26804d5b801cefafb3e852d52555bcac4bf58320f2731bb144300e706c93e91"}, {"category": "company", "datetime": 1606502700, "headline": "Abiomed Inc. stock rises Friday, outperforms market", "id": 61525826, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. rallied 3.06% to $271.90 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...", "url": "https://finnhub.io/api/news?id=92e6e1e4918cce69e5154a6b6810c6c0550a1884ae32789d04f0dea28e8ab3b2"}, {"category": "company", "datetime": 1606262400, "headline": "Abiomed to Hold Fireside Chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference", "id": 61488769, "image": "https://mms.businesswire.com/media/20201125005082/en/722993/23/AbioLogo_TAGLINE_COLOR.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed to hold fireside chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference.", "url": "https://finnhub.io/api/news?id=9e76b775c1a5ef17ecb02655a71b32c74aacceffd156d85938924eb3db82f1ff"}, {"category": "company", "datetime": 1606242600, "headline": "Abiomed Inc. stock underperforms Tuesday when compared to competitors", "id": 61487229, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. shed 0.29% to $265.67 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...", "url": "https://finnhub.io/api/news?id=fea012fa9fa286cd67fcac80c09a0892b57fa821db602a92c31855f5505f3bad"}, {"category": "company", "datetime": 1606156200, "headline": "Abiomed Inc. stock falls Monday, underperforms market", "id": 61463814, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. shed 0.66% to $266.43 Monday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500...", "url": "https://finnhub.io/api/news?id=43dcf6f7d4f355a68005c7813d8e106ea634cd776a7c02413a3d23968009b288"}, {"category": "company", "datetime": 1605896940, "headline": "Abiomed Inc. stock falls Friday, underperforms market", "id": 61441971, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. sank 0.89% to $268.21 Friday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index...", "url": "https://finnhub.io/api/news?id=7ac5d07841109c8e04d83bddc96e485a4482b5a10a3c5f2df7b77867411969b9"}, {"category": "company", "datetime": 1605810540, "headline": "Abiomed Inc. stock outperforms market on strong trading day", "id": 61426338, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. rose 1.65% to $270.61 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500...", "url": "https://finnhub.io/api/news?id=3b1340d8586b8483a7ebefe698991e21ca50f4e657890ca19072871b1b01a2e8"}, {"category": "company", "datetime": 1605773045, "headline": "Sum Up The Parts: CURE Could Be Worth $76", "id": 61420730, "image": "https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?125592738", "related": "ABMD", "source": "Nasdaq", "summary": "Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itsel", "url": "https://finnhub.io/api/news?id=c0731cb08a33c27e3695a7d5d64ac75df1b7dddca809e0dc8382cf070a83a72b"}, {"category": "company", "datetime": 1605724200, "headline": "Abiomed Inc. stock falls Wednesday, underperforms market", "id": 61408610, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. shed 1.38% to $266.21 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500...", "url": "https://finnhub.io/api/news?id=41d4f853a2f5f635b0d68b34b828d8402ac11029f9df76bc21aa2fe4a488bc66"}, {"category": "company", "datetime": 1605681360, "headline": "These 3 Medical Device Stocks Leave Biotech in the Dust", "id": 61400528, "image": "https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?1379767473", "related": "ABMD", "source": "Nasdaq", "summary": "Even though the biotech sector's coronavirus vaccine efforts have dominated the 2020 news cycle, those stocks don't always beat the market. When it comes to consistent profitability, long-term growth, large competitive moats, and innovation, medical device companies can provide b", "url": "https://finnhub.io/api/news?id=146834faaf1c1caecaf212383fe83437227977411281ea44ad27af46d1a6b1bf"}, {"category": "company", "datetime": 1605637800, "headline": "Abiomed Inc. stock falls Tuesday, underperforms market", "id": 61387553, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. shed 1.03% to $269.93 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index...", "url": "https://finnhub.io/api/news?id=3abc499b01b93fbb97e1e0ff0fcea166d35323a3a33053f031fdcad5166ffa07"}, {"category": "company", "datetime": 1605551400, "headline": "Abiomed Inc. stock rises Monday, still underperforms market", "id": 61369390, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. inched 0.24% higher to $272.75 Monday, on what proved to be an all-around favorable trading session for the stock market, with the S&P...", "url": "https://finnhub.io/api/news?id=813e4116b5152da5d421617ca8434d7a223896ee699a17f3db8fb4dde02eb9c1"}, {"category": "company", "datetime": 1605292200, "headline": "Abiomed Inc. stock rises Friday, outperforms market", "id": 61344395, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. advanced 1.42% to $272.10 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...", "url": "https://finnhub.io/api/news?id=af49d4537eb56a7d69d130c811ca18baf9a2b2938c4c6672b5aec38f945d7b52"}, {"category": "company", "datetime": 1605205800, "headline": "Abiomed Inc. stock falls Thursday, still outperforms market", "id": 61320393, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. dropped 0.37% to $268.29 Thursday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500...", "url": "https://finnhub.io/api/news?id=bfd528af3ecc8ac03944ea1f5cd852a1c2db5d3c903721b052d35b37ca567ffc"}, {"category": "company", "datetime": 1605052800, "headline": "Abiomed to Hold Fireside Chat at the Stephens Annual Investment Conference 2020", "id": 61274935, "image": "https://mms.businesswire.com/media/20201111005069/en/722993/23/AbioLogo_TAGLINE_COLOR.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed to hold fireside chat at the Stephens Annual Investment Conference 2020.", "url": "https://finnhub.io/api/news?id=9d0cf3c773d5c04a93908602bb2dc7c156537794d4611e9e1fa7164e97b11c44"}, {"category": "company", "datetime": 1605016976, "headline": "Noteworthy Tuesday Option Activity: V, RMD, ABMD", "id": 61305279, "image": "https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?201850126", "related": "ABMD", "source": "Nasdaq", "summary": "Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in Visa Inc (Symbol: V), where a total volume of 36,871 contracts has been traded thus far today, a contract volume which is representative of approximately 3.7 mil", "url": "https://finnhub.io/api/news?id=50ff019a536f7299dff50224a513366af3e0ca4429fafe45cbd38a4bc8e5ad63"}, {"category": "company", "datetime": 1605005528, "headline": "BUZZ-U.S. STOCKS ON THE MOVE-AnPac Bio, CureVac, Square, PayPal", "id": 61278121, "image": "https://www.nasdaq.com/sites/acquia.prod/files/2020-05-26T152334Z_1130223900_RC2FWG98Z79D_RTRMADP_2_USA-STOCKS.JPG?1087416887", "related": "ABMD", "source": "Nasdaq", "summary": "A compilation of the most active stocks on U.S. exchanges. For faster updates on individual market-movers, Eikon users please use search string \"STXBZ US\" and Thomson One users please search \"RT/STXBZ US\".", "url": "https://finnhub.io/api/news?id=6122f249a96c7f2d2a7f1295f99ee0e31a948456a73cdc23e7a46903100c6473"}, {"category": "company", "datetime": 1604831683, "headline": "Open Kitchens: The YouTubers celebrating food and friendship in Manchester", "id": 62602548, "image": "https://i2-prod.manchestereveningnews.co.uk/incoming/article19156911.ece/ALTERNATES/s1200/0_AMR_MEN_23102020_HeartParcelClasses_10.jpg", "related": "ABMD", "source": "https://www.manchestereveningnews.co.uk", "summary": "\u201cSuccess isn\u2019t just about what you accomplish in life; it\u2019s about what you inspire others to do.\u201d", "url": "https://finnhub.io/api/news?id=900ec271f41e97863e50220071897a49ec455c440982c19478da3916c52d4ecb"}, {"category": "company", "datetime": 1604818963, "headline": "Abiomed, Inc. (NASDAQ:ABMD) Shares Sold by Dupont Capital Management Corp", "id": 61174718, "image": "https://www.marketbeat.com/logos/abiomed-logo.gif", "related": "ABMD", "source": "https://www.thelincolnianonline.com", "summary": "Dupont Capital Management Corp trimmed its position in shares of Abiomed, Inc. (NASDAQ:ABMD) by 13.7% in the third quarter, HoldingsChannel reports. The firm owned 1,865 shares of the medical equipment provider\u2019s stock after selling 295 shares during the period. Dupont Capital Management Corp\u2019s holdings in Abiomed were worth $517,000 as of its most recent filing [\u2026]", "url": "https://finnhub.io/api/news?id=2aa6647159d2baac64e9ef554e32041ca57863e48d06c1e1ba2a5c7b919e55c8"}, {"category": "company", "datetime": 1604750820, "headline": "Is Abiomed Stock a Buy? | The Motley Fool", "id": 61076529, "image": "https://g.foolcdn.com/editorial/images/598687/gettyimages-1146913659.jpg", "related": "ABMD", "source": "https://www.fool.com", "summary": "It depends on whether or not the company's decelerating revenue growth is a symptom of larger problems.", "url": "https://finnhub.io/api/news?id=4344a824db13b5d4173994cc083e06730eaf65d575ded42709c223f88c276ce3"}, {"category": "company", "datetime": 1604732820, "headline": "Is Abiomed Stock a Buy?", "id": 61172125, "image": "https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?1010917501", "related": "ABMD", "source": "Nasdaq", "summary": "Abiomed (NASDAQ: ABMD) is a well known manufacturer of cardiac and circulatory support devices, including Impella heart pumps and the Breethe OXY-1 cardiopulmonary system. While many consumers -- and many of the company's own investors -- may go their whole lives without hearing", "url": "https://finnhub.io/api/news?id=10634093b95b4d31fd716133f0ee503c20554490604687d0ddd4edb1be51c360"}, {"category": "company", "datetime": 1604620800, "headline": "Les 1.000 premiers patients ont \u00e9t\u00e9 trait\u00e9s avec la pompe Impella 5.5 avec SmartAssist, une pompe cardiaque con\u00e7ue pour les chirurgiens", "id": 61034487, "image": "https://mms.businesswire.com/media/20201106005408/fr/836158/23/Keith_Brown.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ: ABMD) annonce que 1.000 patients ont \u00e9t\u00e9 trait\u00e9s avec la pompe cardiaque Impella 5.5 avec SmartAssist au cours de la premi\u00e8re ann\u00e9e s", "url": "https://finnhub.io/api/news?id=1a9735487fc4674fbc15082b4b96dbb0d8456ed479c31d32086634c4e9bf598c"}, {"category": "company", "datetime": 1604620800, "headline": "Les 1.000 premiers patients ont \u00e9t\u00e9 trait\u00e9s avec la pompe Impella 5.5 avec SmartAssist, une pompe cardiaque con\u00e7ue pour les chirurgiens", "id": 61034486, "image": "https://mms.businesswire.com/media/20201106005408/fr/836158/23/Keith_Brown.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ: ABMD) annonce que 1.000 patients ont \u00e9t\u00e9 trait\u00e9s avec la pompe cardiaque Impella 5.5 avec SmartAssist au cours de la premi\u00e8re ann\u00e9e s", "url": "https://finnhub.io/api/news?id=b158c6b5a4a68350df8265199c1dab5d92ed4b6746ee534fcd71505b7148f15a"}, {"category": "company", "datetime": 1604620800, "headline": "Les 1.000 premiers patients ont \u00e9t\u00e9 trait\u00e9s avec la pompe Impella 5.5 avec SmartAssist, une pompe cardiaque con\u00e7ue pour les chirurgiens", "id": 61034065, "image": "https://mms.businesswire.com/media/20201106005408/fr/836158/23/Keith_Brown.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ: ABMD) annonce que 1.000 patients ont \u00e9t\u00e9 trait\u00e9s avec la pompe cardiaque Impella 5.5 avec SmartAssist au cours de la premi\u00e8re ann\u00e9e s", "url": "https://finnhub.io/api/news?id=37dcc6c5c2ae27a3507b062d96480757f91fa61c271f488f11e24c9c766e22f5"}, {"category": "company", "datetime": 1604620800, "headline": "Les 1.000 premiers patients ont \u00e9t\u00e9 trait\u00e9s avec la pompe Impella 5.5 avec SmartAssist, une pompe cardiaque con\u00e7ue pour les chirurgiens", "id": 61034062, "image": "https://mms.businesswire.com/media/20201106005408/fr/836158/23/Keith_Brown.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ: ABMD) annonce que 1.000 patients ont \u00e9t\u00e9 trait\u00e9s avec la pompe cardiaque Impella 5.5 avec SmartAssist au cours de la premi\u00e8re ann\u00e9e s", "url": "https://finnhub.io/api/news?id=fac82de46a592b8a922447f1015bfe583837a90c7a3e7ea9604879dcb40ddf06"}, {"category": "company", "datetime": 1604620800, "headline": "Les 1.000 premiers patients ont \u00e9t\u00e9 trait\u00e9s avec la pompe Impella 5.5 avec SmartAssist, une pompe cardiaque con\u00e7ue pour les chirurgiens", "id": 61033380, "image": "https://mms.businesswire.com/media/20201106005408/fr/836158/23/Keith_Brown.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ: ABMD) annonce que 1.000 patients ont \u00e9t\u00e9 trait\u00e9s avec la pompe cardiaque Impella 5.5 avec SmartAssist au cours de la premi\u00e8re ann\u00e9e s", "url": "https://finnhub.io/api/news?id=cc05f612a147c13f344ee3df5104bc24e8d3f3fcc90fbf97c892aba9282aecb0"}, {"category": "company", "datetime": 1604581200, "headline": "First 1,000 Patients Treated with Impella 5.5 with SmartAssist, a Heart Pump Designed for Surgeons", "id": 60519850, "image": "", "related": "ABMD", "source": "Yahoo", "summary": "Abiomed (NASDAQ: ABMD) announces 1,000 patients have been treated with the Impella 5.5 with SmartAssist heart pump in the first year after the U.S. Food and Drug Administration (FDA) granted Impella 5.5 with SmartAssist its highest level of approval for safety and efficacy.", "url": "https://finnhub.io/api/news?id=e119ff0efe4db3e206bf0a7d168f4a05fd902cb34cb112348792e79887720461"}, {"category": "company", "datetime": 1604534400, "headline": "Resumen: Primeros 1.000 pacientes tratados con Impella 5.5 with SmartAssist, una bomba cardiaca dise\u00f1ada por cirujanos", "id": 60445927, "image": "https://mms.businesswire.com/media/20201105005691/es/836158/23/Keith_Brown.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ: ABMD) ha anunciado que 1.000 pacientes han sido tratados con la bomba cardiaca Impella 5.5 with SmartAssist en el primer a\u00f1o despu\u00e9s", "url": "https://finnhub.io/api/news?id=6da1ea3b3ced0f5cefd874d9e2507217ee2e674333c214c81cb4f7e4d3cc0ff7"}, {"category": "company", "datetime": 1604534400, "headline": "Resumen: Primeros 1.000 pacientes tratados con Impella 5.5 with SmartAssist, una bomba cardiaca dise\u00f1ada por cirujanos", "id": 60445926, "image": "https://mms.businesswire.com/media/20201105005691/es/836158/23/Keith_Brown.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ: ABMD) ha anunciado que 1.000 pacientes han sido tratados con la bomba cardiaca Impella 5.5 with SmartAssist en el primer a\u00f1o despu\u00e9s", "url": "https://finnhub.io/api/news?id=8ef1af1993bb23d4ad23f5baa3ff5e614354a4a53e6a96c7b00e7c2e4723768d"}, {"category": "company", "datetime": 1604534400, "headline": "Resumen: Primeros 1.000 pacientes tratados con Impella 5.5 with SmartAssist, una bomba cardiaca dise\u00f1ada por cirujanos", "id": 60445925, "image": "https://mms.businesswire.com/media/20201105005691/es/836158/23/Keith_Brown.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ: ABMD) ha anunciado que 1.000 pacientes han sido tratados con la bomba cardiaca Impella 5.5 with SmartAssist en el primer a\u00f1o despu\u00e9s", "url": "https://finnhub.io/api/news?id=3b186309f782085bfae9e59c386a683d30bbc4e336df5966421fe4b81686f56e"}, {"category": "company", "datetime": 1604534400, "headline": "Resumen: Primeros 1.000 pacientes tratados con Impella 5.5 with SmartAssist, una bomba cardiaca dise\u00f1ada por cirujanos", "id": 60445924, "image": "https://mms.businesswire.com/media/20201105005691/es/836158/23/Keith_Brown.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ: ABMD) ha anunciado que 1.000 pacientes han sido tratados con la bomba cardiaca Impella 5.5 with SmartAssist en el primer a\u00f1o despu\u00e9s", "url": "https://finnhub.io/api/news?id=a91cc6b69a4ab97371e595538f49c15bf41643ba94b1e0d7fb874db80b281282"}, {"category": "company", "datetime": 1604534400, "headline": "Resumen: Primeros 1.000 pacientes tratados con Impella 5.5 with SmartAssist, una bomba cardiaca dise\u00f1ada por cirujanos", "id": 60445513, "image": "https://mms.businesswire.com/media/20201105005691/es/836158/23/Keith_Brown.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ: ABMD) ha anunciado que 1.000 pacientes han sido tratados con la bomba cardiaca Impella 5.5 with SmartAssist en el primer a\u00f1o despu\u00e9s", "url": "https://finnhub.io/api/news?id=2d1998b6b382616cfb2cb854819bb65eb3ecd933e22b28d098bd4e607535566f"}, {"category": "company", "datetime": 1604534400, "headline": "First 1,000 Patients Treated with Impella 5.5 with SmartAssist, a Heart Pump Designed for Surgeons", "id": 60441474, "image": "https://mms.businesswire.com/media/20201105005280/en/836158/23/Keith_Brown.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ: ABMD) announces 1,000 patients have been treated with the Impella 5.5 with SmartAssist heart pump in the first year after the U.S. Fo", "url": "https://finnhub.io/api/news?id=2bb43bd31165ca53d8a949a883816b39e3ed3131ff6b9f5e04085e01efaab2f3"}, {"category": "company", "datetime": 1604477573, "headline": "Abiomed, Inc. (NASDAQ:ABMD) Shares Purchased by Cambridge Investment Research Advisors Inc.", "id": 60079350, "image": "https://www.marketbeat.com/logos/abiomed-logo.gif", "related": "ABMD", "source": "https://www.thelincolnianonline.com", "summary": "Cambridge Investment Research Advisors Inc. increased its holdings in Abiomed, Inc. (NASDAQ:ABMD) by 865.3% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 14,952 shares of the medical equipment provider\u2019s stock after purchasing an additional 13,403 shares during the quarter. Cambridge Investment Research Advisors Inc.\u2019s [\u2026]", "url": "https://finnhub.io/api/news?id=c747dfdf4e222bbc55f1f5e7efdcc694bb4696ca3179389254a3f422e69f8e08"}, {"category": "company", "datetime": 1604477565, "headline": "Abiomed, Inc. (NASDAQ:ABMD) Shares Acquired by Sumitomo Mitsui DS Asset Management Company Ltd", "id": 60228306, "image": "https://www.marketbeat.com/logos/abiomed-logo.gif", "related": "ABMD", "source": "https://www.thelincolnianonline.com", "summary": "Sumitomo Mitsui DS Asset Management Company Ltd increased its holdings in shares of Abiomed, Inc. (NASDAQ:ABMD) by 1.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,779 shares of the medical equipment provider\u2019s stock after purchasing an additional 39 [\u2026]", "url": "https://finnhub.io/api/news?id=f62ef17b9f74c355b49cfe344a612202db3a41e700bc85084b58a119e3a6733e"}, {"category": "company", "datetime": 1604473870, "headline": "New Mexico Educational Retirement Board Raises Holdings in Abiomed, Inc. (NASDAQ:ABMD)", "id": 60063139, "image": "https://www.marketbeat.com/logos/abiomed-logo.gif", "related": "ABMD", "source": "https://www.thelincolnianonline.com", "summary": "New Mexico Educational Retirement Board increased its stake in shares of Abiomed, Inc. (NASDAQ:ABMD) by 14.8% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 3,500 shares of the medical equipment provider\u2019s stock after buying an additional 450 shares during the quarter. [\u2026]", "url": "https://finnhub.io/api/news?id=dbea19fd7d92c30978e9e4b7bfd24044f59c4cf3064c02ed556cde2c130f908b"}, {"category": "company", "datetime": 1604275200, "headline": "\u4e16\u754c\u6700\u5c0f\u5fc3\u81d3\u30dd\u30f3\u30d7\u306e9Fr Impella ECP\u3067\u521d\u3081\u3066\u60a3\u8005\u3092\u6cbb\u7642", "id": 57811393, "image": "https://mms.businesswire.com/media/20201101005072/ja/834159/23/Impella_ECP_Solo_Graphic.jpg", "related": "ABMD", "source": "businesswire", "summary": "\uff08\u30d3\u30b8\u30cd\u30b9\u30ef\u30a4\u30e4\uff09 -- \u30a2\u30d3\u30aa\u30e1\u30c3\u30c9\uff08NASDAQ: ABMD\uff09\u306f\u3001\u62e1\u5f35\u578b\u7d4c\u76ae\u7684\u5fc3\u81d3\u30dd\u30f3\u30d7Impella ECP\u306b\u3088\u308b\u6cbb\u7642\u30922\u4eba\u306e\u60a3\u8005\u304c\u521d\u3081\u3066\u53d7\u3051\u305f\u3053\u3068\u3092\u767a\u8868\u3057\u307e\u3057\u305f\u3002Impella ECP\u306f\u4e16\u754c\u6700\u5c0f\u306e\u5fc3\u81d3\u30dd\u30f3\u30d7\u3067\u3059\u3002\u4f53\u5185\u3078\u306e\u633f\u5165\u304a\u3088\u3073\u629c\u53bb\u306b\u969b\u3057\u3066\u306e\u76f4\u5f84\u306f9\u30d5\u30ec\u30f3\u30c1\uff08Fr\uff09\uff083\u30df\u30ea\u30e1\u30fc\u30c8\u30eb\uff09\u3067\u3059\u3002", "url": "https://finnhub.io/api/news?id=02079218f5fab4b4dca49c8472f50bd61defae94fcbbd61898281be4da15f2ff"}, {"category": "company", "datetime": 1604275200, "headline": "\u4e16\u754c\u6700\u5c0f\u5fc3\u81d3\u30dd\u30f3\u30d7\u306e9Fr Impella ECP\u3067\u521d\u3081\u3066\u60a3\u8005\u3092\u6cbb\u7642", "id": 57811166, "image": "https://mms.businesswire.com/media/20201101005072/ja/834159/23/Impella_ECP_Solo_Graphic.jpg", "related": "ABMD", "source": "businesswire", "summary": "\uff08\u30d3\u30b8\u30cd\u30b9\u30ef\u30a4\u30e4\uff09 -- \u30a2\u30d3\u30aa\u30e1\u30c3\u30c9\uff08NASDAQ: ABMD\uff09\u306f\u3001\u62e1\u5f35\u578b\u7d4c\u76ae\u7684\u5fc3\u81d3\u30dd\u30f3\u30d7Impella ECP\u306b\u3088\u308b\u6cbb\u7642\u30922\u4eba\u306e\u60a3\u8005\u304c\u521d\u3081\u3066\u53d7\u3051\u305f\u3053\u3068\u3092\u767a\u8868\u3057\u307e\u3057\u305f\u3002Impella ECP\u306f\u4e16\u754c\u6700\u5c0f\u306e\u5fc3\u81d3\u30dd\u30f3\u30d7\u3067\u3059\u3002\u4f53\u5185\u3078\u306e\u633f\u5165\u304a\u3088\u3073\u629c\u53bb\u306b\u969b\u3057\u3066\u306e\u76f4\u5f84\u306f9\u30d5\u30ec\u30f3\u30c1\uff08Fr\uff09\uff083\u30df\u30ea\u30e1\u30fc\u30c8\u30eb\uff09\u3067\u3059\u3002", "url": "https://finnhub.io/api/news?id=6c7c5f1e16d8053c367e021e0eb38ff61b3e2546c0edeefef990d9dc6711ca49"}, {"category": "company", "datetime": 1604275200, "headline": "\u4e16\u754c\u6700\u5c0f\u5fc3\u81d3\u30dd\u30f3\u30d7\u306e9Fr Impella ECP\u3067\u521d\u3081\u3066\u60a3\u8005\u3092\u6cbb\u7642", "id": 57810699, "image": "https://mms.businesswire.com/media/20201101005072/ja/834159/23/Impella_ECP_Solo_Graphic.jpg", "related": "ABMD", "source": "businesswire", "summary": "\uff08\u30d3\u30b8\u30cd\u30b9\u30ef\u30a4\u30e4\uff09 -- \u30a2\u30d3\u30aa\u30e1\u30c3\u30c9\uff08NASDAQ: ABMD\uff09\u306f\u3001\u62e1\u5f35\u578b\u7d4c\u76ae\u7684\u5fc3\u81d3\u30dd\u30f3\u30d7Impella ECP\u306b\u3088\u308b\u6cbb\u7642\u30922\u4eba\u306e\u60a3\u8005\u304c\u521d\u3081\u3066\u53d7\u3051\u305f\u3053\u3068\u3092\u767a\u8868\u3057\u307e\u3057\u305f\u3002Impella ECP\u306f\u4e16\u754c\u6700\u5c0f\u306e\u5fc3\u81d3\u30dd\u30f3\u30d7\u3067\u3059\u3002\u4f53\u5185\u3078\u306e\u633f\u5165\u304a\u3088\u3073\u629c\u53bb\u306b\u969b\u3057\u3066\u306e\u76f4\u5f84\u306f9\u30d5\u30ec\u30f3\u30c1\uff08Fr\uff09\uff083\u30df\u30ea\u30e1\u30fc\u30c8\u30eb\uff09\u3067\u3059\u3002", "url": "https://finnhub.io/api/news?id=0e126c5cce15a6662eb489183e832bc157c5f0ca6c1938254caf9ee5e04347ba"}, {"category": "company", "datetime": 1604275200, "headline": "\u4e16\u754c\u6700\u5c0f\u5fc3\u81d3\u30dd\u30f3\u30d7\u306e9Fr Impella ECP\u3067\u521d\u3081\u3066\u60a3\u8005\u3092\u6cbb\u7642", "id": 57810311, "image": "https://mms.businesswire.com/media/20201101005072/ja/834159/23/Impella_ECP_Solo_Graphic.jpg", "related": "ABMD", "source": "businesswire", "summary": "\uff08\u30d3\u30b8\u30cd\u30b9\u30ef\u30a4\u30e4\uff09 -- \u30a2\u30d3\u30aa\u30e1\u30c3\u30c9\uff08NASDAQ: ABMD\uff09\u306f\u3001\u62e1\u5f35\u578b\u7d4c\u76ae\u7684\u5fc3\u81d3\u30dd\u30f3\u30d7Impella ECP\u306b\u3088\u308b\u6cbb\u7642\u30922\u4eba\u306e\u60a3\u8005\u304c\u521d\u3081\u3066\u53d7\u3051\u305f\u3053\u3068\u3092\u767a\u8868\u3057\u307e\u3057\u305f\u3002Impella ECP\u306f\u4e16\u754c\u6700\u5c0f\u306e\u5fc3\u81d3\u30dd\u30f3\u30d7\u3067\u3059\u3002\u4f53\u5185\u3078\u306e\u633f\u5165\u304a\u3088\u3073\u629c\u53bb\u306b\u969b\u3057\u3066\u306e\u76f4\u5f84\u306f9\u30d5\u30ec\u30f3\u30c1\uff08Fr\uff09\uff083\u30df\u30ea\u30e1\u30fc\u30c8\u30eb\uff09\u3067\u3059\u3002", "url": "https://finnhub.io/api/news?id=dc413d7abe017b317e77738d9f064c5537c2a36c0bd17f18e5fb50e57b190574"}, {"category": "company", "datetime": 1604275200, "headline": "\u4e16\u754c\u6700\u5c0f\u5fc3\u81d3\u30dd\u30f3\u30d7\u306e9Fr Impella ECP\u3067\u521d\u3081\u3066\u60a3\u8005\u3092\u6cbb\u7642", "id": 57809869, "image": "https://mms.businesswire.com/media/20201101005072/ja/834159/23/Impella_ECP_Solo_Graphic.jpg", "related": "ABMD", "source": "businesswire", "summary": "\uff08\u30d3\u30b8\u30cd\u30b9\u30ef\u30a4\u30e4\uff09 -- \u30a2\u30d3\u30aa\u30e1\u30c3\u30c9\uff08NASDAQ: ABMD\uff09\u306f\u3001\u62e1\u5f35\u578b\u7d4c\u76ae\u7684\u5fc3\u81d3\u30dd\u30f3\u30d7Impella ECP\u306b\u3088\u308b\u6cbb\u7642\u30922\u4eba\u306e\u60a3\u8005\u304c\u521d\u3081\u3066\u53d7\u3051\u305f\u3053\u3068\u3092\u767a\u8868\u3057\u307e\u3057\u305f\u3002Impella ECP\u306f\u4e16\u754c\u6700\u5c0f\u306e\u5fc3\u81d3\u30dd\u30f3\u30d7\u3067\u3059\u3002\u4f53\u5185\u3078\u306e\u633f\u5165\u304a\u3088\u3073\u629c\u53bb\u306b\u969b\u3057\u3066\u306e\u76f4\u5f84\u306f9\u30d5\u30ec\u30f3\u30c1\uff08Fr\uff09\uff083\u30df\u30ea\u30e1\u30fc\u30c8\u30eb\uff09\u3067\u3059\u3002", "url": "https://finnhub.io/api/news?id=a02e3794593871037cc13e7934402de8fa834cfac83ccbb7810d7c7931a30d78"}, {"category": "company", "datetime": 1604275200, "headline": "\u4e16\u754c\u6700\u5c0f\u5fc3\u81d3\u30dd\u30f3\u30d7\u306e9Fr Impella ECP\u3067\u521d\u3081\u3066\u60a3\u8005\u3092\u6cbb\u7642", "id": 57809510, "image": "https://mms.businesswire.com/media/20201101005072/ja/834159/23/Impella_ECP_Solo_Graphic.jpg", "related": "ABMD", "source": "businesswire", "summary": "\uff08\u30d3\u30b8\u30cd\u30b9\u30ef\u30a4\u30e4\uff09 -- \u30a2\u30d3\u30aa\u30e1\u30c3\u30c9\uff08NASDAQ: ABMD\uff09\u306f\u3001\u62e1\u5f35\u578b\u7d4c\u76ae\u7684\u5fc3\u81d3\u30dd\u30f3\u30d7Impella ECP\u306b\u3088\u308b\u6cbb\u7642\u30922\u4eba\u306e\u60a3\u8005\u304c\u521d\u3081\u3066\u53d7\u3051\u305f\u3053\u3068\u3092\u767a\u8868\u3057\u307e\u3057\u305f\u3002Impella ECP\u306f\u4e16\u754c\u6700\u5c0f\u306e\u5fc3\u81d3\u30dd\u30f3\u30d7\u3067\u3059\u3002\u4f53\u5185\u3078\u306e\u633f\u5165\u304a\u3088\u3073\u629c\u53bb\u306b\u969b\u3057\u3066\u306e\u76f4\u5f84\u306f9\u30d5\u30ec\u30f3\u30c1\uff08Fr\uff09\uff083\u30df\u30ea\u30e1\u30fc\u30c8\u30eb\uff09\u3067\u3059\u3002", "url": "https://finnhub.io/api/news?id=71cf3467656187107c036517c8aa3e37fb452411e776b97f818a8f013332c038"}, {"category": "company", "datetime": 1604275200, "headline": "\u4e16\u754c\u6700\u5c0f\u5fc3\u81d3\u30dd\u30f3\u30d7\u306e9Fr Impella ECP\u3067\u521d\u3081\u3066\u60a3\u8005\u3092\u6cbb\u7642", "id": 57797687, "image": "https://mms.businesswire.com/media/20201101005072/ja/834159/23/Impella_ECP_Solo_Graphic.jpg", "related": "ABMD", "source": "businesswire", "summary": "\uff08\u30d3\u30b8\u30cd\u30b9\u30ef\u30a4\u30e4\uff09 -- \u30a2\u30d3\u30aa\u30e1\u30c3\u30c9\uff08NASDAQ: ABMD\uff09\u306f\u3001\u62e1\u5f35\u578b\u7d4c\u76ae\u7684\u5fc3\u81d3\u30dd\u30f3\u30d7Impella ECP\u306b\u3088\u308b\u6cbb\u7642\u30922\u4eba\u306e\u60a3\u8005\u304c\u521d\u3081\u3066\u53d7\u3051\u305f\u3053\u3068\u3092\u767a\u8868\u3057\u307e\u3057\u305f\u3002Impella ECP\u306f\u4e16\u754c\u6700\u5c0f\u306e\u5fc3\u81d3\u30dd\u30f3\u30d7\u3067\u3059\u3002\u4f53\u5185\u3078\u306e\u633f\u5165\u304a\u3088\u3073\u629c\u53bb\u306b\u969b\u3057\u3066\u306e\u76f4\u5f84\u306f9\u30d5\u30ec\u30f3\u30c1\uff08Fr\uff09\uff083\u30df\u30ea\u30e1\u30fc\u30c8\u30eb\uff09\u3067\u3059\u3002", "url": "https://finnhub.io/api/news?id=c456fdb789ead97fed31449a39caee92456f2b65a681957a447bc350507c4561"}, {"category": "company", "datetime": 1604055600, "headline": "Validea Peter Lynch Strategy Daily Upgrade Report - 10/30/2020", "id": 61108531, "image": "https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?101610783", "related": "ABMD", "source": "Nasdaq", "summary": "The following are today's upgrades for Validea's P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relative to earnings growth that also possess strong balance sheets.SCHNEIDER NATIONAL INC (SNDR", "url": "https://finnhub.io/api/news?id=f2b27b54de7d5055f253116c9c985a5aa71d503f38a839bcde83eb774e95494b"}, {"category": "company news", "datetime": 1604055600, "headline": "Validea Peter Lynch Strategy Daily Upgrade Report - 10/30/2020", "id": 59069743, "image": "https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?1765867523", "related": "ABMD", "source": "Nasdaq", "summary": "The following are today's upgrades for Validea's P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relative to earnings growth that also possess strong balance sheets.SCHNEIDER NATIONAL INC (SNDR", "url": "https://finnhub.io/api/news?id=96168eb3a42e5464eb8e922232177f1253358a838ed57b5fbd4b73eaf78f0691"}, {"category": "company", "datetime": 1604009280, "headline": "Here's Why Abiomed Dropped Today | The Motley Fool", "id": 55333649, "image": "https://g.foolcdn.com/editorial/images/597489/doctor-patient-3.jpg", "related": "ABMD", "source": "https://www.fool.com", "summary": "Revenue bounces back, but growth is still lacking.", "url": "https://finnhub.io/api/news?id=39f4f8def7f99c596b8f7f4786d1557d42972ef92fd4db7125cbe1bd8787bb1e"}, {"category": "company news", "datetime": 1604001660, "headline": "Axogen, Inc. Reports Third Quarter 2020 Financial Results", "id": 55228250, "image": "", "related": "ABMD", "source": "Yahoo", "summary": "ALACHUA, Fla., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the second quarter ended September 30, 2020.  Third Quarter 2020 Financial Results and Recent Business Highlights  * Net revenue was $33.4 million during the quarter, an increase of 17% compared to third quarter 2019 revenue of $28.6 million.  * Gross margin was 83.0% for the quarter, compared to 84.2% in the third quarter of 2019.  * Net loss was $1.5 million for the quarter, or $0.04 per share, compared to a net loss of $5.6 million, or $0.14 per share, in the third quarter of 2019.  * Adjusted net income was $1.5 million for the quarter, or $0.04 per share, compared with adjusted net loss of $2.6 million, or $0.07 per share, in the third quarter of 2019.  * Adjusted EBITDA was $2.3 million for the quarter, compared to an adjusted EBITDA loss of $3.0 million in the third quarter of 2019.  * The balance of cash, cash equivalents, and investments on September 30, 2020 was $106.7 million, compared to a balance of $109.9 million on June 30, 2020. The net change includes capital expenditures of $5.2 million related to our new facilities in Tampa and Dayton, partially offset by positive operating cash flow of $2.0 million in the third quarter.  * Appointed Paul G. Thomas to the Axogen, Inc. Board of Directors. Thomas has more than 30 years of experience in the medtech industry, currently serves on the board of directors of Abiomed (NASDAQ: ABMD) and Surgalign Spine Technologies (NASDAQ: SRGA) and is the CEO and Co-Founder of Prominex, Inc. He also previously served as Chairman and CEO of LifeCell Corporation.  \u201cI am very pleased with our third quarter performance and return to growth despite the ongoing COVID-19 pandemic,\u201d commented Karen Zaderej, chairman, CEO, and president of Axogen, Inc. \u201cWe believe the strength of our performance reflects our team\u2019s improved commercial execution, the priority that surgeons and hospitals have placed on the timely repair of nerve injuries, and the clinical and economic benefits of Axogen technologies for patients, surgeons, and healthcare facilities. We remain focused on our commercial strategy of driving deeper adoption of our technologies in our largest market opportunity, extremity trauma, and achieving long term, sustainable growth.\u201dAdditional Recent Operational and Business Highlights  * Ended the third quarter with 110 direct sales representatives, a decrease of two from last quarter, and up from 105 at the end of Q3 2019.  * Active accounts in the third quarter were 875, an increase of 11% compared to 791 in the third quarter a year ago.  * Ended the quarter with 138 peer-reviewed clinical publications featuring Axogen\u2019s nerve repair product portfolio.  * Axogen\u2019s peripheral nerve repair portfolio was featured at the clinical and scientific sessions of the 75th Annual Meeting of the American Society for Surgery of the Hand (ASSH) held virtually from October 1-3, 2020, including key presentations highlighting the clinical and economic value of Avance\u00ae Nerve Graft as compared to traditional nerve autograft.MATCHSM Conduit Cohort of RANGER\u00ae Registry Published  On October 1, 2020, clinical data from the MATCH\u00a0conduit cohort of the RANGER registry comparing Avance Nerve Graft repairs to manufactured conduits was published in the Journal of Hand Surgery. The scientific article, titled A Multicenter Matched Cohort Study of Processed Nerve Allograft and Conduit in Digital Nerve Reconstruction, included 162 nerve repairs with gaps up to 25mm and found that Avance Nerve Graft outcomes were significantly better than conduits with a meaningful recovery rate of 88% vs. 61% for conduits (p=0.001) and improved average static two-point discrimination of 9.7mm vs. 12.2mm for conduits (p=0.018). More specifically, the study stratified injuries into gap length groups of those less than 15mm, and those between 15mm and 25mm. Avance outcomes exceeded those of conduit with meaningful recovery rates of 92% versus 67% in the less than 15mm group (p=0.008) and 85% versus 45% in the 15mm to 25mm group (p=0.001). This study is the largest nerve repair study to date comparing Avance Nerve Graft and conduits.About the RANGER Registry  The RANGER Registry, a multicenter Registry of Avance Nerve Graft's Utilization and Recovery Outcomes Post Peripheral Nerve Reconstruction, is an active, multicenter clinical registry designed to continuously monitor and collect injury, repair, safety, and outcomes data for peripheral nerve injuries repaired with processed nerve allograft (Avance Nerve Graft), nerve autograft, and manufactured conduits. The study, launched in 2008, includes more than 30 centers. RANGER is an Axogen sponsored ongoing open label registry study. Each patient outcome is dependent upon the nature and extent of nerve loss or damage, timing between nerve loss and repair, and the natural course of the patient\u2019s recovery.Conference Call  The Company will host a conference call and webcast for the investment community today at 4:30 p.m. ET. Investors interested in participating by phone are invited to call toll free at 1-877-407-0993 or use the direct dial-in number 1-201-689-8795. Those interested in listening to the conference call live via the Internet can do so by visiting the Investors page of the Company\u2019s website at www.axogeninc.com and clicking on the webcast link on the Investors home page.Following the conference call, a replay will be available on the Company\u2019s website at www.axogeninc.com under Investors.About Axogen  Axogen (AXGN) is the leading company focused specifically on the science, development and commercialization of technologies for peripheral nerve regeneration and repair. Axogen employees are passionate about helping to restore peripheral nerve function and quality of life to patients with physical damage or transection to peripheral nerves by providing innovative, clinically proven and economically effective repair solutions for surgeons and health care providers. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body. Every day, people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves.\u00a0Physical damage to a peripheral nerve, or the inability to properly reconnect peripheral nerves, can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain.Axogen's platform for peripheral nerve repair features a comprehensive portfolio of products, including Avance\u00ae Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; Axoguard\u00ae Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; Axoguard\u00ae Nerve Protector, a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments; Axoguard\u00ae Nerve Cap, a porcine submucosa ECM product used to protect a peripheral nerve end and separate the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive\u00ae\u00a0Soft Tissue Membrane, a processed human umbilical cord intended for surgical use as a resorbable soft tissue barrier. The Axogen portfolio of products is available in the United States, Canada, the United Kingdom, South Korea, and several other European and international countries.Cautionary Statements Concerning Forward-Looking Statements  This press release contains \u201cforward-looking\u201d statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations or predictions of future conditions, events, or results based on various assumptions and management's estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as \u201cexpects,\u201d \u201canticipates,\u201d \u201cintends,\u201d \u201cplans,\u201d \u201cbelieves,\u201d \u201cseeks,\u201d \u201cestimates,\u201d \u201cprojects,\u201d \u201cforecasts,\u201d \u201ccontinue,\u201d \u201cmay,\u201d \u201cshould,\u201d \u201cwill,\u201d \u201cgoals,\u201d and variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements related to the expected impact of COVID-19 on our business, statements regarding our growth, product development, product potential, financial performance, sales growth, product adoption, market awareness of our products, data validation, our assessment of our internal controls over financial reporting, our visibility at and sponsorship of conferences and educational events. The forward-looking statements are and will be subject to risks and uncertainties, which may cause actual results to differ materially from those expressed or implied in such forward-looking statements. Forward-looking statements contained in this press release should be evaluated together with the many uncertainties that affect our business and our market, particularly those discussed under Part I, Item 1A., \u201cRisk Factors,\u201d of our Annual Report on Form 10-K, as amended on Form 10-K/A, for the fiscal year ended December 31, 2019, as well as other risks and cautionary statements set forth in our filings with the U.S. Securities and Exchange Commission. Forward-looking statements are not a guarantee of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made and, except as required by applicable law, we assume no responsibility to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changed circumstances, or otherwise.About Non-GAAP Financial Measures   To supplement our consolidated financial statements, we use the non-GAAP financial measures of EBITDA, which measures earnings before interest, income taxes, depreciation and amortization, and Adjusted EBITDA which further excludes non-cash stock compensation expense and litigation and related expenses. We also use the non-GAAP financial measures of Adjusted Net Income or Loss and Adjusted Net Income or Loss Per Common Share - basic and diluted which excludes non-cash stock compensation expense and litigation and related expenses from Net Loss and Net Loss Per Common Share - basic and diluted, respectively. These non-GAAP measures are not based on any comprehensive set of accounting rules or principles and should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP, and may be different from non-GAAP measures used by other companies. In addition, these non-GAAP measures should be read in conjunction with our financial statements prepared in accordance with GAAP. The reconciliations of Axogen\u2019s GAAP financial measures to the corresponding non-GAAP measures should be carefully evaluated.We use these non-GAAP financial measures for financial and operational decision-making and as a means to evaluate period-to-period comparisons. We believe that these non-GAAP financial measures provide meaningful supplemental information regarding our performance and that both management and investors benefit from referring to these non-GAAP financial measures in assessing our performance and when planning, forecasting, and analyzing future periods. We believe these non-GAAP financial measures are useful to investors because (1) they allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making and (2) they are used by our institutional investors and the analyst community to help them analyze the performance of our business.Contact:  Axogen, Inc.  Peter J. Mariani, Chief Financial Officer  pmariani@axogeninc.com  InvestorRelations@AxogenInc.com  \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  AXOGEN, INC.\u00a0\u00a0\u00a0\u00a0  CONDENSED CONSOLIDATED BALANCE SHEETS\u00a0\u00a0\u00a0\u00a0  (unaudited)\u00a0\u00a0\u00a0\u00a0  \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \u00a0\u00a0September 30,December\u00a031,\u00a0\u00a0\u00a0\u00a0  \u00a0\u00a0\u00a02020\u00a0\u00a02019\u00a0\u00a0\u00a0\u00a0\u00a0  Assets\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  Current assets:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  Cash and cash equivalents\u00a0$60,002\u00a0\u00a0$35,724\u00a0\u00a0\u00a0\u00a0\u00a0  Restricted Cash\u00a0\u00a07,607\u00a0\u00a0\u00a06,000\u00a0\u00a0\u00a0\u00a0\u00a0  Short-term investments\u00a0\u00a039,126\u00a0\u00a0\u00a060,786\u00a0\u00a0\u00a0\u00a0\u00a0  Accounts receivable, net\u00a0\u00a018,758\u00a0\u00a0\u00a016,944\u00a0\u00a0\u00a0\u00a0\u00a0  Inventory\u00a0\u00a011,929\u00a0\u00a0\u00a013,861\u00a0\u00a0\u00a0\u00a0\u00a0  Prepaid expenses and other\u00a0\u00a02,551\u00a0\u00a0\u00a01,706\u00a0\u00a0\u00a0\u00a0\u00a0  Total current assets\u00a0\u00a0139,973\u00a0\u00a0\u00a0135,021\u00a0\u00a0\u00a0\u00a0\u00a0  Property and equipment, net\u00a0\u00a036,110\u00a0\u00a0\u00a014,887\u00a0\u00a0\u00a0\u00a0\u00a0  Operating lease right-of-use assets\u00a0\u00a015,987\u00a0\u00a0\u00a03,133\u00a0\u00a0\u00a0\u00a0\u00a0  Finance lease right-of-use assets\u00a0\u00a070\u00a0\u00a0\u00a087\u00a0\u00a0\u00a0\u00a0\u00a0  Intangible assets\u00a0\u00a01,797\u00a0\u00a0\u00a01,515\u00a0\u00a0\u00a0\u00a0\u00a0  Total assets\u00a0$193,937\u00a0\u00a0$154,643\u00a0\u00a0\u00a0\u00a0\u00a0  \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  Liabilities and Shareholders\u2019 Equity\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  Current liabilities:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  Accounts payable and accrued expenses\u00a0$16,279\u00a0\u00a0$19,130\u00a0\u00a0\u00a0\u00a0\u00a0  Current maturities of long term obligations\u00a0\u00a02,499\u00a0\u00a0\u00a01,736\u00a0\u00a0\u00a0\u00a0\u00a0  Contract liabilities, current\u00a0\u00a014\u00a0\u00a0\u00a014\u00a0\u00a0\u00a0\u00a0\u00a0  Total current liabilities\u00a0\u00a018,792\u00a0\u00a0\u00a020,880\u00a0\u00a0\u00a0\u00a0\u00a0  Long-term debt, net of financing fees\u00a0\u00a031,817\u00a0\u00a0\u00a0\u2014\u00a0\u00a0\u00a0\u00a0\u00a0  Debt derivative liability\u00a0\u00a02,450\u00a0\u00a0\u00a0\u2014\u00a0\u00a0\u00a0\u00a0\u00a0  Common stock derivative option liability\u00a0\u00a0183\u00a0\u00a0\u00a0\u2014\u00a0\u00a0\u00a0\u00a0\u00a0  Long-term lease obligations\u00a0\u00a018,976\u00a0\u00a0\u00a01,595\u00a0\u00a0\u00a0\u00a0\u00a0  Other long-term liabilities\u00a0\u00a06\u00a0\u00a0\u00a015\u00a0\u00a0\u00a0\u00a0\u00a0  Total liabilities\u00a0\u00a072,224\u00a0\u00a0\u00a022,490\u00a0\u00a0\u00a0\u00a0\u00a0  Shareholders\u2019 equity:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  Common stock, $.01 par value; 100,000,000 shares authorized; 40,123,841 and 39,589,775 shares issued and outstanding\u00a0\u00a0401\u00a0\u00a0\u00a0396\u00a0\u00a0\u00a0\u00a0\u00a0  Additional paid-in capital\u00a0\u00a0318,949\u00a0\u00a0\u00a0311,618\u00a0\u00a0\u00a0\u00a0\u00a0  Accumulated deficit\u00a0\u00a0(197,637)\u00a0\u00a0(179,861)\u00a0\u00a0\u00a0\u00a0  Total shareholders\u2019 equity \u00a0\u00a0121,713\u00a0\u00a0\u00a0132,153\u00a0\u00a0\u00a0\u00a0\u00a0  Total liabilities and shareholders' equity\u00a0$193,937\u00a0\u00a0$154,643\u00a0\u00a0\u00a0\u00a0\u00a0  \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  AXOGEN, INC.  CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS  Three and Nine Months ended September 30, 2020 and 2019  (unaudited)  \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \u00a0\u00a0Three Months Ended\u00a0Nine Months Ended  \u00a0\u00a0Sept 30,\u00a0Sept 30,\u00a0Sept 30,\u00a0Sept 30,  \u00a0\u00a0\u00a02020\u00a0\u00a0\u00a02019\u00a0\u00a0\u00a02020\u00a0\u00a0\u00a02019\u00a0  Revenues \u00a0$33,428\u00a0\u00a0$28,564\u00a0\u00a0$79,805\u00a0\u00a0$78,550\u00a0  Cost of goods sold\u00a0\u00a05,697\u00a0\u00a0\u00a04,510\u00a0\u00a0\u00a016,118\u00a0\u00a0\u00a012,468\u00a0  Gross profit\u00a0\u00a027,731\u00a0\u00a0\u00a024,054\u00a0\u00a0\u00a063,687\u00a0\u00a0\u00a066,082\u00a0  Costs and expenses:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  Sales and marketing\u00a0\u00a017,726\u00a0\u00a0\u00a018,245\u00a0\u00a0\u00a049,854\u00a0\u00a0\u00a053,146\u00a0  Research and development\u00a0\u00a04,230\u00a0\u00a0\u00a04,181\u00a0\u00a0\u00a012,915\u00a0\u00a0\u00a012,602\u00a0  General and administrative\u00a0\u00a06,820\u00a0\u00a0\u00a07,740\u00a0\u00a0\u00a018,726\u00a0\u00a0\u00a024,321\u00a0  Total costs and expenses\u00a0\u00a028,776\u00a0\u00a0\u00a030,166\u00a0\u00a0\u00a081,495\u00a0\u00a0\u00a090,069\u00a0  Loss from operations\u00a0\u00a0(1,045)\u00a0\u00a0(6,112)\u00a0\u00a0(17,808)\u00a0\u00a0(23,987)  Other income (expense):\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  Interest income\u00a0\u00a028\u00a0\u00a0\u00a0555\u00a0\u00a0\u00a0576\u00a0\u00a0\u00a01,925\u00a0  Interest expense\u00a0\u00a0(397)\u00a0\u00a0(7)\u00a0\u00a0(459)\u00a0\u00a0(32)  Change in fair value of derivative liabilities\u00a0\u00a0(71)\u00a0\u00a0\u2014\u00a0\u00a0\u00a0(71)\u00a0\u00a0\u2014\u00a0  Other expense\u00a0\u00a06\u00a0\u00a0\u00a0(7)\u00a0\u00a0(14)\u00a0\u00a0(3)  Total other income (expense) \u00a0\u00a0(434)\u00a0\u00a0541\u00a0\u00a0\u00a032\u00a0\u00a0\u00a01,890\u00a0  Net loss\u00a0$(1,479)\u00a0$(5,571)\u00a0$(17,776)\u00a0$(22,097)  Weighted average common shares outstanding \u2013 basic and diluted\u00a0\u00a040,094\u00a0\u00a0\u00a039,340\u00a0\u00a0\u00a039,873\u00a0\u00a0\u00a039,151\u00a0  Loss per common share \u2013 basic and diluted\u00a0$(0.04)\u00a0$(0.14)\u00a0$(0.45)\u00a0$(0.56)  \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  Adjusted net income (loss) - non GAAP\u00a0\u00a01,468\u00a0\u00a0\u00a0(2,644)\u00a0\u00a0(12,016)\u00a0\u00a0(12,386)  Adjusted net income (loss) per common share - basic and diluted\u00a0$0.04\u00a0\u00a0$(0.07)\u00a0$(0.30)\u00a0$(0.32)  \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  AXOGEN, INC.  RECONCILIATION OF GAAP FINANCIAL MEASURES TO NON-GAAP FINANCIAL MEASURES  Three and Nine Months ended September 30, 2020 and 2019  (unaudited)  \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \u00a0\u00a0Three Months Ended\u00a0Nine Months Ended  \u00a0\u00a0Sept 30,\u00a0Sept 30,\u00a0Sept 30,\u00a0Sept 30,  \u00a0\u00a0\u00a02020\u00a0\u00a0\u00a02019\u00a0\u00a0\u00a02020\u00a0\u00a0\u00a02019\u00a0  Net loss\u00a0$(1,479)\u00a0$(5,571)\u00a0$(17,776)\u00a0$(22,097)  Depreciation and amortization expense\u00a0\u00a0439\u00a0\u00a0\u00a0244\u00a0\u00a0\u00a01,104\u00a0\u00a0\u00a0757\u00a0  Investment income\u00a0\u00a0(28)\u00a0\u00a0(555)\u00a0\u00a0(576)\u00a0\u00a0(1,925)  Income tax\u00a0\u00a0\u2014\u00a0\u00a0\u00a0(3)\u00a0\u00a0\u2014\u00a0\u00a0\u00a0(15)  Interest expense\u00a0\u00a0397\u00a0\u00a0\u00a07\u00a0\u00a0\u00a0459\u00a0\u00a0\u00a032\u00a0  EBITDA - non GAAP\u00a0$(671)\u00a0$(5,878)\u00a0$(16,789)\u00a0$(23,248)  \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  Non cash stock compensation expense\u00a0\u00a02,947\u00a0\u00a0\u00a02,395\u00a0\u00a0\u00a05,725\u00a0\u00a0\u00a07,384\u00a0  Litigation and related costs\u00a0\u00a0\u2014\u00a0\u00a0\u00a0532\u00a0\u00a0\u00a035\u00a0\u00a0\u00a02,327\u00a0  Adjusted EBITDA - non GAAP\u00a0$2,276\u00a0\u00a0$(2,951)\u00a0$(11,029)\u00a0$(13,537)  \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  Net loss\u00a0$(1,479)\u00a0$(5,571)\u00a0$(17,776)\u00a0$(22,097)  Non cash stock compensation expense\u00a0\u00a02,947\u00a0\u00a0\u00a02,395\u00a0\u00a0\u00a05,725\u00a0\u00a0\u00a07,384\u00a0  Litigation and related costs\u00a0\u00a0\u2014\u00a0\u00a0\u00a0532\u00a0\u00a0\u00a035\u00a0\u00a0\u00a02,327\u00a0  Adjusted Net Income (Loss) - non GAAP\u00a0$1,468\u00a0\u00a0$(2,644)\u00a0$(12,016)\u00a0$(12,386)  Weighted average common shares outstanding \u2013 basic and diluted\u00a0\u00a040,094\u00a0\u00a0\u00a039,340\u00a0\u00a0\u00a039,873\u00a0\u00a0\u00a039,151\u00a0  Adjusted net income (loss) per common share - basic and diluted\u00a0$0.04\u00a0\u00a0$(0.07)\u00a0$(0.30)\u00a0$(0.32)  \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  AXOGEN, INC.  CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY  Three and Nine Months Ended September 30, 2020 and 2019  (unaudited)  \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \u00a0\u00a0Common Stock  \u00a0Additional Paid-in Capital\u00a0Accumulated Deficit\u00a0Total Shareholders' Equity  For the Three Months Ended September 30, 2020:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  Balance at June 30, 2020\u00a0$400\u00a0\u00a0$315,518\u00a0\u00a0$(196,158)\u00a0$119,760\u00a0  Net loss\u00a0\u00a0-\u00a0\u00a0\u00a0-\u00a0\u00a0\u00a0(1,479)\u00a0\u00a0(1,479)  Stock-based compensation\u00a0\u00a0-\u00a0\u00a0\u00a02,947\u00a0\u00a0\u00a0-\u00a0\u00a0\u00a02,947\u00a0  Shares surrendered by employees to pay taxes\u00a0\u00a0-\u00a0\u00a0\u00a0(8)\u00a0\u00a0-\u00a0\u00a0\u00a0(8)  Exercise of stock options and employee stock purchase plan\u00a0\u00a01\u00a0\u00a0\u00a0492\u00a0\u00a0\u00a0-\u00a0\u00a0\u00a0493\u00a0  Balance at September 30, 2020\u00a0$401\u00a0\u00a0$318,949\u00a0\u00a0$(197,637)\u00a0$121,713\u00a0  \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  For the Nine Months Ended September 30, 2020:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  Balance at December 31, 2019\u00a0$396\u00a0\u00a0$311,618\u00a0\u00a0$(179,861)\u00a0$132,153\u00a0  Net loss\u00a0\u00a0-\u00a0\u00a0\u00a0-\u00a0\u00a0\u00a0(17,776)\u00a0\u00a0(17,776)  Stock-based compensation\u00a0\u00a0-\u00a0\u00a0\u00a05,725\u00a0\u00a0\u00a0-\u00a0\u00a0\u00a05,725\u00a0  Issuance of restricted /performance service awards\u00a0\u00a02\u00a0\u00a0\u00a0(2)\u00a0\u00a0-\u00a0\u00a0\u00a0-\u00a0  Shares surrendered by employees to pay taxes\u00a0\u00a0(1)\u00a0\u00a0(664)\u00a0\u00a0-\u00a0\u00a0\u00a0(665)  Exercise of stock options and employee stock purchase plan\u00a0\u00a04\u00a0\u00a0\u00a02,272\u00a0\u00a0\u00a0-\u00a0\u00a0\u00a02,276\u00a0  Balance at September 30, 2020\u00a0$401\u00a0\u00a0$318,949\u00a0\u00a0$(197,637)\u00a0$121,713\u00a0  \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  For the Three Months Ended September 30, 2019:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  Balance at June 30, 2019\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  Net loss\u00a0$393\u00a0\u00a0$304,820\u00a0\u00a0$(167,252)\u00a0$137,960\u00a0  Stock-based compensation\u00a0\u00a0-\u00a0\u00a0\u00a0-\u00a0\u00a0\u00a0(5,571)\u00a0\u00a0(5,571)  Shares surrendered by employees to pay taxes\u00a0\u00a0-\u00a0\u00a0\u00a02,397\u00a0\u00a0\u00a0-\u00a0\u00a0\u00a02,397\u00a0  Exercise of stock options and employee stock purchase plan\u00a0\u00a02\u00a0\u00a0\u00a0623\u00a0\u00a0\u00a0-\u00a0\u00a0\u00a0625\u00a0  Balance at September 30, 2019\u00a0$395\u00a0\u00a0$307,839\u00a0\u00a0$(172,823)\u00a0$135,411\u00a0  \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  For the Nine Months Ended September 30, 2019:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  Balance at December 31, 2018\u00a0$389\u00a0\u00a0$297,319\u00a0\u00a0$(150,726)\u00a0$146,982\u00a0  Net loss\u00a0\u00a0-\u00a0\u00a0\u00a0-\u00a0\u00a0\u00a0(22,097)\u00a0\u00a0(22,097)  Stock-based compensation\u00a0\u00a0-\u00a0\u00a0\u00a07,384\u00a0\u00a0\u00a0-\u00a0\u00a0\u00a07,384\u00a0  Exercise of stock options and employee stock purchase plan\u00a0\u00a06\u00a0\u00a0\u00a03,136\u00a0\u00a0\u00a0-\u00a0\u00a0\u00a03,142\u00a0  Balance at September 30, 2019\u00a0$395\u00a0\u00a0$307,839\u00a0\u00a0$(172,823)\u00a0$135,411\u00a0  \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  AXOGEN, INC.\u00a0\u00a0\u00a0\u00a0  CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\u00a0\u00a0\u00a0\u00a0  Nine Months Ended September 30, 2020 and 2019\u00a0\u00a0\u00a0\u00a0  (unaudited)\u00a0\u00a0\u00a0\u00a0  \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \u00a0\u00a0Six Months Ended\u00a0\u00a0\u00a0\u00a0  \u00a0\u00a0Sept 30,\u00a0Sept 30,\u00a0\u00a0\u00a0\u00a0  \u00a0\u00a0\u00a02020\u00a0\u00a0\u00a02019\u00a0\u00a0\u00a0\u00a0\u00a0  Cash flows from operating activities:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  Net loss\u00a0$(17,776)\u00a0\u00a0(22,097)\u00a0\u00a0\u00a0\u00a0  Adjustments to reconcile net loss to net cash used in operating activities:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  Depreciation\u00a0\u00a0993\u00a0\u00a0\u00a0631\u00a0\u00a0\u00a0\u00a0\u00a0  Amortization of right-of-use assets\u00a0\u00a01,282\u00a0\u00a0\u00a01,352\u00a0\u00a0\u00a0\u00a0\u00a0  Amortization of intangible assets\u00a0\u00a0111\u00a0\u00a0\u00a089\u00a0\u00a0\u00a0\u00a0\u00a0  Amortization of deferred financing fees\u00a0\u00a022\u00a0\u00a0\u00a0\u2014\u00a0\u00a0\u00a0\u00a0\u00a0  Provision for bad debt\u00a0\u00a0(115)\u00a0\u00a0(150)\u00a0\u00a0\u00a0\u00a0  Provision for inventory write down\u00a0\u00a02,108\u00a0\u00a0\u00a0(44)\u00a0\u00a0\u00a0\u00a0  Change in fair value of derivatives\u00a0\u00a071\u00a0\u00a0\u00a0\u2014\u00a0\u00a0\u00a0\u00a0\u00a0  Change in investment gains and losses\u00a0\u00a0(29)\u00a0\u00a0(957)\u00a0\u00a0\u00a0\u00a0  Share-based compensation\u00a0\u00a05,725\u00a0\u00a0\u00a07,384\u00a0\u00a0\u00a0\u00a0\u00a0  Change in assets and liabilities:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  Accounts receivable\u00a0\u00a0(1,700)\u00a0\u00a020\u00a0\u00a0\u00a0\u00a0\u00a0  Inventory\u00a0\u00a0(176)\u00a0\u00a0(1,657)\u00a0\u00a0\u00a0\u00a0  Prepaid expenses and other\u00a0\u00a0(844)\u00a0\u00a0(1,099)\u00a0\u00a0\u00a0\u00a0  Accounts payable and accrued expenses\u00a0\u00a0(911)\u00a0\u00a01,288\u00a0\u00a0\u00a0\u00a0\u00a0  Operating Lease Obligations\u00a0\u00a0(1,213)\u00a0\u00a0(1,276)\u00a0\u00a0\u00a0\u00a0  Cash paid for interest portion of Finance Leases\u00a0\u00a0(2)\u00a0\u00a0(3)\u00a0\u00a0\u00a0\u00a0  Contract and other liabilities\u00a0\u00a0(9)\u00a0\u00a0(23)\u00a0\u00a0\u00a0\u00a0  Net cash used in operating activities\u00a0\u00a0(12,463)\u00a0\u00a0(16,542)\u00a0\u00a0\u00a0\u00a0  \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  Cash flows from investing activities:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  Purchase of property and equipment\u00a0\u00a0(18,907)\u00a0\u00a0(3,676)\u00a0\u00a0\u00a0\u00a0  Purchase of short-term investments\u00a0\u00a0(41,794)\u00a0\u00a0(104,314)\u00a0\u00a0\u00a0\u00a0  Sale/Maturities of short-term investments\u00a0\u00a063,483\u00a0\u00a0\u00a0122,071\u00a0\u00a0\u00a0\u00a0\u00a0  Cash payments for intangible assets\u00a0\u00a0(393)\u00a0\u00a0(396)\u00a0\u00a0\u00a0\u00a0  Net cash provided by investing activities\u00a0\u00a02,389\u00a0\u00a0\u00a013,685\u00a0\u00a0\u00a0\u00a0\u00a0  \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  Cash flows from financing activities:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  Proceeds from the issuance long term debt\u00a0\u00a035,000\u00a0\u00a0\u00a0\u2014\u00a0\u00a0\u00a0\u00a0\u00a0  Proceeds from the paycheck protection plan\u00a0\u00a07,820\u00a0\u00a0\u00a0\u2014\u00a0\u00a0\u00a0\u00a0\u00a0  Payment of paycheck protection plan\u00a0\u00a0(7,820)\u00a0\u00a0\u2014\u00a0\u00a0\u00a0\u00a0\u00a0  Payments of debt issuance costs\u00a0\u00a0(642)\u00a0\u00a0\u2014\u00a0\u00a0\u00a0\u00a0\u00a0  Payments for repurchase of common stock for employee tax withholding\u00a0\u00a0(665)\u00a0\u00a0\u2014\u00a0\u00a0\u00a0\u00a0\u00a0  Cash paid for debt portion of finance leases\u00a0\u00a0(10)\u00a0\u00a0(24)\u00a0\u00a0\u00a0\u00a0  Proceeds from exercise of stock options and warrants\u00a0\u00a02,276\u00a0\u00a0\u00a03,142\u00a0\u00a0\u00a0\u00a0\u00a0  Net cash provided by financing activities\u00a0\u00a035,959\u00a0\u00a0\u00a03,118\u00a0\u00a0\u00a0\u00a0\u00a0  \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  Net increase in cash, cash equivalents and restricted cash\u00a0\u00a025,885\u00a0\u00a0\u00a0261\u00a0\u00a0\u00a0\u00a0\u00a0  Cash, cash equivalents and restricted cash, beginning of year\u00a0\u00a041,724\u00a0\u00a0\u00a030,294\u00a0\u00a0\u00a0\u00a0\u00a0  Cash, cash equivalents and restricted cash, end of period\u00a0$67,609\u00a0\u00a0$30,555\u00a0\u00a0\u00a0\u00a0\u00a0  \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  Supplemental disclosures of cash flow activity:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  Cash paid for interest\u00a0\u00a0379\u00a0\u00a0\u00a031\u00a0\u00a0\u00a0\u00a0\u00a0  Supplemental disclosure of non-cash investing and financing activities\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  Acquisition of fixed assets in accounts payable and accrued expenses\u00a0\u00a01,271\u00a0\u00a0\u00a0684\u00a0\u00a0\u00a0\u00a0\u00a0  Right-of-use asset and operating lease liability\u00a0\u00a014,119\u00a0\u00a0\u00a026\u00a0\u00a0\u00a0\u00a0\u00a0  Embedded derivative associated with the long-term debt\u00a0\u00a02,562\u00a0\u00a0\u00a0\u2014", "url": "https://finnhub.io/api/news?id=769ecde6bc7fc784211578227c7667f59fb4df7b1696c537c74a8ed351b1f2d0"}, {"category": "company news", "datetime": 1603998300, "headline": "Abiomed Off After 3rd-Quarter Revenue Guidance Falls Short", "id": 55228251, "image": "", "related": "ABMD", "source": "Yahoo", "summary": "Abiomed beats Wall Street's second-quarter earnings expectations but revenue guidance disappoints.", "url": "https://finnhub.io/api/news?id=e092cf44cedb4cb93ec62d77aa63595f507fd5c8e415565c9f2e123bd80fa34f"}, {"category": "company", "datetime": 1603994880, "headline": "Here's Why Abiomed Dropped Today", "id": 61099007, "image": "https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?2014673897", "related": "ABMD", "source": "Nasdaq", "summary": "Shares of Abiomed (NASDAQ: ABMD) closed down 10% today after the medical-device maker reported earnings from its second fiscal quarter and muted guidance for the quarter ahead due to the COVID-19 pandemic.Revenue was up 27% from the first quarter as hospitals opened up and doctor", "url": "https://finnhub.io/api/news?id=8e39a9f7218c0eca266545c969051366da45440cb01d6d885e77ff120df27dbb"}, {"category": "company news", "datetime": 1603994880, "headline": "Here's Why Abiomed Dropped Today", "id": 59069744, "image": "https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?1229150465", "related": "ABMD", "source": "Nasdaq", "summary": "Shares of Abiomed (NASDAQ: ABMD) closed down 10% today after the medical-device maker reported earnings from its second fiscal quarter and muted guidance for the quarter ahead due to the COVID-19 pandemic.Revenue was up 27% from the first quarter as hospitals opened up and doctor", "url": "https://finnhub.io/api/news?id=12aa23efeb62d59083e590439f25b5ccaede8a3f2c2d5456c9d40bb3db066d58"}, {"category": "company news", "datetime": 1603976881, "headline": "ABIOMED (ABMD) Earnings and Revenues Beat Estimates in Q2", "id": 55228252, "image": "", "related": "ABMD", "source": "Yahoo", "summary": "ABIOMED's (ABMD) international Impella revenues improved in Q2.", "url": "https://finnhub.io/api/news?id=a6f0bea509f91be3fead02dcbd3425b4c5fe3934ea85cfad25c4a1d8adfc398f"}, {"category": "company", "datetime": 1603974745, "headline": "BUZZ-U.S. STOCKS ON THE MOVE-Tricida, Cancer Genetics, Penumbra Inc", "id": 61104040, "image": "https://www.nasdaq.com/sites/acquia.prod/files/2020-10-08T212527Z_1348430446_RC2LEJ9EEQU4_RTRMADP_2_USA-BANKS-TRADING.JPG?6070766", "related": "ABMD", "source": "Nasdaq", "summary": "A compilation of the most active stocks on U.S. exchanges. For faster updates on individual market-movers, Eikon users please use search string \"STXBZ US\" and Thomson One users please search \"RT/STXBZ US\".", "url": "https://finnhub.io/api/news?id=835ca3a7ffe40d7be4a5edac20cdd4297777f8f6876f56a4d982d8330955e5fb"}, {"category": "company news", "datetime": 1603974745, "headline": "BUZZ-U.S. STOCKS ON THE MOVE-Tricida, Cancer Genetics, Penumbra Inc", "id": 59069745, "image": "https://www.nasdaq.com/sites/acquia.prod/files/2020-10-08T212527Z_1348430446_RC2LEJ9EEQU4_RTRMADP_2_USA-BANKS-TRADING.JPG?621386908", "related": "ABMD", "source": "Nasdaq", "summary": "A compilation of the most active stocks on U.S. exchanges. For faster updates on individual market-movers, Eikon users please use search string \"STXBZ US\" and Thomson One users please search \"RT/STXBZ US\".", "url": "https://finnhub.io/api/news?id=e1d3f39a72b20f0fdddb2d23a7f5e95502365d39296033bbe8ea7a10af1c298a"}, {"category": "company news", "datetime": 1603973712, "headline": "Abiomed (ABMD) Q2 Earnings and Revenues Surpass Estimates", "id": 55228253, "image": "", "related": "ABMD", "source": "Yahoo", "summary": "Abiomed (ABMD) delivered earnings and revenue surprises of 16.09% and 4.16%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?", "url": "https://finnhub.io/api/news?id=b42d83289cec7c174455528c7f5fb535a29fc375a852f376767f3f625f998ebb"}, {"category": "company news", "datetime": 1603969200, "headline": "Abiomed Announces Q2 FY 2021 Revenue of $210 Million, Up 27% Over Q1 FY 2021 and Up 2% Over Q2 FY 2020 With 29.2% Operating Margin", "id": 55228254, "image": "", "related": "ABMD", "source": "Yahoo", "summary": "Abiomed announces Q2 FY 2021 revenue of $210 million, up 27% over Q1 FY 2021 and up 2% over Q2 FY 2020 with 29.2% operating margin.", "url": "https://finnhub.io/api/news?id=56648a913323c734a4a18ead6f30d97a85bf7def7ddaba9f6b02da9396a5650d"}, {"category": "company news", "datetime": 1603965600, "headline": "ABIOMED, Inc. to Host Earnings Call", "id": 55228255, "image": "", "related": "ABMD", "source": "Yahoo", "summary": "NEW YORK, NY / ACCESSWIRE / October 29, 2020 / ABIOMED, Inc.", "url": "https://finnhub.io/api/news?id=bcefcab846d444e9e742b7b187170af30567a8ebc679b1af3341d01e04c62daa"}, {"category": "company", "datetime": 1603965317, "headline": "BUZZ-U.S. STOCKS ON THE MOVE-Tricida, Pinterest, Blue Apron Holdings", "id": 61107919, "image": "https://www.nasdaq.com/sites/acquia.prod/files/2020-10-08T212527Z_1348430446_RC2LEJ9EEQU4_RTRMADP_2_USA-BANKS-TRADING.JPG?868975898", "related": "ABMD", "source": "Nasdaq", "summary": "A compilation of the most active stocks on U.S. exchanges. For faster updates on individual market-movers, Eikon users please use search string \"STXBZ US\" and Thomson One users please search \"RT/STXBZ US\".", "url": "https://finnhub.io/api/news?id=c7081620fbd06da1d726f2ffdb6fae8743afff0f29f3c4c0c7b1a76e9f43cea3"}, {"category": "company news", "datetime": 1603965317, "headline": "BUZZ-U.S. STOCKS ON THE MOVE-Tricida, Pinterest, Blue Apron Holdings", "id": 59070204, "image": "https://www.nasdaq.com/sites/acquia.prod/files/2020-10-08T212527Z_1348430446_RC2LEJ9EEQU4_RTRMADP_2_USA-BANKS-TRADING.JPG?2078052151", "related": "ABMD", "source": "Nasdaq", "summary": "A compilation of the most active stocks on U.S. exchanges. For faster updates on individual market-movers, Eikon users please use search string \"STXBZ US\" and Thomson One users please search \"RT/STXBZ US\".", "url": "https://finnhub.io/api/news?id=bfbd6a464f75b8262b460191903045c4c1ba3cba25d96536eb327eff19eccb4e"}, {"category": "company", "datetime": 1603958295, "headline": "Abiomed Inc. Q2 Income Rises", "id": 61305286, "image": "https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?1347082660", "related": "ABMD", "source": "Nasdaq", "summary": "(RTTNews) - Abiomed Inc. (ABMD) released a profit for its second quarter that rose from last year.The company's bottom line came in at $62.21 million, or $1.36 per share.  This compares with $13.07 million, or $0.28 per share, in last year's second quarter.", "url": "https://finnhub.io/api/news?id=d894cd3b11ce908c41ba643ac332d9a37e0fccdda9dd4be20f6e3ee6d3c4ed16"}, {"category": "company news", "datetime": 1603958295, "headline": "Abiomed Inc. Q2 Income Rises", "id": 59070432, "image": "https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?886909469", "related": "ABMD", "source": "Nasdaq", "summary": "(RTTNews) - Abiomed Inc. (ABMD) released a profit for its second quarter that rose from last year.The company's bottom line came in at $62.21 million, or $1.36 per share.  This compares with $13.07 million, or $0.28 per share, in last year's second quarter.", "url": "https://finnhub.io/api/news?id=76d94c17456f1e19ad7ca6b484b2fe16dcd7834c16a955c4fee8ee02c0e757d0"}, {"category": "company", "datetime": 1603929600, "headline": "The Daily Biotech Pulse: Novartis Acquires Gene Therapy Company, Moderna's Japanese Vaccine Supply Deal", "id": 59801226, "image": "https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/microscope-3184432_1920_104.jpg", "related": "ABMD", "source": "benzinga", "summary": "Here's a roundup of top developments in the biotech space over the last 24 hours.\nScaling The Peaks\n(Biotech Stocks Hitting 52-week Highs Oct. 28)\n\nBlueprint Medicines Corp (...", "url": "https://finnhub.io/api/news?id=a8775f87c7530b95a9bd2d52068cc9ed8a22f321b0f5e1bf02cb42e6d658046d"}, {"category": "company", "datetime": 1603951248, "headline": "Standard Life Aberdeen plc Decreases Stock Position in ABIOMED, Inc. (NASDAQ:ABMD)", "id": 55209181, "image": "https://www.marketbeat.com/logos/abiomed-logo.gif", "related": "ABMD", "source": "https://www.thelincolnianonline.com", "summary": "Standard Life Aberdeen plc cut its position in ABIOMED, Inc. (NASDAQ:ABMD) by 12.8% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 13,899 shares of the medical equipment provider\u2019s stock after selling 2,037 shares during the quarter. Standard Life Aberdeen plc\u2019s holdings in ABIOMED were [\u2026]", "url": "https://finnhub.io/api/news?id=bde3b51801a4b101394e95a139197306ebff952a867a3d8a1941e0d46a06c7b7"}, {"category": "company", "datetime": 1603929600, "headline": "Abiomed Announces Q2 FY 2021 Revenue of $210 Million, Up 27% Over Q1 FY 2021 and Up 2% Over Q2 FY 2020 With 29.2% Operating Margin", "id": 55208673, "image": "https://mms.businesswire.com/media/20201029005304/en/722993/23/AbioLogo_TAGLINE_COLOR.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed announces Q2 FY 2021 revenue of $210 million, up 27% over Q1 FY 2021 and up 2% over Q2 FY 2020 with 29.2% operating margin.", "url": "https://finnhub.io/api/news?id=5e83861fa17dc9a9f39a0a33359ce0ab593cba1dbc58e0b64c8fdcdc67c50ddc"}, {"category": "company", "datetime": 1603929600, "headline": "Erste Patienten mit 9Fr Impella ECP, der kleinsten Herzpumpe der Welt, behandelt", "id": 55208481, "image": "https://mms.businesswire.com/media/20201029005558/de/834159/23/Impella_ECP_Solo_Graphic.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ: ABMD) hat die Behandlung der ersten beiden Patienten mit der expandierbaren perkutanen Herzpumpe Impella ECP bekannt gegeben. Impella", "url": "https://finnhub.io/api/news?id=7d7c69a0f16a65c2cc415bfbe30c78a2fef4be3c951771830150e8778a54640b"}, {"category": "company", "datetime": 1603920841, "headline": "Abiomed : Premiers patients trait\u00e9s avec la plus petite pompe cardiaque au monde, l'Impella ECP 9Fr | Zone bourse", "id": 55209759, "image": "https://www.zonebourse.com/images/twitter_ZB_fdblanc.png", "related": "ABMD", "source": "https://www.zonebourse.com", "summary": "", "url": "https://finnhub.io/api/news?id=58d2ab08e7357ce94a9ce548ba42b764bca825d459fa435bf030ea30d76be133"}, {"category": "company news", "datetime": 1603893181, "headline": "Medical Products' Oct 29 Earnings Roster: SYK, BAX & More", "id": 55228256, "image": "", "related": "ABMD", "source": "Yahoo", "summary": "Medical Product companies have shown strength in the third quarter on the back of huge adoption of COVID-19 related healthcare-support products and services despite the impact of the ongoing pandemic.", "url": "https://finnhub.io/api/news?id=20d5da66b9071a58978eee4f84a57e2a4aa2d728ac79ff2e87c78f9fd3bb2183"}, {"category": "company news", "datetime": 1603886580, "headline": "First Patients Treated with the World\u2019s Smallest Heart Pump, the 9Fr Impella ECP", "id": 55228257, "image": "", "related": "ABMD", "source": "Yahoo", "summary": "Abiomed (NASDAQ: ABMD) announces the first two patients have been treated with the Impella ECP expandable percutaneous heart pump. Impella ECP is the smallest heart pump in the world. It measures 9 French (Fr) (3 millimeters) in diameter upon insertion and removal from the body. While in the heart, it expands while supporting the heart\u2019s pumping function, providing peak flows greater than 3.5 L/min.", "url": "https://finnhub.io/api/news?id=d379b318620064566b8697917dc023d01485556d471f73b6522e20750f39f366"}, {"category": "company", "datetime": 1603843200, "headline": "Riassunto: I primi pazienti vengono trattati con la pompa cardiaca pi\u00f9 piccola del mondo, la Impella ECP da 9Fr", "id": 55206858, "image": "https://mms.businesswire.com/media/20201028006239/it/834159/23/Impella_ECP_Solo_Graphic.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ: ABMD) annuncia che sono stati trattati con la pompa cardiaca percutanea espandibile Impella ECP, la pi\u00f9 piccola al mondo, i primi due", "url": "https://finnhub.io/api/news?id=71030ac34fffd171c1f792505619a07aa63acfb0684f5ec58c367bf9d407e7e3"}, {"category": "company", "datetime": 1603843200, "headline": "Premiers patients trait\u00e9s avec la plus petite pompe cardiaque au monde, l\u2019Impella ECP 9Fr", "id": 55206850, "image": "https://mms.businesswire.com/media/20201028006237/fr/834159/23/Impella_ECP_Solo_Graphic.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ : ABMD) annonce que deux premiers patients ont \u00e9t\u00e9 trait\u00e9s avec la pompe cardiaque percutan\u00e9e expansible Impella ECP. Impella ECP est", "url": "https://finnhub.io/api/news?id=4a5cd8f97bdeb03ddb1b78321040c2029357a674102a58fd5bfae54209f680e7"}, {"category": "company", "datetime": 1603843200, "headline": "Premiers patients trait\u00e9s avec la plus petite pompe cardiaque au monde, l\u2019Impella ECP 9Fr", "id": 55206848, "image": "https://mms.businesswire.com/media/20201028006237/fr/834159/23/Impella_ECP_Solo_Graphic.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ : ABMD) annonce que deux premiers patients ont \u00e9t\u00e9 trait\u00e9s avec la pompe cardiaque percutan\u00e9e expansible Impella ECP. Impella ECP est", "url": "https://finnhub.io/api/news?id=2b236ef6fb5bc36135d3e9260638e219a491ab47e7b03e0d41518e7be91b7eec"}, {"category": "company", "datetime": 1603843200, "headline": "Premiers patients trait\u00e9s avec la plus petite pompe cardiaque au monde, l\u2019Impella ECP 9Fr", "id": 55206847, "image": "https://mms.businesswire.com/media/20201028006237/fr/834159/23/Impella_ECP_Solo_Graphic.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ : ABMD) annonce que deux premiers patients ont \u00e9t\u00e9 trait\u00e9s avec la pompe cardiaque percutan\u00e9e expansible Impella ECP. Impella ECP est", "url": "https://finnhub.io/api/news?id=0393fa3c09aaa70b5a61f43f261479eb61c2217fb617bfbcf211fb02fa2eb4b3"}, {"category": "company", "datetime": 1603843200, "headline": "Premiers patients trait\u00e9s avec la plus petite pompe cardiaque au monde, l\u2019Impella ECP 9Fr", "id": 55206846, "image": "https://mms.businesswire.com/media/20201028006237/fr/834159/23/Impella_ECP_Solo_Graphic.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ : ABMD) annonce que deux premiers patients ont \u00e9t\u00e9 trait\u00e9s avec la pompe cardiaque percutan\u00e9e expansible Impella ECP. Impella ECP est", "url": "https://finnhub.io/api/news?id=58972fed9351c75bdc368e50d9ca5b4b5dc142335e88cba2f1a4ccf7bd5fdd8a"}, {"category": "company", "datetime": 1603843200, "headline": "Premiers patients trait\u00e9s avec la plus petite pompe cardiaque au monde, l\u2019Impella ECP 9Fr", "id": 55206845, "image": "https://mms.businesswire.com/media/20201028006237/fr/834159/23/Impella_ECP_Solo_Graphic.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ : ABMD) annonce que deux premiers patients ont \u00e9t\u00e9 trait\u00e9s avec la pompe cardiaque percutan\u00e9e expansible Impella ECP. Impella ECP est", "url": "https://finnhub.io/api/news?id=aaed496cb3d733063f4bde2b779f36db32225ea05ab93b98c91f3c3dd82a56ff"}, {"category": "company", "datetime": 1603843200, "headline": "Premiers patients trait\u00e9s avec la plus petite pompe cardiaque au monde, l\u2019Impella ECP 9Fr", "id": 55206838, "image": "https://mms.businesswire.com/media/20201028006237/fr/834159/23/Impella_ECP_Solo_Graphic.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ : ABMD) annonce que deux premiers patients ont \u00e9t\u00e9 trait\u00e9s avec la pompe cardiaque percutan\u00e9e expansible Impella ECP. Impella ECP est", "url": "https://finnhub.io/api/news?id=a39c92adbdf9d7598f20c6ec6dbf569a504a3737a6bea5e4972648140a4d4620"}, {"category": "company", "datetime": 1603843200, "headline": "Premiers patients trait\u00e9s avec la plus petite pompe cardiaque au monde, l\u2019Impella ECP 9Fr", "id": 55206794, "image": "https://mms.businesswire.com/media/20201028006237/fr/834159/23/Impella_ECP_Solo_Graphic.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ : ABMD) annonce que deux premiers patients ont \u00e9t\u00e9 trait\u00e9s avec la pompe cardiaque percutan\u00e9e expansible Impella ECP. Impella ECP est", "url": "https://finnhub.io/api/news?id=5af3bf61b0bbebdf34670eed48d683b9a0be8978591811efecd22dfe5c8f3f95"}, {"category": "company", "datetime": 1603843200, "headline": "Samenvatting: Eerste pati\u00ebnten behandeld met \u2018s werelds kleinste hartpomp, de 9Fr Impella ECP", "id": 55205922, "image": "https://mms.businesswire.com/media/20201028005888/nl/834159/23/Impella_ECP_Solo_Graphic.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ: ABMD) kondigt aan dat de eerste twee pati\u00ebnten zijn behandeld met de Impella ECP uitbreidbare percutane hartpomp. Impella ECP is de k", "url": "https://finnhub.io/api/news?id=dfd0d13ae0755cf83c4b6208bedaab4ff304fd723ceaeaf32803cb26158968e7"}, {"category": "company", "datetime": 1603843200, "headline": "Resumen: Primeros pacientes tratados con la bomba card\u00edaca m\u00e1s peque\u00f1a del mundo, la 9Fr Impella ECP", "id": 55205915, "image": "https://mms.businesswire.com/media/20201028005879/es/834159/23/Impella_ECP_Solo_Graphic.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ: ABMD) ha anunciado que el tratamiento de los dos primeros pacientes con la bomba card\u00edaca percut\u00e1nea expandible Impella ECP. Se trata", "url": "https://finnhub.io/api/news?id=88fbbe1a99c2fd1ce635ea4c1fa82c2a149a4d7bed4ebfa5c5ce56ef9dd51269"}, {"category": "company", "datetime": 1603843200, "headline": "Resumen: Primeros pacientes tratados con la bomba card\u00edaca m\u00e1s peque\u00f1a del mundo, la 9Fr Impella ECP", "id": 55205913, "image": "https://mms.businesswire.com/media/20201028005879/es/834159/23/Impella_ECP_Solo_Graphic.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ: ABMD) ha anunciado que el tratamiento de los dos primeros pacientes con la bomba card\u00edaca percut\u00e1nea expandible Impella ECP. Se trata", "url": "https://finnhub.io/api/news?id=acd86b642091b9e8399af28d53281ae2f033f68db94159b7d1d8472e39258a23"}, {"category": "company", "datetime": 1603843200, "headline": "Resumen: Primeros pacientes tratados con la bomba card\u00edaca m\u00e1s peque\u00f1a del mundo, la 9Fr Impella ECP", "id": 55205912, "image": "https://mms.businesswire.com/media/20201028005879/es/834159/23/Impella_ECP_Solo_Graphic.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ: ABMD) ha anunciado que el tratamiento de los dos primeros pacientes con la bomba card\u00edaca percut\u00e1nea expandible Impella ECP. Se trata", "url": "https://finnhub.io/api/news?id=ba0d2368cfa27542e4e9f7492524c3d68dd789af86da16420c84807b85354122"}, {"category": "company", "datetime": 1603843200, "headline": "Resumen: Primeros pacientes tratados con la bomba card\u00edaca m\u00e1s peque\u00f1a del mundo, la 9Fr Impella ECP", "id": 55205910, "image": "https://mms.businesswire.com/media/20201028005879/es/834159/23/Impella_ECP_Solo_Graphic.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ: ABMD) ha anunciado que el tratamiento de los dos primeros pacientes con la bomba card\u00edaca percut\u00e1nea expandible Impella ECP. Se trata", "url": "https://finnhub.io/api/news?id=36ea40cbbd40e64978792bac468d7d828665d403910d2d882da5da512c9724c9"}, {"category": "company", "datetime": 1603843200, "headline": "Resumen: Primeros pacientes tratados con la bomba card\u00edaca m\u00e1s peque\u00f1a del mundo, la 9Fr Impella ECP", "id": 55205908, "image": "https://mms.businesswire.com/media/20201028005879/es/834159/23/Impella_ECP_Solo_Graphic.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ: ABMD) ha anunciado que el tratamiento de los dos primeros pacientes con la bomba card\u00edaca percut\u00e1nea expandible Impella ECP. Se trata", "url": "https://finnhub.io/api/news?id=b6de7ca8a4d7da001b6f8f60d6d5e7d47cb61e98975baea27d0d368634ae828d"}, {"category": "company", "datetime": 1603843200, "headline": "Resumen: Primeros pacientes tratados con la bomba card\u00edaca m\u00e1s peque\u00f1a del mundo, la 9Fr Impella ECP", "id": 55205907, "image": "https://mms.businesswire.com/media/20201028005879/es/834159/23/Impella_ECP_Solo_Graphic.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ: ABMD) ha anunciado que el tratamiento de los dos primeros pacientes con la bomba card\u00edaca percut\u00e1nea expandible Impella ECP. Se trata", "url": "https://finnhub.io/api/news?id=3759cca202b0869ebe20113fb2d351bb596decb47aa0cd16a886803b5cd15f0d"}, {"category": "company", "datetime": 1603843200, "headline": "Resumen: Primeros pacientes tratados con la bomba card\u00edaca m\u00e1s peque\u00f1a del mundo, la 9Fr Impella ECP", "id": 55205874, "image": "https://mms.businesswire.com/media/20201028005879/es/834159/23/Impella_ECP_Solo_Graphic.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ: ABMD) ha anunciado que el tratamiento de los dos primeros pacientes con la bomba card\u00edaca percut\u00e1nea expandible Impella ECP. Se trata", "url": "https://finnhub.io/api/news?id=70c3fb0eb551c7f1e3e9fa3ac1c495384055b2cf0e7fd4b6a7e2f996bd230d60"}, {"category": "company", "datetime": 1603843200, "headline": "First Patients Treated with the World\u2019s Smallest Heart Pump, the 9Fr Impella ECP", "id": 55205166, "image": "https://mms.businesswire.com/media/20201028005398/en/834159/23/Impella_ECP_Solo_Graphic.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ: ABMD) announces the first two patients have been treated with the Impella ECP expandable percutaneous heart pump. Impella ECP is the", "url": "https://finnhub.io/api/news?id=b227bb357b6b1e26a5671133f97bf0d2490d6d3a824278ad3295625a63c9b768"}, {"category": "company", "datetime": 1603837080, "headline": "Abiomed Inc. stock rises Tuesday, outperforms market", "id": 55209546, "image": "https://images.mktw.net/im-220105/social", "related": "ABMD", "source": "MarketWatch", "summary": "Shares of Abiomed Inc. inched 0.76% higher to $290.51 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the S&P...", "url": "https://finnhub.io/api/news?id=116c06f2876a860bf421a7cc48da4001f4cc212659fa58149e295b8eb16ec2cc"}, {"category": "company news", "datetime": 1603810082, "headline": "ABIOMED (ABMD) to Report Q2 Earnings: What's in the Offing?", "id": 55228258, "image": "", "related": "ABMD", "source": "Yahoo", "summary": "The full commercial launch of Impella 5.5 in May is expected to have contributed to ABIOMED's (ABMD) fiscal second-quarter results", "url": "https://finnhub.io/api/news?id=a8f588f4962ac84bea34514156bfbd3171d66a9206a21ac944bf06d9e379ad22"}, {"category": "company", "datetime": 1603756800, "headline": "La FDA accorde l'accr\u00e9ditation 510(k) \u00e0 la technologie d'assistance cardiopulmonaire innovante d'Abiomed", "id": 55202586, "image": "https://mms.businesswire.com/media/20201027005870/fr/833238/23/Breethe_Full_Machine_10.22.20.jpg", "related": "ABMD", "source": "businesswire", "summary": "L'Agence am\u00e9ricaine des produits alimentaires et m\u00e9dicamenteux (FDA) vient d'accorder \u00e0 Abiomed (NASDAQ: ABMD) une autorisation 510(k) pour le syst\u00e8me", "url": "https://finnhub.io/api/news?id=4db1bbc0f74a5b2fb5c6b637ee8395949e973faedb5aa66767309ad8db93dceb"}, {"category": "company", "datetime": 1603756800, "headline": "FDA erteilt 510(k)-Genehmigung f\u00fcr innovatives kardiopulmonales Unterst\u00fctzungssystem von Abiomed", "id": 55201816, "image": "https://mms.businesswire.com/media/20201027005557/de/833237/23/ECpella_Bar_Chart_for_Breethe_Press_Release_10.22.20.jpg", "related": "ABMD", "source": "businesswire", "summary": "Die US-amerikanische Arzneimittelaufsichtsbeh\u00f6rde FDA hat Abiomed (NASDAQ: ABMD) eine 510(k)-Genehmigung f\u00fcr das kompakte kardiopulmonale All-in-One-B", "url": "https://finnhub.io/api/news?id=30432ad264ea2571cd2eb45529c31e77715e74758d55b93836144a9b6fe3927f"}, {"category": "company", "datetime": 1603756800, "headline": "FDA erteilt 510(k)-Genehmigung f\u00fcr innovatives kardiopulmonales Unterst\u00fctzungssystem von Abiomed", "id": 55201815, "image": "https://mms.businesswire.com/media/20201027005557/de/833237/23/ECpella_Bar_Chart_for_Breethe_Press_Release_10.22.20.jpg", "related": "ABMD", "source": "businesswire", "summary": "Die US-amerikanische Arzneimittelaufsichtsbeh\u00f6rde FDA hat Abiomed (NASDAQ: ABMD) eine 510(k)-Genehmigung f\u00fcr das kompakte kardiopulmonale All-in-One-B", "url": "https://finnhub.io/api/news?id=9d66c39721591ff37f4031490096f3c22ce471f0e6d90c0fb6ef4195b2a0b7af"}, {"category": "company", "datetime": 1603756800, "headline": "FDA erteilt 510(k)-Genehmigung f\u00fcr innovatives kardiopulmonales Unterst\u00fctzungssystem von Abiomed", "id": 55201813, "image": "https://mms.businesswire.com/media/20201027005557/de/833237/23/ECpella_Bar_Chart_for_Breethe_Press_Release_10.22.20.jpg", "related": "ABMD", "source": "businesswire", "summary": "Die US-amerikanische Arzneimittelaufsichtsbeh\u00f6rde FDA hat Abiomed (NASDAQ: ABMD) eine 510(k)-Genehmigung f\u00fcr das kompakte kardiopulmonale All-in-One-B", "url": "https://finnhub.io/api/news?id=c7633a3c472570551ec4810b11d7bc9344b3cd9f1283d3cc73110e9fcb0b3899"}, {"category": "company", "datetime": 1603756800, "headline": "FDA erteilt 510(k)-Genehmigung f\u00fcr innovatives kardiopulmonales Unterst\u00fctzungssystem von Abiomed", "id": 55201798, "image": "https://mms.businesswire.com/media/20201027005557/de/833237/23/ECpella_Bar_Chart_for_Breethe_Press_Release_10.22.20.jpg", "related": "ABMD", "source": "businesswire", "summary": "Die US-amerikanische Arzneimittelaufsichtsbeh\u00f6rde FDA hat Abiomed (NASDAQ: ABMD) eine 510(k)-Genehmigung f\u00fcr das kompakte kardiopulmonale All-in-One-B", "url": "https://finnhub.io/api/news?id=8a5c7264ef854f51182c3a37f21ff3956107db6eaa44402c68cc3ed6a1cb56b2"}, {"category": "company", "datetime": 1603741987, "headline": "Abiomed: A Heartbeat Away From Next Uptick (NASDAQ:ABMD)", "id": 55209395, "image": "https://static3.seekingalpha.com/assets/og_image_192-59bfd51c9fe6af025b2f9f96c807e46f8e2f06c5ae787b15bf1423e6c676d4db.png", "related": "ABMD", "source": "seekingalpha", "summary": "Shareholders have enjoyed +113% gains since the selloff in March, however, volatility to the downside has crept in since August.", "url": "https://finnhub.io/api/news?id=dd0ac65bdcedb532ef49bf27894bf8f734bd97b8ad7ee9c0e3deafc865415cf4"}, {"category": "company", "datetime": 1603723127, "headline": "Monday Sector Leaders: Utilities, Healthcare", "id": 61115731, "image": "https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?1918403991", "related": "ABMD", "source": "Nasdaq", "summary": "Looking at the sectors faring best as of midday Monday, shares of Utilities companies are outperforming other sectors, losing just 0.2%.  Within that group, American Electric Power Co Inc (Symbol: AEP) and Consolidated Edison Inc (Symbol: ED) are two large stocks leading the wa", "url": "https://finnhub.io/api/news?id=77285a393aa5f1d404117238531b682a1f04d99ffc5ce5c0b881f74a58c0ca6a"}, {"category": "company news", "datetime": 1603723127, "headline": "Monday Sector Leaders: Utilities, Healthcare", "id": 59070496, "image": "https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?440570699", "related": "ABMD", "source": "Nasdaq", "summary": "Looking at the sectors faring best as of midday Monday, shares of Utilities companies are outperforming other sectors, losing just 0.2%.  Within that group, American Electric Power Co Inc (Symbol: AEP) and Consolidated Edison Inc (Symbol: ED) are two large stocks leading the wa", "url": "https://finnhub.io/api/news?id=b0859312542dc388575dcb20040c2321418b8583122fe96cee1ab44dc4a4e22b"}, {"category": "company news", "datetime": 1603713300, "headline": "FDA Grants 510(k) Clearance for Abiomed\u2019s Innovative Cardiopulmonary Support Technology", "id": 55228259, "image": "", "related": "ABMD", "source": "Yahoo", "summary": "The U.S. FDA has granted Abiomed 510(k) clearance for an all-in-one, compact cardiopulmonary bypass system called the Abiomed Breethe OXY-1 System\u2122.", "url": "https://finnhub.io/api/news?id=e600abdb8ab4aed3ea1f00887472d078c0555c1251d7add280eefe5e470968b7"}, {"category": "company", "datetime": 1603700208, "headline": "FDA Approves Abiomed's Cardiopulmonary Support Technology", "id": 61305288, "image": "https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?1966168052", "related": "ABMD", "source": "Nasdaq", "summary": "(RTTNews) - Abiomed Inc. (ABMD) said Monday that the United States Food and Drug Administration has approved the Abiomed Breethe OXY-1 System,  an all-in-one compact cardiopulmonary bypass system.The company plans to have a controlled launch of the Breethe system at hospitals in", "url": "https://finnhub.io/api/news?id=90e4e699b3e0e15c86ae2251ee9672597f6a3a0d1819aed079fa6dfe78fcdeb5"}, {"category": "company news", "datetime": 1603700208, "headline": "FDA Approves Abiomed's Cardiopulmonary Support Technology", "id": 59070530, "image": "https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?840433091", "related": "ABMD", "source": "Nasdaq", "summary": "(RTTNews) - Abiomed Inc. (ABMD) said Monday that the United States Food and Drug Administration has approved the Abiomed Breethe OXY-1 System,  an all-in-one compact cardiopulmonary bypass system.The company plans to have a controlled launch of the Breethe system at hospitals in", "url": "https://finnhub.io/api/news?id=a1aa73149ecc94964562cdf7ddbd1e38c026a9e521eba989016ae05c26d4cab9"}, {"category": "company", "datetime": 1603670400, "headline": "FDA Grants 510(k) Clearance for Abiomed\u2019s Innovative Cardiopulmonary Support Technology", "id": 55199507, "image": "https://mms.businesswire.com/media/20201026005299/en/833238/23/Breethe_Full_Machine_10.22.20.jpg", "related": "ABMD", "source": "businesswire", "summary": "The U.S. FDA has granted Abiomed 510(k) clearance for an all-in-one, compact cardiopulmonary bypass system called the Abiomed Breethe OXY-1 System\u2122.", "url": "https://finnhub.io/api/news?id=9e7fc034bb701861eb91ffd1ccf55548c1e2cc6ce4d1c02d958afc7ba720e542"}, {"category": "company", "datetime": 1603584000, "headline": "The Week Ahead In Biotech: Kala FDA Decision, Merck & Pfizer Earnings, Vaccine Updates And IPOs", "id": 55199108, "image": "https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/medic-563423_1920_386_10.jpg", "related": "ABMD", "source": "benzinga", "summary": "Biotech stocks posted weekly declines in the week ended Oct. 23, pressured by the broader market decline amid mixed earnings reports and the impasse on fiscal stimulus.\nAfter...", "url": "https://finnhub.io/api/news?id=734dff78a2ff7c091c7fbea560152bf6234f8d3b844b56a56ca2d200264410c1"}, {"category": "company", "datetime": 1603411200, "headline": "TCT\u30b3\u30cd\u30af\u30c8\u767a\u8868\u306e\u30c7\u30fc\u30bf\u304b\u3089\u3001\u6025\u6027\u5fc3\u7b4b\u6897\u585e\u306b\u4f34\u3046\u5fc3\u539f\u6027\u30b7\u30e7\u30c3\u30af\uff08AMICS\uff09\u306b\u5bfe\u3059\u308bPCI\u524d\u306eImpella\u4f7f\u7528\u304c\u7279\u306b\u5973\u6027\u60a3\u8005\u3067\u751f\u5b58\u7387\u5411\u4e0a\u306b\u3064\u306a\u304c\u308b\u3068\u5224\u660e", "id": 55194102, "image": "https://mms.businesswire.com/media/20201022006254/ja/830825/23/Fig-1_highres.jpg", "related": "ABMD", "source": "businesswire", "summary": "\uff08\u30d3\u30b8\u30cd\u30b9\u30ef\u30a4\u30e4\uff09 --\u00a0\u6025\u6027\u5fc3\u7b4b\u6897\u585e\u306b\u4f34\u3046\u5fc3\u539f\u6027\u30b7\u30e7\u30c3\u30af\uff08AMICS\uff09\u60a3\u8005\u3092\u5bfe\u8c61\u3068\u3057\u305f2\u3064\u306e\u7814\u7a76\u3067\u3001PCI\u524d\u306bImpella\u3092\u7559\u7f6e\u3057\u305f\u5834\u5408\u3001PCI\u5f8c\u306bImpella\u3092\u7559\u7f6e\u3057\u305f\u5834\u5408\u3068\u6bd4\u8f03\u3057\u3066\u751f\u5b58\u7387\u304c\u9ad8\u3044\u3053\u3068\u304c\u660e\u3089\u304b\u306b\u306a\u308a\u307e\u3057\u305f\u3002\u3053\u308c\u3089\u306e\u7814\u7a76\u7d50\u679c\u306f\u3001\u5fc3\u81d3\u8840\u7ba1\u7814\u7a76\u8ca1\u56e3\u306e\u7b2c32\u56de\u5e74\u6b21\u79d1\u5b66\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0\u3067\u3042\u308b", "url": "https://finnhub.io/api/news?id=b1410ff10e02162c55c862a18f10112c052fba4fd3dc8ebec1c7d97006b41fa0"}, {"category": "company news", "datetime": 1603384384, "headline": "Analysts Estimate Abiomed (ABMD) to Report a Decline in Earnings: What to Look Out for", "id": 55228260, "image": "", "related": "ABMD", "source": "Yahoo", "summary": "Abiomed (ABMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.", "url": "https://finnhub.io/api/news?id=4872fee487213aaa41007051bfabe7ed17344deb8352c7e91354e8a0427ea899"}, {"category": "company", "datetime": 1603353882, "headline": "Capital Investment Advisory Services LLC Has $237,000 Stake in ABIOMED, Inc. (NASDAQ:ABMD)", "id": 55193624, "image": "https://www.marketbeat.com/logos/abiomed-logo.gif", "related": "ABMD", "source": "https://www.thelincolnianonline.com", "summary": "Capital Investment Advisory Services LLC decreased its stake in shares of ABIOMED, Inc. (NASDAQ:ABMD) by 5.5% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 855 shares of the medical equipment provider\u2019s stock after selling 50 shares during the period. Capital Investment Advisory Services LLC\u2019s [\u2026]", "url": "https://finnhub.io/api/news?id=6f26ba7d1599a992865dc2e021e8357f38f35a290491c26cf0e923362d3fb6c0"}, {"category": "company", "datetime": 1603324800, "headline": "\u9ad8\u30ea\u30b9\u30afPCI\u60a3\u8005\u3092\u5bfe\u8c61\u3068\u3057\u305f\u5927\u898f\u6a21\u81e8\u5e8a\u7814\u7a76\u3067\u3001Impella\u306b\u3088\u308b\u5faa\u74b0\u88dc\u52a9\u4e0b\u3067\u306e\u5b8c\u5168\u306a\u8840\u884c\u518d\u5efa\u304c\u60a3\u8005\u8ee2\u5e30\u306e\u6539\u5584\u306b\u3064\u306a\u304c\u308b\u3053\u3068\u3092\u793a\u3057\u305f", "id": 55191203, "image": "https://mms.businesswire.com/media/20201021006160/ja/830280/23/TCT_2020_P3_Key_Slide_10.14.jpg", "related": "ABMD", "source": "businesswire", "summary": "(\u30d3\u30b8\u30cd\u30b9\u30ef\u30a4\u30e4\uff09 --\u00a0\u30a2\u30d3\u30aa\u30e1\u30c3\u30c9\uff08NASDAQ: ABMD\uff09\u306f\u3001\u9ad8\u30ea\u30b9\u30af\u306e\u7d4c\u76ae\u7684\u51a0\u52d5\u8108\u30a4\u30f3\u30bf\u30fc\u30d9\u30f3\u30b7\u30e7\u30f3\uff08PCI\uff09\u60a3\u8005\u3067\u3001\u5358\u4e00\u6761\u4ef6\u3067\u3088\u308a\u5b8c\u5168\u306a\u8840\u884c\u518d\u5efa\u306e\u305f\u3081\u306bImpella\u306b\u3088\u308b\u5faa\u74b0\u88dc\u52a9\u3092\u4f7f\u7528\u3057\u305f\u5834\u5408\u3001MACCE\uff08\u5168\u6b7b\u4ea1\u3001\u8133\u5352\u4e2d\u3001\u5fc3\u7b4b\u6897\u585e\u3001\u518d\u624b\u8853\uff09\u306e\u767a\u73fe\u7387\u304c\u4f4e\u4e0b\u3059\u308b\u3053\u3068\u3092\u793a\u3059PROTECT I", "url": "https://finnhub.io/api/news?id=507721a1fbb52afa948c6445426358b26b418e97be0eebdd7139d2b3a33c89b7"}, {"category": "company", "datetime": 1603324800, "headline": "\u9ad8\u30ea\u30b9\u30afPCI\u60a3\u8005\u3092\u5bfe\u8c61\u3068\u3057\u305f\u5927\u898f\u6a21\u81e8\u5e8a\u7814\u7a76\u3067\u3001Impella\u306b\u3088\u308b\u5faa\u74b0\u88dc\u52a9\u4e0b\u3067\u306e\u5b8c\u5168\u306a\u8840\u884c\u518d\u5efa\u304c\u60a3\u8005\u8ee2\u5e30\u306e\u6539\u5584\u306b\u3064\u306a\u304c\u308b\u3053\u3068\u3092\u793a\u3057\u305f", "id": 55191202, "image": "https://mms.businesswire.com/media/20201021006160/ja/830280/23/TCT_2020_P3_Key_Slide_10.14.jpg", "related": "ABMD", "source": "businesswire", "summary": "(\u30d3\u30b8\u30cd\u30b9\u30ef\u30a4\u30e4\uff09 --\u00a0\u30a2\u30d3\u30aa\u30e1\u30c3\u30c9\uff08NASDAQ: ABMD\uff09\u306f\u3001\u9ad8\u30ea\u30b9\u30af\u306e\u7d4c\u76ae\u7684\u51a0\u52d5\u8108\u30a4\u30f3\u30bf\u30fc\u30d9\u30f3\u30b7\u30e7\u30f3\uff08PCI\uff09\u60a3\u8005\u3067\u3001\u5358\u4e00\u6761\u4ef6\u3067\u3088\u308a\u5b8c\u5168\u306a\u8840\u884c\u518d\u5efa\u306e\u305f\u3081\u306bImpella\u306b\u3088\u308b\u5faa\u74b0\u88dc\u52a9\u3092\u4f7f\u7528\u3057\u305f\u5834\u5408\u3001MACCE\uff08\u5168\u6b7b\u4ea1\u3001\u8133\u5352\u4e2d\u3001\u5fc3\u7b4b\u6897\u585e\u3001\u518d\u624b\u8853\uff09\u306e\u767a\u73fe\u7387\u304c\u4f4e\u4e0b\u3059\u308b\u3053\u3068\u3092\u793a\u3059PROTECT I", "url": "https://finnhub.io/api/news?id=c1bce76f7b45f14a37ccaff9e0edded8502c83e10b554457a6d14388a8138b39"}, {"category": "company", "datetime": 1603324800, "headline": "\u9ad8\u30ea\u30b9\u30afPCI\u60a3\u8005\u3092\u5bfe\u8c61\u3068\u3057\u305f\u5927\u898f\u6a21\u81e8\u5e8a\u7814\u7a76\u3067\u3001Impella\u306b\u3088\u308b\u5faa\u74b0\u88dc\u52a9\u4e0b\u3067\u306e\u5b8c\u5168\u306a\u8840\u884c\u518d\u5efa\u304c\u60a3\u8005\u8ee2\u5e30\u306e\u6539\u5584\u306b\u3064\u306a\u304c\u308b\u3053\u3068\u3092\u793a\u3057\u305f", "id": 55191201, "image": "https://mms.businesswire.com/media/20201021006160/ja/830280/23/TCT_2020_P3_Key_Slide_10.14.jpg", "related": "ABMD", "source": "businesswire", "summary": "(\u30d3\u30b8\u30cd\u30b9\u30ef\u30a4\u30e4\uff09 --\u00a0\u30a2\u30d3\u30aa\u30e1\u30c3\u30c9\uff08NASDAQ: ABMD\uff09\u306f\u3001\u9ad8\u30ea\u30b9\u30af\u306e\u7d4c\u76ae\u7684\u51a0\u52d5\u8108\u30a4\u30f3\u30bf\u30fc\u30d9\u30f3\u30b7\u30e7\u30f3\uff08PCI\uff09\u60a3\u8005\u3067\u3001\u5358\u4e00\u6761\u4ef6\u3067\u3088\u308a\u5b8c\u5168\u306a\u8840\u884c\u518d\u5efa\u306e\u305f\u3081\u306bImpella\u306b\u3088\u308b\u5faa\u74b0\u88dc\u52a9\u3092\u4f7f\u7528\u3057\u305f\u5834\u5408\u3001MACCE\uff08\u5168\u6b7b\u4ea1\u3001\u8133\u5352\u4e2d\u3001\u5fc3\u7b4b\u6897\u585e\u3001\u518d\u624b\u8853\uff09\u306e\u767a\u73fe\u7387\u304c\u4f4e\u4e0b\u3059\u308b\u3053\u3068\u3092\u793a\u3059PROTECT I", "url": "https://finnhub.io/api/news?id=5d0dde48ccbab722d4fa4c5e3e8827ccccd9a516a11b9130ca782dca1f022e55"}, {"category": "company", "datetime": 1603324800, "headline": "Restore EF\u8a66\u9a13\u3067Impella\u88dc\u52a9\u4e0b\u306e\u9ad8\u30ea\u30b9\u30afPCI\u304c\u5de6\u5ba4\u99c6\u51fa\u7387\u3092\u6539\u5584\u3059\u308b\u3053\u3068\u3092\u8a3c\u660e", "id": 55191186, "image": "https://mms.businesswire.com/media/20201021006160/ja/830280/23/TCT_2020_P3_Key_Slide_10.14.jpg", "related": "ABMD", "source": "businesswire", "summary": "\uff08\u30d3\u30b8\u30cd\u30b9\u30ef\u30a4\u30e4\uff09 -- Restore EF\u8a66\u9a13\u306b\u3088\u308a\u3001 Impella\u88dc\u52a9\u4e0b\u306e\u9ad8\u30ea\u30b9\u30afPCI\u3067\u3088\u308a\u5b8c\u5168\u306a\u8840\u884c\u518d\u5efa\u3092\u8a66\u307f\u305f\u30b1\u30fc\u30b9\u3092\u542b\u3081\u3001\u6700\u65b0\u306e\u30d9\u30b9\u30c8\u30d7\u30e9\u30af\u30c6\u30a3\u30b9\u306e\u4f7f\u7528\u304c\u3001\u30d5\u30a9\u30ed\u30fc\u30a2\u30c3\u30d7\u6642\u306b\u304a\u3051\u308b\u5de6\u5ba4\u99c6\u51fa\u7387\uff08LVEF\uff09\u3001\u5fc3\u4e0d\u5168\u306e\u75c7\u72b6\u3001\u72ed\u5fc3\u75c7\u306e\u75c7\u72b6\u306e\u6709\u610f\u306a\u6539\u5584\u3092\u3082\u305f\u3089\u3059\u3053\u3068\u304c\u793a\u3055\u308c\u307e\u3057\u305f\u3002\u7814\u7a76\u306e\u4e2d\u9593\u89e3", "url": "https://finnhub.io/api/news?id=8100c7bc1af1328c4652090618da8e76df744ec6f5ce543f129df978cc8610a6"}, {"category": "company", "datetime": 1603263169, "headline": "IBM Retirement Fund Raises Holdings in ABIOMED, Inc. (NASDAQ:ABMD)", "id": 55190373, "image": "https://www.marketbeat.com/logos/abiomed-logo.gif", "related": "ABMD", "source": "https://www.thelincolnianonline.com", "summary": "IBM Retirement Fund boosted its stake in shares of ABIOMED, Inc. (NASDAQ:ABMD) by 39.0% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,439 shares of the medical equipment provider\u2019s stock after purchasing an additional 404 shares during the quarter. IBM [\u2026]", "url": "https://finnhub.io/api/news?id=4054dbd71c9a70f986132cd92563973baaeb5c12c3a7a2187144f64ffeea7010"}, {"category": "company", "datetime": 1603157587, "headline": "Abiomed Is Up 60% This Year, Can The Rally Continue?", "id": 61125615, "image": "https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?120795946", "related": "ABMD", "source": "Nasdaq", "summary": "The stock price of Abiomed (NASDAQ:ABMD), a medical devices company best known for Impella, the world\u2019s smallest heart pump, is up roughly 60% since the beginning of this year, significantly outperforming the broader markets, with S&P 500 up a mere 7%. Despite the ral", "url": "https://finnhub.io/api/news?id=19bf3e2832336c1b5c27e629b54cc23579406ae43af0aeef134ae71f1d4fec16"}, {"category": "company news", "datetime": 1603157587, "headline": "Abiomed Is Up 60% This Year, Can The Rally Continue?", "id": 59070531, "image": "https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?911585149", "related": "ABMD", "source": "Nasdaq", "summary": "The stock price of Abiomed (NASDAQ:ABMD), a medical devices company best known for Impella, the world\u2019s smallest heart pump, is up roughly 60% since the beginning of this year, significantly outperforming the broader markets, with S&P 500 up a mere 7%. Despite the ral", "url": "https://finnhub.io/api/news?id=aaa738f3ef8735e903293c65fbc4cdee6e6bbdaa455918ab6b867cdbe0ed137a"}, {"category": "company", "datetime": 1603065600, "headline": "Restore EF-Studie zeigt Verbesserung der linksventrikul\u00e4ren Ejektionsfraktion durch Impella gest\u00fctzte Hochrisiko-PCI", "id": 55182731, "image": "https://mms.businesswire.com/media/20201019005480/de/830109/23/Restore_EF_Figure_1.jpg", "related": "ABMD", "source": "businesswire", "summary": "Die Restore EF-Studie zeigt, dass die Verwendung moderner Best-Practice-Methoden, einschlie\u00dflich des Versuchs einer vollst\u00e4ndigeren Revaskularisierung", "url": "https://finnhub.io/api/news?id=9b1a8609cfb4f1286ffde761577c2720f7dea378ea4ab884496fa4bfcb426ea3"}, {"category": "company", "datetime": 1603065600, "headline": "Restore EF-Studie zeigt Verbesserung der linksventrikul\u00e4ren Ejektionsfraktion durch Impella gest\u00fctzte Hochrisiko-PCI", "id": 55182730, "image": "https://mms.businesswire.com/media/20201019005480/de/830109/23/Restore_EF_Figure_1.jpg", "related": "ABMD", "source": "businesswire", "summary": "Die Restore EF-Studie zeigt, dass die Verwendung moderner Best-Practice-Methoden, einschlie\u00dflich des Versuchs einer vollst\u00e4ndigeren Revaskularisierung", "url": "https://finnhub.io/api/news?id=2d2372a824d4cd092cc093d36ca5f6d896ca2ef2f1828f9ca89bb9c0f1e51a6b"}, {"category": "company", "datetime": 1603065600, "headline": "Restore EF-Studie zeigt Verbesserung der linksventrikul\u00e4ren Ejektionsfraktion durch Impella gest\u00fctzte Hochrisiko-PCI", "id": 55182729, "image": "https://mms.businesswire.com/media/20201019005480/de/830109/23/Restore_EF_Figure_1.jpg", "related": "ABMD", "source": "businesswire", "summary": "Die Restore EF-Studie zeigt, dass die Verwendung moderner Best-Practice-Methoden, einschlie\u00dflich des Versuchs einer vollst\u00e4ndigeren Revaskularisierung", "url": "https://finnhub.io/api/news?id=ed012eba4c7f4e4165002b2189d46832b4fb82262c2e903c874faaec33b2b516"}, {"category": "company", "datetime": 1603065600, "headline": "Restore EF-Studie zeigt Verbesserung der linksventrikul\u00e4ren Ejektionsfraktion durch Impella gest\u00fctzte Hochrisiko-PCI", "id": 55182728, "image": "https://mms.businesswire.com/media/20201019005480/de/830109/23/Restore_EF_Figure_1.jpg", "related": "ABMD", "source": "businesswire", "summary": "Die Restore EF-Studie zeigt, dass die Verwendung moderner Best-Practice-Methoden, einschlie\u00dflich des Versuchs einer vollst\u00e4ndigeren Revaskularisierung", "url": "https://finnhub.io/api/news?id=cef848b1a6225c5f8124f33d0bc44f6dcdc18f94cafb0251d136fc88c767829c"}, {"category": "company", "datetime": 1603065600, "headline": "Restore EF-Studie zeigt Verbesserung der linksventrikul\u00e4ren Ejektionsfraktion durch Impella gest\u00fctzte Hochrisiko-PCI", "id": 55182706, "image": "https://mms.businesswire.com/media/20201019005480/de/830109/23/Restore_EF_Figure_1.jpg", "related": "ABMD", "source": "businesswire", "summary": "Die Restore EF-Studie zeigt, dass die Verwendung moderner Best-Practice-Methoden, einschlie\u00dflich des Versuchs einer vollst\u00e4ndigeren Revaskularisierung", "url": "https://finnhub.io/api/news?id=6a64bed6654df3c1a0a413ee034ff2e3ca6c229763d52f2cae29a4aa0a69024b"}, {"category": "company", "datetime": 1603065600, "headline": "Daten, die bei TCT Connect vorgestellt worden sind, zeigen, dass ein Pr\u00e4-PCI-Einsatz von Impella bei akutem Myokardinfarkt mit kardiogenem Schock zu einer h\u00f6heren \u00dcberlebensrate f\u00fchrt \u2013 insbesondere bei Frauen", "id": 55182697, "image": "https://mms.businesswire.com/media/20201019005467/de/830825/23/Fig-1.jpg", "related": "ABMD", "source": "businesswire", "summary": "Wie zwei Studien an Patienten mit akutem Myokardinfarkt und kardiogenem Schock (AMICS) zeigen, ist die \u00dcberlebensrate beim Einsatz von Impella vor ein", "url": "https://finnhub.io/api/news?id=e1964a99b5aa1e6251320ed9a566646382dd64321edcb7bce89547a97263143c"}, {"category": "company", "datetime": 1603065600, "headline": "Daten, die bei TCT Connect vorgestellt worden sind, zeigen, dass ein Pr\u00e4-PCI-Einsatz von Impella bei akutem Myokardinfarkt mit kardiogenem Schock zu einer h\u00f6heren \u00dcberlebensrate f\u00fchrt \u2013 insbesondere bei Frauen", "id": 55182696, "image": "https://mms.businesswire.com/media/20201019005467/de/830825/23/Fig-1.jpg", "related": "ABMD", "source": "businesswire", "summary": "Wie zwei Studien an Patienten mit akutem Myokardinfarkt und kardiogenem Schock (AMICS) zeigen, ist die \u00dcberlebensrate beim Einsatz von Impella vor ein", "url": "https://finnhub.io/api/news?id=2d4faab5cb2db08e10bf221a4f7834a8fe4db7f1b707e155b9486ad2b378ffba"}, {"category": "company", "datetime": 1603065600, "headline": "Daten, die bei TCT Connect vorgestellt worden sind, zeigen, dass ein Pr\u00e4-PCI-Einsatz von Impella bei akutem Myokardinfarkt mit kardiogenem Schock zu einer h\u00f6heren \u00dcberlebensrate f\u00fchrt \u2013 insbesondere bei Frauen", "id": 55182695, "image": "https://mms.businesswire.com/media/20201019005467/de/830825/23/Fig-1.jpg", "related": "ABMD", "source": "businesswire", "summary": "Wie zwei Studien an Patienten mit akutem Myokardinfarkt und kardiogenem Schock (AMICS) zeigen, ist die \u00dcberlebensrate beim Einsatz von Impella vor ein", "url": "https://finnhub.io/api/news?id=7d61d921dad5f638129ed9baa9e7da4c47f8171de93139a8f4e217d49a0a437f"}, {"category": "company", "datetime": 1603065600, "headline": "Daten, die bei TCT Connect vorgestellt worden sind, zeigen, dass ein Pr\u00e4-PCI-Einsatz von Impella bei akutem Myokardinfarkt mit kardiogenem Schock zu einer h\u00f6heren \u00dcberlebensrate f\u00fchrt \u2013 insbesondere bei Frauen", "id": 55182694, "image": "https://mms.businesswire.com/media/20201019005467/de/830825/23/Fig-1.jpg", "related": "ABMD", "source": "businesswire", "summary": "Wie zwei Studien an Patienten mit akutem Myokardinfarkt und kardiogenem Schock (AMICS) zeigen, ist die \u00dcberlebensrate beim Einsatz von Impella vor ein", "url": "https://finnhub.io/api/news?id=54a6fd63411866631ab33d781aa409072f678bf005152c64ffb18f1902bc1d0d"}, {"category": "company", "datetime": 1603065600, "headline": "Daten, die bei TCT Connect vorgestellt worden sind, zeigen, dass ein Pr\u00e4-PCI-Einsatz von Impella bei akutem Myokardinfarkt mit kardiogenem Schock zu einer h\u00f6heren \u00dcberlebensrate f\u00fchrt \u2013 insbesondere bei Frauen", "id": 55182693, "image": "https://mms.businesswire.com/media/20201019005467/de/830825/23/Fig-1.jpg", "related": "ABMD", "source": "businesswire", "summary": "Wie zwei Studien an Patienten mit akutem Myokardinfarkt und kardiogenem Schock (AMICS) zeigen, ist die \u00dcberlebensrate beim Einsatz von Impella vor ein", "url": "https://finnhub.io/api/news?id=6f7922900788aedf93360057087eb4762761210ae64d551b8d26808142c4307a"}, {"category": "company", "datetime": 1603065600, "headline": "Daten, die bei TCT Connect vorgestellt worden sind, zeigen, dass ein Pr\u00e4-PCI-Einsatz von Impella bei akutem Myokardinfarkt mit kardiogenem Schock zu einer h\u00f6heren \u00dcberlebensrate f\u00fchrt \u2013 insbesondere bei Frauen", "id": 55182681, "image": "https://mms.businesswire.com/media/20201019005467/de/830825/23/Fig-1.jpg", "related": "ABMD", "source": "businesswire", "summary": "Wie zwei Studien an Patienten mit akutem Myokardinfarkt und kardiogenem Schock (AMICS) zeigen, ist die \u00dcberlebensrate beim Einsatz von Impella vor ein", "url": "https://finnhub.io/api/news?id=ad6c6c7a18250c872b6f9587fcf4595178eb9fbbbe24178a9cb2737696803c14"}, {"category": "company", "datetime": 1602882480, "headline": "Abiomed : Les donn\u00e9es pr\u00e9sent\u00e9es lors du TCT Connect r\u00e9v\u00e8lent que l'utilisation de l'Impella avant l'ICP pour le choc cardiog\u00e9nique lors d'un IAM est associ\u00e9e \u00e0 un taux de survie plus \u00e9lev\u00e9, en particulier chez les femmes | Zone bourse", "id": 55180696, "image": "https://www.zonebourse.com/images/twitter_ZB_fdgris.png", "related": "ABMD", "source": "https://www.zonebourse.com", "summary": "", "url": "https://finnhub.io/api/news?id=251c3c5cc2dd7094c1e37f708dc186edc6377ffd69dd09a721353ea42bc8d432"}, {"category": "company news", "datetime": 1602849900, "headline": "Studies Presented at TCT Connect Associate Higher Survival With Early Identification of Right Heart Failure and Early Use of Impella RP", "id": 55228261, "image": "", "related": "ABMD", "source": "Yahoo", "summary": "Data presented at TCT Connect, the 32nd annual scientific symposium of the Cardiovascular Research Foundation, finds early identification of right heart failure and early use of Impella RP is associated with significantly higher survival rates. Early identification of patients requiring right-heart support is critical because prior studies have shown 37% of AMI cardiogenic shock (AMICS) patients exhibit right heart dysfunction1, which results in an eight times increased risk of mortality2.", "url": "https://finnhub.io/api/news?id=33c04d9a4e9aa76c75bed7c46127739b4a247bad2307470782077a0ae03d0239"}, {"category": "company news", "datetime": 1602846300, "headline": "Data Presented at TCT Connect Finds Pre-PCI Use of Impella for AMI Cardiogenic Shock is Associated with Higher Survival, Particularly in Women", "id": 55228262, "image": "", "related": "ABMD", "source": "Yahoo", "summary": "Two studies of AMI cardiogenic shock (AMICS) patients found higher survival when Impella was placed pre-PCI, compared to when Impella was placed after PCI. The findings were presented at TCT Connect, the 32nd annual scientific symposium of the Cardiovascular Research Foundation.", "url": "https://finnhub.io/api/news?id=4e1de75c8c9e4bc5807e3278569987691fa9e762ec58aed9715b2e32eb63f695"}, {"category": "company", "datetime": 1602806400, "headline": "Resumen: El mayor estudio de pacientes con ICP de alto riesgo con apoyo hemodin\u00e1mico muestra que una revascularizaci\u00f3n m\u00e1s completa con Impella produce mejores resultados", "id": 55179516, "image": "https://mms.businesswire.com/media/20201016005675/es/830280/23/TCT_2020_P3_Key_Slide_10.14.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ: ABMD) ha anunciado nuevos datos del estudio PROTECT III que demuestran tasas reducidas de MACCE (resultado compuesto de deceso, ictus", "url": "https://finnhub.io/api/news?id=04329e7ddfe6dd34f1e2e852b3479947a29d66b1fcf170f95ebda8ecbb43cc68"}, {"category": "company", "datetime": 1602806400, "headline": "Resumen: El mayor estudio de pacientes con ICP de alto riesgo con apoyo hemodin\u00e1mico muestra que una revascularizaci\u00f3n m\u00e1s completa con Impella produce mejores resultados", "id": 55179515, "image": "https://mms.businesswire.com/media/20201016005675/es/830280/23/TCT_2020_P3_Key_Slide_10.14.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ: ABMD) ha anunciado nuevos datos del estudio PROTECT III que demuestran tasas reducidas de MACCE (resultado compuesto de deceso, ictus", "url": "https://finnhub.io/api/news?id=95ba377e85451c3d0dcf903f0104ef59caa0699062e1e06f47e6ad8cc92a027b"}, {"category": "company", "datetime": 1602806400, "headline": "Resumen: El mayor estudio de pacientes con ICP de alto riesgo con apoyo hemodin\u00e1mico muestra que una revascularizaci\u00f3n m\u00e1s completa con Impella produce mejores resultados", "id": 55179514, "image": "https://mms.businesswire.com/media/20201016005675/es/830280/23/TCT_2020_P3_Key_Slide_10.14.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ: ABMD) ha anunciado nuevos datos del estudio PROTECT III que demuestran tasas reducidas de MACCE (resultado compuesto de deceso, ictus", "url": "https://finnhub.io/api/news?id=cfa8d566203af38524cd40d3148a4fb0276d5b9e9f532916e47d92e7ed45e0df"}, {"category": "company", "datetime": 1602806400, "headline": "Samenvatting: Grootste studie van hemodynamisch ondersteunde hoog-risico PCI-pati\u00ebnten vindt meer complete revascularisatie met Impella leidt tot betere resultaten", "id": 55179511, "image": "https://mms.businesswire.com/media/20201016005677/nl/830280/23/TCT_2020_P3_Key_Slide_10.14.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ: ABMD) kondigt nieuwe PROTECT III-studiegegevens aan die lagere percentages MACCE (samenstelling van overlijden, beroerte, myocardinfa", "url": "https://finnhub.io/api/news?id=8b993e005b6a9e28aba99d0c4617be31d3e7ec8d404743ae79ad9155181065b7"}, {"category": "company", "datetime": 1602806400, "headline": "Samenvatting: Grootste studie van hemodynamisch ondersteunde hoog-risico PCI-pati\u00ebnten vindt meer complete revascularisatie met Impella leidt tot betere resultaten", "id": 55179510, "image": "https://mms.businesswire.com/media/20201016005677/nl/830280/23/TCT_2020_P3_Key_Slide_10.14.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ: ABMD) kondigt nieuwe PROTECT III-studiegegevens aan die lagere percentages MACCE (samenstelling van overlijden, beroerte, myocardinfa", "url": "https://finnhub.io/api/news?id=7ee68b528176a99d9d986e73014540215e60947efbbc52d3e1c32e84312dcb19"}, {"category": "company", "datetime": 1602806400, "headline": "Samenvatting: Grootste studie van hemodynamisch ondersteunde hoog-risico PCI-pati\u00ebnten vindt meer complete revascularisatie met Impella leidt tot betere resultaten", "id": 55179508, "image": "https://mms.businesswire.com/media/20201016005677/nl/830280/23/TCT_2020_P3_Key_Slide_10.14.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ: ABMD) kondigt nieuwe PROTECT III-studiegegevens aan die lagere percentages MACCE (samenstelling van overlijden, beroerte, myocardinfa", "url": "https://finnhub.io/api/news?id=d51478cc436aa645fdf84ec982e307e3522d20a6a8169487777ff36e4b950612"}, {"category": "company", "datetime": 1602806400, "headline": "Resumen: El mayor estudio de pacientes con ICP de alto riesgo con apoyo hemodin\u00e1mico muestra que una revascularizaci\u00f3n m\u00e1s completa con Impella produce mejores resultados", "id": 55179502, "image": "https://mms.businesswire.com/media/20201016005675/es/830280/23/TCT_2020_P3_Key_Slide_10.14.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ: ABMD) ha anunciado nuevos datos del estudio PROTECT III que demuestran tasas reducidas de MACCE (resultado compuesto de deceso, ictus", "url": "https://finnhub.io/api/news?id=7e0f45c3cf0fc6d432f842d8a348a6519919b4b3a9cef5e5d313f597c2a52922"}, {"category": "company", "datetime": 1602806400, "headline": "Samenvatting: Grootste studie van hemodynamisch ondersteunde hoog-risico PCI-pati\u00ebnten vindt meer complete revascularisatie met Impella leidt tot betere resultaten", "id": 55179500, "image": "https://mms.businesswire.com/media/20201016005677/nl/830280/23/TCT_2020_P3_Key_Slide_10.14.jpg", "related": "ABMD", "source": "businesswire", "summary": "Abiomed (NASDAQ: ABMD) kondigt nieuwe PROTECT III-studiegegevens aan die lagere percentages MACCE (samenstelling van overlijden, beroerte, myocardinfa", "url": "https://finnhub.io/api/news?id=1d915b1bd5f831b87302c9b4a00e799a627c614ddd613c6f7e509ca71e306b82"}, {"category": "company", "datetime": 1602806400, "headline": "Auf TCT vorgestellte Studien bringen h\u00f6here \u00dcberlebensrate mit fr\u00fcher Erkennung von Rechtsherzinsuffizienz und fr\u00fchem Einsatz von Impella RP in Verbindung", "id": 55179441, "image": "https://mms.businesswire.com/media/20201016005670/de/830826/23/Figure+1.jpg", "related": "ABMD", "source": "businesswire", "summary": "Auf der TCT Connect, dem 32. j\u00e4hrlichen wissenschaftlichen Symposium der Cardiovascular Research Foundation, vorgestellte Daten zeigen, dass eine fr\u00fch", "url": "https://finnhub.io/api/news?id=1d152cbc1b4e21d44bf9abeb9df6952ae557e7b3574e43a668f97fd84c8e2f7d"}, {"category": "company", "datetime": 1602806400, "headline": "Auf TCT vorgestellte Studien bringen h\u00f6here \u00dcberlebensrate mit fr\u00fcher Erkennung von Rechtsherzinsuffizienz und fr\u00fchem Einsatz von Impella RP in Verbindung", "id": 55179440, "image": "https://mms.businesswire.com/media/20201016005670/de/830826/23/Figure+1.jpg", "related": "ABMD", "source": "businesswire", "summary": "Auf der TCT Connect, dem 32. j\u00e4hrlichen wissenschaftlichen Symposium der Cardiovascular Research Foundation, vorgestellte Daten zeigen, dass eine fr\u00fch", "url": "https://finnhub.io/api/news?id=18d7c532f4c1b66a86d19e776f5501129a6f9ebc19f74343241de916da4d8964"}, {"category": "company", "datetime": 1602806400, "headline": "Auf TCT vorgestellte Studien bringen h\u00f6here \u00dcberlebensrate mit fr\u00fcher Erkennung von Rechtsherzinsuffizienz und fr\u00fchem Einsatz von Impella RP in Verbindung", "id": 55179438, "image": "https://mms.businesswire.com/media/20201016005670/de/830826/23/Figure+1.jpg", "related": "ABMD", "source": "businesswire", "summary": "Auf der TCT Connect, dem 32. j\u00e4hrlichen wissenschaftlichen Symposium der Cardiovascular Research Foundation, vorgestellte Daten zeigen, dass eine fr\u00fch", "url": "https://finnhub.io/api/news?id=94fc9531f63aa9b9171fd22506d084f3a606645f03996f39b627a7c3823d5480"}, {"category": "company", "datetime": 1602806400, "headline": "Auf TCT vorgestellte Studien bringen h\u00f6here \u00dcberlebensrate mit fr\u00fcher Erkennung von Rechtsherzinsuffizienz und fr\u00fchem Einsatz von Impella RP in Verbindung", "id": 55179414, "image": "https://mms.businesswire.com/media/20201016005670/de/830826/23/Figure+1.jpg", "related": "ABMD", "source": "businesswire", "summary": "Auf der TCT Connect, dem 32. j\u00e4hrlichen wissenschaftlichen Symposium der Cardiovascular Research Foundation, vorgestellte Daten zeigen, dass eine fr\u00fch", "url": "https://finnhub.io/api/news?id=0be78187a2333da5ed118b5ea5a166d2d55c920f447834bf2e01a2c5d7787c6e"}, {"category": "company", "datetime": 1602806400, "headline": "Les donn\u00e9es pr\u00e9sent\u00e9es lors du TCT Connect r\u00e9v\u00e8lent que l'utilisation de l'Impella avant l'ICP pour le choc cardiog\u00e9nique lors d'un IAM est associ\u00e9e \u00e0 un taux de survie plus \u00e9lev\u00e9, en particulier chez les femmes", "id": 55179306, "image": "https://mms.businesswire.com/media/20201016005651/fr/830825/23/Fig-1.jpg", "related": "ABMD", "source": "businesswire", "summary": "Deux \u00e9tudes r\u00e9alis\u00e9es sur des patients ayant subi un choc cardiog\u00e9nique (AMICS) ont r\u00e9v\u00e9l\u00e9 un taux de survie plus \u00e9lev\u00e9 lorsque l'Impella \u00e9tait plac\u00e9", "url": "https://finnhub.io/api/news?id=14e22afee9b80b2b1581d2e65722d866440966c20400ece94356b64254688771"}, {"category": "company", "datetime": 1602806400, "headline": "Les donn\u00e9es pr\u00e9sent\u00e9es lors du TCT Connect r\u00e9v\u00e8lent que l'utilisation de l'Impella avant l'ICP pour le choc cardiog\u00e9nique lors d'un IAM est associ\u00e9e \u00e0 un taux de survie plus \u00e9lev\u00e9, en particulier chez les femmes", "id": 55179305, "image": "https://mms.businesswire.com/media/20201016005651/fr/830825/23/Fig-1.jpg", "related": "ABMD", "source": "businesswire", "summary": "Deux \u00e9tudes r\u00e9alis\u00e9es sur des patients ayant subi un choc cardiog\u00e9nique (AMICS) ont r\u00e9v\u00e9l\u00e9 un taux de survie plus \u00e9lev\u00e9 lorsque l'Impella \u00e9tait plac\u00e9", "url": "https://finnhub.io/api/news?id=38293539ba6b94bb0d668b3fdb609cda7dd18ba1061b3ed4c8459edffb3d2bbf"}, {"category": "company", "datetime": 1602806400, "headline": "Les donn\u00e9es pr\u00e9sent\u00e9es lors du TCT Connect r\u00e9v\u00e8lent que l'utilisation de l'Impella avant l'ICP pour le choc cardiog\u00e9nique lors d'un IAM est associ\u00e9e \u00e0 un taux de survie plus \u00e9lev\u00e9, en particulier chez les femmes", "id": 55179304, "image": "https://mms.businesswire.com/media/20201016005651/fr/830825/23/Fig-1.jpg", "related": "ABMD", "source": "businesswire", "summary": "Deux \u00e9tudes r\u00e9alis\u00e9es sur des patients ayant subi un choc cardiog\u00e9nique (AMICS) ont r\u00e9v\u00e9l\u00e9 un taux de survie plus \u00e9lev\u00e9 lorsque l'Impella \u00e9tait plac\u00e9", "url": "https://finnhub.io/api/news?id=70f228fb6b4a779e5ab22a6b55e0ef4fe2f61b604df127d829f01e471dfbfb02"}, {"category": "company", "datetime": 1602806400, "headline": "Les donn\u00e9es pr\u00e9sent\u00e9es lors du TCT Connect r\u00e9v\u00e8lent que l'utilisation de l'Impella avant l'ICP pour le choc cardiog\u00e9nique lors d'un IAM est associ\u00e9e \u00e0 un taux de survie plus \u00e9lev\u00e9, en particulier chez les femmes", "id": 55179303, "image": "https://mms.businesswire.com/media/20201016005651/fr/830825/23/Fig-1.jpg", "related": "ABMD", "source": "businesswire", "summary": "Deux \u00e9tudes r\u00e9alis\u00e9es sur des patients ayant subi un choc cardiog\u00e9nique (AMICS) ont r\u00e9v\u00e9l\u00e9 un taux de survie plus \u00e9lev\u00e9 lorsque l'Impella \u00e9tait plac\u00e9", "url": "https://finnhub.io/api/news?id=2f246798ed472e6b23ae13bab169452db9b848ef4e968dbbc49986ed6d397753"}, {"category": "company", "datetime": 1602806400, "headline": "Les donn\u00e9es pr\u00e9sent\u00e9es lors du TCT Connect r\u00e9v\u00e8lent que l'utilisation de l'Impella avant l'ICP pour le choc cardiog\u00e9nique lors d'un IAM est associ\u00e9e \u00e0 un taux de survie plus \u00e9lev\u00e9, en particulier chez les femmes", "id": 55179302, "image": "https://mms.businesswire.com/media/20201016005651/fr/830825/23/Fig-1.jpg", "related": "ABMD", "source": "businesswire", "summary": "Deux \u00e9tudes r\u00e9alis\u00e9es sur des patients ayant subi un choc cardiog\u00e9nique (AMICS) ont r\u00e9v\u00e9l\u00e9 un taux de survie plus \u00e9lev\u00e9 lorsque l'Impella \u00e9tait plac\u00e9", "url": "https://finnhub.io/api/news?id=3ee5a3076cbb65880602407f57e474666ed9c83e00d1a0c30c27eafbb0a6bd98"}, {"category": "company", "datetime": 1602806400, "headline": "Les donn\u00e9es pr\u00e9sent\u00e9es lors du TCT Connect r\u00e9v\u00e8lent que l'utilisation de l'Impella avant l'ICP pour le choc cardiog\u00e9nique lors d'un IAM est associ\u00e9e \u00e0 un taux de survie plus \u00e9lev\u00e9, en particulier chez les femmes", "id": 55179287, "image": "https://mms.businesswire.com/media/20201016005651/fr/830825/23/Fig-1.jpg", "related": "ABMD", "source": "businesswire", "summary": "Deux \u00e9tudes r\u00e9alis\u00e9es sur des patients ayant subi un choc cardiog\u00e9nique (AMICS) ont r\u00e9v\u00e9l\u00e9 un taux de survie plus \u00e9lev\u00e9 lorsque l'Impella \u00e9tait plac\u00e9", "url": "https://finnhub.io/api/news?id=5dddc2ae008e3645f5199cd39f4c52b07b0915196c40e09c29921211eb0ef115"}, {"category": "company", "datetime": 1602806400, "headline": "Les \u00e9tudes pr\u00e9sent\u00e9es lors du TCT Connect d\u00e9montrent que l\u2019identification pr\u00e9coce d\u2019une insuffisance cardiaque droite et l'utilisation pr\u00e9coce de l\u2019Impella RP favorisent un meilleur taux de survie", "id": 55178882, "image": "https://mms.businesswire.com/media/20201016005595/fr/830826/23/Figure+1.jpg", "related": "ABMD", "source": "businesswire", "summary": "Les donn\u00e9es pr\u00e9sent\u00e9es lors du TCT Connect, 32e symposium scientifique annuel de la Cardiovascular Research Foundation, d\u00e9montrent que l'identificatio", "url": "https://finnhub.io/api/news?id=211f1b13282014b375318d97ba6bb0e040d717a4477e1ee5905b74259dbfc99a"}, {"category": "company", "datetime": 1602806400, "headline": "Studies Presented at TCT Connect Associate Higher Survival With Early Identification of Right Heart Failure and Early Use of Impella RP", "id": 55178050, "image": "https://mms.businesswire.com/media/20201016005123/en/830826/23/Figure+1.jpg", "related": "ABMD", "source": "businesswire", "summary": "Data presented at TCT Connect, the 32nd annual scientific symposium of the Cardiovascular Research Foundation, finds early identification of right hea", "url": "https://finnhub.io/api/news?id=dea58c2c05953e9ce4db0dd04f85f5cdc25b83c4ab19be44bc4c55d27da787a1"}, {"category": "company", "datetime": 1602806400, "headline": "Studies Presented at TCT Connect Associate Higher Survival With Early Identification of Right Heart Failure and Early Use of Impella RP", "id": 55178049, "image": "https://mms.businesswire.com/media/20201016005123/en/830826/23/Figure+1.jpg", "related": "ABMD", "source": "businesswire", "summary": "Data presented at TCT Connect, the 32nd annual scientific symposium of the Cardiovascular Research Foundation, finds early identification of right hea", "url": "https://finnhub.io/api/news?id=149285b387f866976e9a430f7aead7024a903e64453ffae04c57097367b34aeb"}, {"category": "company", "datetime": 1602806400, "headline": "Studies Presented at TCT Connect Associate Higher Survival With Early Identification of Right Heart Failure and Early Use of Impella RP", "id": 55178048, "image": "https://mms.businesswire.com/media/20201016005123/en/830826/23/Figure+1.jpg", "related": "ABMD", "source": "businesswire", "summary": "Data presented at TCT Connect, the 32nd annual scientific symposium of the Cardiovascular Research Foundation, finds early identification of right hea", "url": "https://finnhub.io/api/news?id=d2c2163bf6b12008132ca949d445d3b122013e13b267976aaf384449924d8a52"}, {"category": "company", "datetime": 1602806400, "headline": "Studies Presented at TCT Connect Associate Higher Survival With Early Identification of Right Heart Failure and Early Use of Impella RP", "id": 55178036, "image": "https://mms.businesswire.com/media/20201016005123/en/830826/23/Figure+1.jpg", "related": "ABMD", "source": "businesswire", "summary": "Data presented at TCT Connect, the 32nd annual scientific symposium of the Cardiovascular Research Foundation, finds early identification of right hea", "url": "https://finnhub.io/api/news?id=a109da0cf1cf1d05a3cceec6711d5920804a2d1745cdd9dba4a9201885a75b01"}]